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There is currently very little known about early brain development; even less about how 
normal development may be disrupted in individuals genetically predisposed to 
neurodevelopmental conditions, including autism spectrum disorder (ASD). Hence, by using 
magnetic resonance imaging (MRI) to examine the structure and chemistry of the fetal, 
neonatal, and infant human brain, my intention was to provide further insight into early 
neurodevelopment. The additional focus on individuals with a familial risk of ASD, also aimed 
to detect any potential deviations from typical brain development that may be associated with 
an ASD risk status. 
 
The first experimental study of this thesis used MRI at 1.5T to reveal that the early 
environment – specifically, mother-infant interactions – is associated with variations in brain 
biology, within a sample of assumed-to-be typically developing individuals. Therefore, the next 
study, which compared brain volume in infants with and without a familial risk of ASD also 
incorporated measures of mother-infant interactions. In this second study, subcortical and 
cerebellar enlargements were identified in 4-6 month-old infants at risk of ASD, and larger 
volumes were associated with more autistic symptoms at 36 months. Within the high-risk 
group, a higher measure of maternal sensitivity was correlated with lower subcortical brain 
volumes.    
 
Next, to examine even earlier development and to estimate when differences between risk 
groups might first appear, fetuses and neonates with and without a familial risk of ASD were 
scanned using advanced MRI protocols at 3T. At both these timepoints, the cortex and 
cerebellum were identified as the fastest growing brain regions. In addition, fetuses at risk of 
ASD had smaller cortical volumes when compared to low-risk controls. Postnatally, within the 
first month of life, neonates at risk of ASD also had smaller intracranial and total brain 
volumes, as well as a smaller lentiform nucleus. Placed together with the infant findings, these 
studies suggest that an ASD genetic risk constrains brain growth in the perinatal period, but is 
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associated with volumetric expansion of both subcortical and cerebellar regions in infancy. 
The subcortical region also appeared to be particularly affected by the abnormal growth 
trajectory of high-risk participants, as differences in this region were observed amongst high-
risk individuals at both neonatal and infant timepoints. 
 
The subcortex was therefore selected as a region-of-interest in the final study, which mapped 
metabolic maturation from fetal to early postnatal life using magnetic resonance spectroscopy. 
In both low and high-risk groups, choline and myo-inositol decreased significantly with age, 
whilst N-acetylaspartate and creatine increased. In contrast, glutamate (measured as 
glutamate and glutamine; Glx) decreased from fetal to neonatal life, with a marked ‘dip’ 
around the time of birth before increasing in early infancy. The sample size at the 4-6 month 
timepoint also permitted an explicit comparison of low and high-risk infants, and because 
previous studies of older cohorts have linked glutamate abnormalities to ASD, Glx levels were 
compared between groups. The results showed, for the first time, that high-risk infants have 
significantly elevated levels of Glx at 4-6 months of age, when compared to low-risk controls.  
 
In conclusion, both the volume and biochemistry of the human brain undergoes rapid change 
in the late prenatal and early postnatal periods. Moreover, individuals with a familial risk of 
ASD already show differences in brain maturation from fetal life, including neurochemical 
pathways modulating the balance of neuronal excitation and inhibition. This is well before the 
onset of autistic symptoms, and therefore, has important implications for ASD in terms of risk 
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Chapter 1: Introduction 
 
1.1. Motivation and rationale 
New imaging modalities have hugely advanced our understanding of the brain. However, our 
knowledge of how the early prenatal and postnatal periods shape brain development is 
limited. By examining the structure and chemistry of the fetal, neonatal, and infant human 
brain, the studies included in this thesis have therefore attempted to improve our 
understanding of very early brain development. In addition, these studies have considered 
how factors that disrupt typical developmental trajectories may lead to aberrant 
neurodevelopmental processes, and subsequently impact upon behavioural outcomes. 
Specifically, this exploratory section of the research has been accomplished by studying very 
young individuals with and without a genetic (or familial) risk of autism spectrum disorder 
(ASD).  
 
As the name implies, ASD is a complex neurodevelopmental disorder that encompasses a 
broad spectrum of conditions. Although traditionally conceptualised as a categorical condition, 
this view has recently been challenged, and the disorder is now considered to exist as a 
continuum. Whilst a large proportion of affected individuals are highly dependent upon others, 
many on the spectrum lead much more autonomous lives. Moreover, it has become 
increasingly recognised that the presence of ASD-like traits (for example, deficits in social 
functioning, communication difficulties, and rigid personalities) – often referred to as the 
broader autism phenotype (BAP) (Bolton et al., 1998; Piven et al., 1997) – may also be 
evident in first-degree relatives of individuals with the disorder, and especially in siblings 
(Georgiades et al., 2013; Pisula and Ziegart-Sadowska, 2015). In addition, as many as 70% of 
individuals with ASD suffer from co-occurring difficulties, including intellectual disability, 
attention deficits, motor abnormalities, sleep disruptions, and mood disorders such as anxiety 
and/or depression. This has led some to propose that many of these co-occurring conditions 
may share common risk pathways (Rommelse et al., 2010). 
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Individuals with a familial risk of ASD, by virtue of having an older sibling with a diagnosis of 
the condition, are thus an important group to study, even in the absence of outcome data. Not 
only is this because infant siblings may (or may not) go on to receive an ASD diagnosis, but 
because they can provide important insights into what biological pathways are targeted by risk 
factors. Hence, the studies included in this thesis have sought to detect subtle deviations from 
typical brain development that may be associated with an ASD risk status, while recognising 
that the majority of participants studied will not go on to receive a diagnosis of the core 
disorder (but may display other related difficulties). In addition, potential environmental 
influences that may modulate the effect of risk of ASD on brain biology were also explored.  
 
The introductory chapter of this thesis begins by describing what is currently known about 
normal brain development, as well as how it may be altered by some of the risk factors 
associated with ASD. The next section describes some of the key behavioural milestones that 
a child is expected to reach from 0-2 years, along with the most common departures from 
these targets in individuals who go on to receive an ASD diagnosis. Subsequently, since the 
studies included in this thesis have used magnetic resonance imaging (MRI) to examine the 
neuroanatomy and neurochemistry of very young individuals, the chapter then goes on to 
provide a fundamental background on the principles of MRI, and on the practicalities of 
imaging at fetal, neonatal, and infant timepoints. An overview of ASD is then provided, 
followed by an account of the main findings from brain structural and spectroscopic studies of 
the disorder. The chapter concludes with the main aims and hypotheses of the current thesis. 
 
A note on choice of language:  
The term normal and typical will be used interchangeably in this thesis. However, both terms  
are really quite ambiguous, particularly when used in the context of early brain development. 
The truth is that there is no real boundary or cut-off score for what is defined as typical or 
normal. For instance, there is now evidence indicating that ASD-like traits, aside from being 
present in first-degree relatives of individuals with ASD, are also distributed in a continuum 
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within the general population (Constantino and Todd, 2003; Hoekstra et al., 2007). This is true 
for many other behavioural and psychological traits. Indeed, as our understanding of individual 
differences progresses, we are beginning to appreciate that behaviour should in itself also be 
viewed as a spectrum, with individuals who receive a diagnosis of a disorder considered to lie 
on the more atypical end of the spectrum (Plomin et al., 2016). 
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1.2. Normal brain development 
Human brain development involves a series of complex processes that begin shortly after 
conception and continue throughout adolescence; arguably, throughout one’s lifetime. Both 
genetic and environmental factors mediate brain development to such an extent, that a 
disruption in either system could dramatically compromise neurodevelopmental outcome (for 
review see Roth and Sweatt, 2011; Sale et al., 2014). This introductory section will focus on 
the main events leading up to the formation of the mature human brain, with development 
described in four stages: the pre-embryonic period (encompassing the first 2 gestational 
weeks), the embryonic period (from the 3rd to the 8th gestational week), the fetal period 
(extending through to the end of gestation), and the postnatal period (referring to the 
developmental processes taking place after birth).  
 
1.2.1. Pre-embryonic development 
Conception refers to the process by which the male spermatozoon combines with the female 
oocyte inside the fallopian tube, to fertilise an oocyte and form the zygote – a single-cell 
embryo containing 46 chromosomes, half of which come from the spermatozoon and half from 
the oocyte. As soon as it is formed, the zygote undergoes cleavage, dividing repeatedly whilst 
moving down the fallopian tube to form the morula. With the presence of progesterone, the 
fallopian tube relaxes, allowing the morula to move inside the uterus. Here, the morula 
develops into the blastocyst – a fluid-filled cavity with a collection of cells located at one end. 
Blastocyst implantation follows shortly after, when the outer cells of the blastocyst bind to the 
epithelial cells of the endometrium (the inner layer of the uterus), enabling it to become 
embedded within the uterine wall (Figure 1.1). Then, the embryoblast cells of the blastocyst go 
on to form the embryo, whilst the outer trophoblast cells form the placenta. 
 
Genetic mutations and epigenetic modifications (that is, heritable changes in gene expression 
that occur independent of alterations to the DNA sequence) can play a critical role in the pre-
embryonic period (Zhu, 2009), and potentially affect psychopathology in later life. For 
instance, epigenetic modifications of the paternal spermatozoon, including changes in DNA 
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methylation, have been shown to contribute to an elevated risk of ASD in the offspring 
(Feinberg et al., 2015), and may be associated with advanced paternal age (Flanagan et al., 
2006; Reichenberg et al., 2006). Indeed, infants born to parents but especially fathers of an 
advanced age, are at a higher risk of neurodevelopmental conditions such as ASD (Croen et 
al., 2007; Hultman et al., 2011; Reichenberg et al., 2006). This elevated risk could also be due 
to the increased number of spontaneous (de novo) mutations associated with older 
spermatozoon (Buwe et al., 2005; Crow, 2000; Kong et al., 2012). Hence, it seems that both 
genetic and epigenetic modifications associated with aging, may contribute to an increased 
risk of having offspring with ASD.  
 
Figure 1.1: The pre-embryonic period. 
The pre-embryonic period consists of a series of chronological processes, beginning with 
conception (or fertilisation, as referred to above) and terminating with the implantation of the 
blastocyst. This image was adapted from Dey (2010).  
 
 
1.2.2. Embryonic development 
In humans, the embryonic period extends from the end of the 2nd gestational week (at 
approximately 12 days post-conception), through to the 8th gestational week. The main 
processes involved at this time include gastrulation and neurulation, which together ‘set the 
scene’ for brain development, by establishing the basic structure and organisation of the 
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nervous system. This period is so fundamental to development that a failure in any of its 
processes could result in serious neural defects, or worse, compromise the viability of the 
embryo (Copp and Greene, 2013).  
 
 Gastrulation: the formation of the neural plate 
Human brain development starts in the 3rd gestational week with the differentiation of the 
neural progenitor cells; a process commonly referred to as gastrulation (Figure 1.2). This 
process begins with the epiblast and hypoblast, which together comprise the oval-shaped two-
layered structure that is the embryo. At this point, the embryo is positioned between the two 
major placental sacs: the amniotic sac, located above the embryo (and which will eventually 
surround it), and the yolk sac, positioned below it (Stiles, 2008). The onset of gastrulation is 
defined by the appearance of a slit-like opening in the upper layer of the embryo, referred to 
as the primitive streak. The primitive streak provides the epiblast cells with access to lower 
regions of the embryo, and as the cells migrate towards the streak, they pass through the 
primitive node and receive molecular signals that induce gene expression (Stiles, 2008). As 
they pass through the primitive streak, the epiblast cells are displaced to produce the 
ectoderm, composed of both epidermal ectodermal and neuroectodermal stem cells. Likewise, 
hypoblast cells produce the endoderm, which will eventually give rise to structures of the gut 
and respiratory system. Between these two newly formed layers, the mesoderm develops, 
eventually producing structures such as the muscle, bone, and vasculature. Moreover, whilst 
the epidermal ectodermal cells of the ectoderm go on to produce structures such as the skin 
and sweat glands, the neuroectodermal cells are what give rise to the brain and central 
nervous system. Neuroectodermal cells are also referred to as neural progenitor cells and the 
region of the embryo containing them is the neural plate; hence, gastrulation can be defined 
as the formation of the neural plate. 
 
The differentiation of neural progenitor cells requires complex genetic signalling. In addition to 
the first set of signals sent out, the primitive node generates a second set, which informs the 
neural progenitor cells of their specific regional identity. Neural progenitors formed from the 
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first epidermal cells, for instance, will produce the basic building blocks of the forebrain. 
Conversely, neural progenitors formed from some of the later migrating cells will help to 
produce some of the more caudal structures such as the spinal cord. Thus by the end of 
gastrulation, not only do we have a neural plate with the necessary progenitor cells for future 
development, but we also have a clearly defined spatial organisation of the embryonic 
nervous system, with front-back (anterior-posterior), right-left, and top-bottom (dorsal-ventral) 










Figure 1.2: The process of gastrulation. 
(A) The superior view of the two-layered embryo, formed by (B) the epiblast and hypoblast, is 
shown. During gastrulation, epiblast cells move towards lower regions of the embryo to form 
the ectoderm, whilst the hypoblast cells go on to produce the endoderm. In between the two 
layers, (C) the mesoderm develops. This image was adapted from Marieb and Hoehn (2007). 
 
 
 Neurulation: the formation of the neural tube 
Neurulation comprises of a set of processes that give rise to the first identifiable neural 
structure, the neural tube, from which the central nervous system develops. Neurulation 
begins as soon as gastrulation is complete, with the appearance of two ridges alongside each 
end of the neural plate (Copp et al., 2003). Over the course of several days, the ridges rise, 
converge inward, and fuse to form a hollow tube (Figure 1.3). The fusion of the tube begins 
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from the centre and ends with the closing of the anterior neuropore (at the most rostral end of 
the tube), followed by the posterior neuropore (at the most caudal end). When the process is 
complete, the neural progenitors form a single layer of cells that line the centre of the neural 
tube. The hollow cavity within it develops to become the brain’s ventricular system (Copp et 
al., 2003; O’Rahilly and Müller, 2008).   
 
Figure 1.3: The process of neurulation. 
Neurulation begins with the appearance of two ridges either side of the neural plate. Over the 
course of several days, these ridges rise and converge inwards to produce the neural tube, 
which will later develop into the central nervous system. This image was adapted from Marieb 
and Hoehn (2007). 
 
 
Neural tube defects affect 1 in every 1000 pregnancies and can result in severe congenital 
malformations (Copp and Greene, 2013). Prenatal exposure to anti-epileptic drugs such as 
sodium valproate, which cross the placenta and enter the circulation of the developing 
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embryo, can cause a 20-fold increase in neural tube defects (Alsdorf and Wyszynski, 2005). 
Moreover, exposure to sodium valproate during pregnancy can also contribute to an increased 
risk of neurologic abnormalities and neurodevelopmental disorders, including ASD 
(Christensen et al., 2013; Williams et al., 2001). The mechanism(s) underlying the disruptive 
effects of sodium valproate on neurodevelopment are not fully understood. Potential 
explanations include the induction of oxidative stress and the inhibition of histone deacetylase, 
which can result in epigenetic alterations (for review see Ornoy, 2009). Fortunately, 
supplementation of folic acid during pregnancy appears to prevent some neural tube defects 
(Smithells et al., 1980, 2011), and has also been associated with a reduced risk of ASD 
(Schmidt et al., 2012; Suren et al., 2013). Mechanisms for how folate may impact upon ASD 
risk are not yet known. However, plausible suggestions implicate suppression of oxidative 
stress (Solon et al., 2008), as well as epigenetic alterations involving increases in methylation 
(Pufulete et al., 2005). 
 
 The end of the embryonic period 
After neurulation, during the final period of embryonic development, the shape of the neural 
tube changes dramatically. At first, the anterior end of the tube undergoes expansion and 
folding to form the three primary brain vesicles: the prosencephalon, mesencephalon, and 
rhombocephalon – also known as the embryonic precursors of the forebrain, midbrain, and 
hindbrain, respectively (O’Rahilly and Müller, 2008). From here onwards the mesencephalon 
does not divide further, but the remaining two primary vesicles do. The prosencephalon 
divides into the telencephalon and diencephalon, whilst the rhombocephalon separates into 
the metencephalon and myelencephalon. Hence, by the end of the embryonic period, five 
secondary brain vesicles will have emerged and aligned themselves along the rostral-caudal 
axis of the embryo, establishing the primary organisation of the brain (O’Rahilly and Müller, 
2008; Stiles and Jernigan, 2010). Eventually, the telencephalon will become what we know of 
as the cerebrum, encompassing the cerebral hemispheres and cortex. The embryonic region 
of the diencephalon will form the hypothalamus and thalamus, whilst the mesencephalon will 
develop into the midbrain. In turn, the metencephalon will go on to form the pons and 
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cerebellum, whereas the myelencephalon will become the medulla oblongata, leading on to 
the spinal cord (Figure 1.4).  
 
Figure 1.4: Embryonic brain regions and their equivalent postnatal brain structures. 
As shown in the schematic above, the embryonic brain region of the prosencephalon splits 
into the telencephalon and diencephalon, which will eventually become the cerebrum, 
hypothalamus, and thalamus. The mesencephalon develops, but does not divide, and goes on 
to form the midbrain. Finally, the metencephalon matures into the pons and cerebellum, 
whereas the myelencephalon gives rise to the medulla oblongata, leading on to the spinal 
cord. This image was adapted from Marieb and Hoehn (2007). 
 
 
1.2.3. Prenatal development 
Prenatal (or fetal) development is initiated after the end of the embryonic period. It extends up 
until the end of gestation, culminating at birth, and ideally around forty weeks gestation. 
Although longer gestational periods are more favourable to neural development (Davis et al., 
2011), it is extremely common for births to occur within a range of this age.  
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The main processes of fetal development involve the proliferation, migration, and 
differentiation of neurons (Stiles and Jernigan, 2010). Together, they contribute to dramatic 
changes in brain morphology, from the emergence of cortical and subcortical structures, 
through to the establishment of major neural pathways.  
 
 Neuron proliferation 
Neuron proliferation refers to the production of neurons, of which the human brain has billions. 
The number of neural progenitor cells available at the end of gastrulation, however, is far too 
small to accommodate the expected neuron population size. Therefore, one of the first steps 
in proliferation involves the production of more neural progenitor cells. Fortunately, progenitors 
are mitotic cells that undergo symmetrical cell division, resulting in the generation of two 
identical neural progenitors from just one (Paridaen and Huttner, 2014). With time, this mode 
of division begins to shift into an asymmetrical process, whereby each neural progenitor cell 
produces both one neuron and one neural progenitor (Paridaen and Huttner, 2014; Wodarz 
and Huttner, 2003). In humans, at the peak of proliferation, neurons are produced at a rate of 
250,000 per minute, such that the proliferative process is largely complete by mid-gestation 
(Rakic, 1995).  
 
Neurons are almost exclusively produced in the proliferative region of the ventricular zone, 
located at the centre of the neural tube, in what will later become the region of the lateral 
ventricles. In the brains of individuals with neurodevelopmental disorders, there is often a 
concentration of abnormalities within this region (Cardoso et al., 2009; Olsén et al., 1997). For 
example, infants exposed to the rubella infection during pregnancy, which in itself is a risk 
factor for ASD (Carvill and Marston, 2002; Chess, 1977), are more likely to develop 
abnormalities of the proliferative region, including periventricular leukomalacia, periventricular 
cysts, and dilated perivascular spaces (Rorke and Spiro, 1967; Sugita et al., 1991). In 
addition, some of these abnormalities have been identified in individuals with idiopathic ASD, 
and are associated with some of the core ASD symptoms (Blackmon et al., 2016), suggesting 
that neuron proliferation may carry with it inherent vulnerabilities. 
 36 
 Neuron migration  
Unlike neural progenitors, neurons are post-mitotic cells. Once formed, they are incapable of 
further dividing and instead, they migrate away from the proliferative zones towards the 
developing cortex (Figure 1.5) (for review see Nadarajah and Parnavelas, 2002). The first 
neurons to leave the proliferative zone only need to travel for very short distances and thus 
migrate via somal translocation (Nadarajah et al., 2001). In somal translocation (Figure 1.5A), 
neurons extend their basal processes enabling the nucleus to move through them, such that 
by the end of translocation the nucleus has moved out of the ventricular zone and into the 
cortex.  
 
Later on in development, as the brain becomes larger and the cortex begins to thicken, 
neurons are required to travel away from the ventricular zone for longer distances. Hence, 
radial migration (Figure 1.5B) becomes the primary mode of travel (Nadarajah and 
Parnavelas, 2002). Radial glial guides are a specific type of glial cell, which provide support to 
the neurons and act as the main protagonists in this migratory process (Rakic, 1971, 1972). 
The glial guides are comparable to neurons during somal translocation, in the sense that they 
too extend their basal processes. However, unlike in somal translocation, the nucleus of the 
glia remains within the ventricular zone. The basal processes are what guide the migrating 
neurons, allowing them to move up along the glia and out towards the cortex. Importantly, one 
radial glial is enough to support many migratory neurons (Rakic, 1972).   
 
In the late 1990’s, the proliferative region of the ganglionic eminences, mainly responsible for 
producing interneurons, was identified (Anderson et al., 1997). Alongside this discovery, it was 
found that interneurons migrating away from the ganglionic eminences travel via a different 
mode of migration, known as tangential migration (Anderson et al., 2001; Corbin et al., 2001; 
Marín and Rubenstein, 2001). In tangential migration (Figure 1.5C), neurons are guided by 
signalling pathways along their route (Huang, 2009; Valiente and Marín, 2010). This enables 










Figure 1.5: Modes of neuronal migration. 
During early development, neurons migrate via (A) somal translocation. Later on, as neurons 
travel for longer distances, the primary mode of neuronal migration changes to (B) radial 
migration, with radial glia (in green) supporting neurons (in blue). Interneurons travel via (C) 
tangential migration. This image was adapted from Nadarajah et al., (2003). 
 
 
Once neurons reach their final destination, they begin to organise themselves into the six-
layered structure of the cortex (Figure 1.6). Formation of the cerebral cortex occurs in an 
orderly ‘inside-out’ manner (Angevine and Sidman, 1961), with each layer comprising a 
distinct type of neuron. An exception to this orderly formation occurs at the very start, with the 
earliest set of migrating neurons leaving the ventricular zone to form the preplate (Marin-
Padilla, 1978). The next set of migrating neurons splits the preplate into the marginal zone 
and the subplate; within these two regions, the cortical plate emerges (Marin-Padilla, 1978). 
As soon as the cortical plate is present, the first neurons to arrive there will go on to form the 
deepest layer of the cortex (that is, layer VI), and all subsequent sets of migrating neurons will 
successively form more superficial layers (from layer V to I).  
 
Certain embryonic layers including the marginal zone and the subplate, are transient 
structures, which disappear by the end of the fetal period (Bystron et al., 2008; Kostovic, 
2002). These structures, however, are crucial for normal brain development. The appropriate 
development of the subplate, for instance, is essential for both cortical development and 
synaptogenesis (Ghosh and Shatz, 1993; Kostovic and Rakic, 1990). Specifically, it is the 
            A             B      C 
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concurrent process of cortical plate maturation and subplate dissolution, which signals the 













Figure 1.6: The development of the six-layered cortex. 
As shown in the first panel on the left, the earliest set of migrating neurons leaving the 
ventricular zone form the preplate. With the next set of migrating neurons, the preplate splits 
into the marginal zone and subplate. In between these newly formed layers, the cortical plate 
develops, as illustrated in the middle panel above. The panel on the right displays the six-
layered cortex, formed once the brain is fully mature. Image adapted from Stiles (2008). 
 
 
Altogether, the orderly process of neuronal migration is crucial for the normal development of 
the cortex. Reelin, produced by Cajal-Retzius cells in the marginal zone, is essential to 
migration as it plays an important role in the signalling pathway that helps to position neurons 
in their appropriate cortical layers (Huang, 2009; Pearlman et al., 1998; Rice and Curran, 
2001). As such, mutations in the Reelin gene have resulted in mutant mice with a highly 
disrupted cerebral cortex (Caviness and Sidman, 1973; Goffinet, 1984). In addition, post-
mortem reports have shown lowered levels of Reelin and Reelin mRNA in the brain tissue of 
individuals with ASD (Fatemi et al., 2005). The failure of neurons to migrate towards the 
cortex and/or the over proliferation of neurons in the ventricular zone can result in patches of 
heterotopic grey matter within white matter regions, and these have been identified in a range 
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of neurodevelopmental disorders (for review see Gleeson and Walsh, 2000). For example, in 
a recent post-mortem study examining the brains of 13 ASD participants and 14 age-matched 
controls (aged 4-60 years), subcortical, periventricular, hippocampal, and cerebellar 
heterotopias were detected in the brains of 4 ASD cases, compared to none of the controls 
(Wegiel et al., 2010). Together with evidence of abnormalities in the cortical minicolumn (that 
is, the vertical column encompassing all cortical layers of the brain) (Casanova et al., 2002, 
2006), findings suggest that neuron migration may be disrupted in ASD. 
 
 Neuron differentiation   
Once they have arrived safely at their cortical destinations, neurons then need to become 
integrated into brain networks. This process, largely overseen by neuron differentiation, 
results in the derivation of the distinct neuron types necessary for the different layers of the 
cortex. Early in development, neural progenitor cells are multipotent and thus capable of 
producing any type of neuron. However, with time, progenitors begin to exhibit what is known 
as “fate restriction” – an epigenetic phenomena which limits the types of neurons that can be 
produced (Desai and McConnell, 2000; Frantz and McConnell, 1996; McConnell and 
Kaznowski, 1991), and which ultimately results in the end of differentiation.  
 
Neuron differentiation also oversees the maturation of axonal and dendritic processes, which 
enable neurons to communicate and establish connections (or synapses) with one another. 
The establishment of connections, also known as synaptogenesis, is what facilitates 
information processing in the brain. Importantly, distinct neural pathways are responsible for 
transmitting different types of information. The thalamocortical and corticothalamic pathways, 
for instance, transmit sensorimotor information and are considered by some to be two of the 
most important pathways in the human brain. Guided by subplate neurons, these pathways 
begin to form towards the end of the second trimester and appear complete by the 26th week 
of gestation (Kostović and Jovanov-Milošević, 2006). In neuroimaging studies of ASD, 
however, functional and anatomical abnormalities have been identified in both these pathways 
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(Belmonte et al., 2004; Cheon et al., 2011; Nair et al., 2013, 2015), suggesting that atypical 
connectivity may be an underlying feature of this neurodevelopmental disorder.   
 
 Cortical development 
The human brain begins as a smooth “lissencephalic” structure. However, as it expands, the 
cerebral cortex begins to fold so as to ensure that the brain is able to fit within the spatially 
limited cranium. Cortical folding, or gyrification, occurs in an orderly sequence and like most 
other processes described it follows a rostral-to-caudal developmental course (Rakic, 2006; 
Sur and Rubenstein, 2005). Gradually, this causes the brain to develop into a highly 
convoluted “gyrencephalic” structure, formed by an intricate pattern of gyri (ridges) and sulci 
(grooves).  
 
Although there is some variability in the exact timing of when individual gyri and sulci emerge, 
data stemming from both post-mortem and in vivo MRI are in agreement. The first fold to form 
is the interhemispheric fissure, which refers to the deep groove dividing the two cerebral 
hemispheres. Development of the interhemispheric fissure begins in the rostral region as early 
as the 8th gestational week (Chi et al., 1977), but it is only fully formed by the 22nd week (Garel 
et al., 2001). Other primary sulci begin to form at the 14th week of gestation (GW 14), following 
a sequential pattern which includes the sylvian (GW 14-16), central (GW 20-24), and 
intraparietal (GW 25-26) sulci. By the 26th gestational week most primary sulci will have 
developed and from then on, the secondary sulci (GW 30-35) can begin to emerge (Chi et al., 
1977; Garel et al., 2001). The tertiary sulci follow soon after, but their formation extends well 
into the postnatal period, illustrating the protracted nature of gyrification. 
 
The development of the cerebral cortex is an extremely complex process, with faults in its 
appropriate completion implicated in the emergence of many neurodevelopmental disorders 
(Rubenstein, 2011). In a sulcal mapping study of ASD, for instance, affected children were 
observed to have anatomical abnormalities in the cortical surface (Levitt et al., 2003a). 
Researchers reported an anterior and superior shifting of several, sulci with the greatest 
 41 
deviations from the norm localised to the frontal and temporal regions of the brain. Thus these 
findings indicate that there may be aberrant maturation of these specific brain regions in ASD 
– regions crucial for some of the functions commonly impaired in affected individuals.    
 
1.2.4. Postnatal development 
As already mentioned, brain development is far from complete after birth, continuing for an 
extended period of time during the postnatal period. Neurogenesis, for instance, has been 
shown to persist throughout adulthood (Eriksson et al., 1998) and should therefore be 
considered as a postnatal process too. Most essential in postnatal development, however, is 
the proliferation, migration, and differentiation of glial cells. Having said that, it is important to 
note that these processes actually begin prenatally. As glial progenitors themselves, radial glia 
are particularly vital for early cell formation as well as neuronal migration and positioning, 
existing in large numbers during the postnatal period. Moreover, although often overlooked, 
glial cells play a variety of critical roles in the nervous system. Aside from their function in 
neurodevelopment, they also provide support to the mature nervous system by regulating 
neuronal survival, modulating synaptic function, maintaining homeostasis, and intervening in 
the face of injury (for review see Jessen, 2004).  
 
 Glial proliferation, migration, and differentiation 
Glial progenitor cells proliferate in the ventricular and subventricular zones as well as in the 
region of the ganglionic eminences, with different types of glia produced in different zones 
(Kessaris et al., 2006). Once formed, they migrate outward into the white matter and cortex as 
well as into the striatum and hippocampus, where they begin to differentiate. Glial progenitors 
can differentiate into a myriad of different classes of glia. The two main types of glia to 
differentiate at this time include astrocytes (which provide support to the neurons, modulate 
neuronal activity at the synapse, and respond to injury) and oligodendrocytes (which mainly 
produce myelin); together, they are commonly referred to as macroglia. Microglia (not to be 
confused with macroglia) are yet another type of glial cell, which amongst other things support 
immune function, modulate synaptic pruning, and help to regulate neuronal activity. Unlike 
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macroglia, microglia are formed from circulating monocytes, themselves derived from 
haematopoietic stem cells in the bone marrow. These monocytes travel past the blood-brain 
barrier into the brain, where they begin to differentiate into microglia during postnatal life 
(Chan et al., 2007). Unlike neural progenitors, glial progenitors are capable of continuing to 
proliferate whilst they migrate (Cayre et al., 2009). They therefore remain widespread 
throughout the brain for an indefinite period of time, so that they can differentiate into the 
required glial cell whenever needed (for instance, in response to injury). 
 
 Myelination 
Oligodendrocyte progenitors differentiate by extending their processes and increasing their 
myelin expression, so that eventually they can begin to ensheath the axons of neighbouring 
neurons (Back et al., 2002; Nave and Werner, 2014). This procedure, commonly referred to 
as myelination, dramatically improves the efficiency of information transmission in the brain by 
working to accelerate axonal conduction (Jakovcevski and Zecevic, 2005). Myelin can also 
protect axons from damage and is thus of crucial importance to the developing brain. In 
addition, oligodendrocytes can synthesise a variety of trophic factors that contribute to both 
axonal integrity and neuronal survival. The interaction between oligodendrocytes and neurons 
has also been shown to influence the size and diameter of axons, and hence, support the 
functional maturation of developing pathways (McTigue and Tripathi, 2008). 
 
In the typically developing brain, myelination is initiated around the second trimester of 
pregnancy (Brody et al., 1987; Kinney et al., 1994). Between the 21st and 25th gestational 
week, for instance, myelination is established in the medial longitudinal fasciculus and the 
inferior cerebellar peduncles (Jakovcevski and Zecevic, 2005). By the 28th week of gestation, 
myelin can be observed in the inferior colliculi, posterior brainstem, and ventrolateral nuclei of 
the thalamus. Later on, by 36 weeks gestation, myelination is evident in the corona radiata, 
posterior limb of the internal capsule, and corticospinal tracts (Counsell et al., 2002). Other 
brain regions such as the cerebral hemispheres are only myelinated after birth, which may 
explain why myelination is largely considered as a postnatal process.  
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In a recent neuroimaging study aimed at quantifying the regional progression of myelin during 
postnatal life (Deoni et al., 2011), the first evidence of myelination was identified in the region 
of the cerebellum and pons. This then progressed from the splenium of the corpus callosum 
and the optic radiations (by 3-4 months of postnatal life) into the occipital and parietal lobes 
(by 4-6 months), eventually advancing towards the frontal and temporal lobes (by 6-8 
months). Evidence from post-mortem tissue suggests that the peak production of myelin 
terminates at approximately 8 months of age, with adult-like myelination evident by 2 years 
(Brody et al., 1987). It is important to note, however, that these are merely approximations and 
that different studies have reported subtle variations in these timings. 
 
Furthermore, it is now known that an adequate diet, rich in protein and micronutrients, is 
crucial for appropriate myelination. A lack of vitamin B12, for instance, may cause disruptions 
to myelination, resulting in white matter abnormalities and errors in neural connectivity (Black, 
2008). In line with this, a recent post-mortem study showed that children with ASD (aged 4-9 
years) had a 3-fold reduction in cortical B12 levels, when compared to age-matched controls, 
and researchers proposed that this deficit in B12 could contribute to impaired myelination in the 
disorder (Zhang et al., 2016).  
 
1.2.5. Regressive events in the prenatal and postnatal periods 
Brain development involves a dramatic overproduction of cells and synapses, followed by the 
partial removal of these via two major regressive events: cell death (or apoptosis) and 
synaptic pruning. These non-pathological processes are all necessary for normal brain 
maturation, but they each have a specified timing. For example, while neuronal apoptosis 
mainly occurs in the prenatal period, both glial cell death and synaptic pruning are typically 
considered as postnatal processes.  
 
 Apoptosis: programmed cell death  
Apoptosis is responsible for the extensive loss of neurons that occurs towards the end of 
gestation (Rakic and Zecevic, 2000), resulting in maximal death rates of approximately 70% in 
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some cortical brain regions (Rabinowicz et al., 1996). The process of apoptosis involves a 
series of physiological events, which result in the breakdown of the nuclear chromatin of a 
cell, followed by its disintegration. The death of glial cell populations is also regulated by 
apoptosis, but as previously mentioned, this occurs a little later in the developmental time 
course, coinciding with the later process of glial proliferation.   
 
The apoptotic cascade is regulated by a series of genes, which in turn can be influenced by 
various intrinsic and extrinsic factors. Some factors (such as oxidative stress) contribute to a 
more rapid cell death, whilst others (for example neurotrophic factors) protect the cell against 
apoptosis. According to the neurotrophic hypothesis, during development, neurons that have 
already established effective connections are able to obtain more neurotrophic factor and 
thus, are more likely to survive (Oppenheim, 1989). Prenatal apoptosis is therefore necessary 
for maintaining the most effective connections and hence, for strengthening the most 
functionally active neural pathways. However, apoptosis also plays a critical role in the 
elimination of cell populations that are no longer necessary (as is the case of neural progenitor 
cells), or that are no longer involved in the development of brain pathways. Finally, neuronal 
death can also be used to correct errors that may have occurred during earlier processes of 
cell proliferation and migration (Buss and Oppenheim, 2004). Apoptosis is therefore essential 
for the appropriate development of the brain, contributing to the strengthening of neural 
connections. 
 
 Synaptic pruning 
Synaptogenesis (described in section 1.2.3.3 on page 39) results in an overproduction of 
connections, such that by the end of the first postnatal year, neuronal connectivity has 
reached a plateau nearly twice as high as that evidenced in the adult brain (Innocenti and 
Price, 2005). During childhood and adolescence, this exuberant connectivity slowly declines 
with the systematic elimination (or pruning) of up to 50% of synapses. The timing of synaptic 
pruning is largely dependent on that of synaptogenesis, and the two processes occur at 
different times in distinct brain regions (Huttenlocher, 1979; Huttenlocher and Dabholkar, 
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1997). For example, even though synaptogenesis in the primary visual cortex reaches its peak 
at around 6 months of age, neural connectivity in the visual cortex is the last to mature due to 
a more prolonged period of synaptic pruning in this region (Figure 1.7).  
 
Figure 1.7: Synaptic pruning. 
Synaptogenesis results in an overproduction of connections, with mean synaptic density 
peaking around the first year of life. However, during childhood and adolescence, this 
exuberant connectivity declines as synaptic pruning eliminates up to 50% of synapses. As 
shown in the graph above, adapted from Huttenlocher and Dabholkar (1997), different cortical 
regions undergo synaptogenesis and synaptic pruning at distinct times.   
 
 
Alongside changes in the structure and organisation of the developing cortex, synaptic 
pruning results in the inherent fine-tuning and maturation of neuronal circuits (Tau and 
Peterson, 2010). Ultimately, these processes improve the efficiency of neurotransmission, 
critical for cognitive function. It is therefore not surprising that atypical patterns of connectivity, 
which can stem from delayed and/or inappropriate pruning, have recently been associated 
with a series of cognitive and neurodevelopmental disorders, like ASD (Geschwind and Levitt, 
2007; Tau and Peterson, 2010). Evidence from genetic, animal, and neuroimaging work has 
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supported this and in turn, sparked interest in the notion that ASD may be a developmental 
disconnection syndrome, with high-order association areas of the brain partially disconnected 
during development (Geschwind and Levitt, 2007).  
 
1.2.6. Plasticity and the role of experience in brain development 
It should be clear by now that brain development follows a co-ordinated sequence of events; 
but contrary to what was originally thought, this process is vulnerable to change via the 
influence of extrinsic environmental factors (for review see Sale et al., 2014). For a continued 
maturation, for instance, the human brain is reliant on environmental inputs from its 
surroundings. The term “experience-expectant” development refers to exactly this – the notion 
that experience can shape brain development (Greenough et al., 1987). However, this is only 
possible because the developing brain is a plastic organ, receptive and malleable to incoming 
experiences which are then manifested biologically in a variety of forms, from cell proliferation, 
migration and integration, to axonal remodelling and synaptogenesis. Importantly, the 
possibility for neuroplasticity is heightened during sensitive periods of prenatal and postnatal 
life, but with time the brain becomes considerably less plastic (Ismail et al., 2016).  
 
Early infant experiences, therefore, have the exceptional ability to either weaken or strengthen 
any given synapse. In doing so, they can help determine whether or not a connection is to 
become part of the permanent neural network, and hence, whether it maintains its 
functionality (as discussed in section 1.2.5.1 on page 43). Typical and appropriate 
experiences will help to shape major pathways, allowing for adequate patterns of cortical 
organisation to emerge. However, for this to occur, inputs via all major sensory systems 
(visual, auditory, somatic sensory, gustatory, olfactory, and vestibular) are required. If an input 
is lacking, certain brain regions may develop in an abnormal manner (Greenough et al., 1987).   
 
 Parent-infant interactions 
Young infants mainly experience the early environment through interaction with their primary 
caregiver. Hence, parent-infant interactions are critical for child development, as they provide 
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an important source of sensory experience (Belsky and De Haan, 2011; Cabrera et al., 2011; 
Lugo-Gil and Tamis-LeMonda, 2008). Infants exposed to sensitive and responsive early care, 
for instance, will tend to manifest optimal brain, behavioural, and cognitive outcomes (Cabrera 
et al., 2011; Fleming et al., 1999; Lugo-Gil and Tamis-LeMonda, 2008). In contrast, infants 
exposed to insensitive rearing are at an increased risk of developing psychopathology in later 
life (Murray et al., 2010). Although the biological mechanisms mediating these associations 
are not yet fully understood, elevated levels of stress hormones have been identified in both 
children and adults who experienced early life adversity, such as parental loss and/or poor 
maternal care (Luecken, 1998; Lupien et al., 2011; Nicolson, 2004). It has also been proposed 
that elevations in stress hormones are likely to activate the hypothalamic-pituitary-adrenal 
(HPA) system (Atkinson et al., 2013), commonly referred to as the stress system. 
Consequently, this can result in inhibition of neurogenesis, acceleration of apoptosis, altered 
synaptic pruning (Teicher et al., 2006; Tupler and De Bellis, 2006), and perhaps also aberrant 
connectivity (Sarkar et al., 2014), leading to a disruption in normal brain development. Having 
said that, it is imperative that we do not disregard the importance of the normal temporary 
increases in stress hormones. These temporary increases play a protective role in the 
developing brain, and are considered essential for survival. It is only when stress hormones 
reach excessively high levels, or individuals are exposed to them for prolonged periods of 
time, that they can inflict harmful and chronic effects on the brain and other developing organs 
(Shonkoff et al., 2012).  
 
All things considered, one can be sure that the innate plasticity of the developing brain confers 
great survival value, particularly when considering that positive environmental experiences 
can work advantageously to influence brain maturation and cognitive development. However, 
neuroplasticity becomes increasingly more important when we begin to think of what might 
happen when an infant is exposed to adverse environmental influences. Couple that with a 
genetic susceptibility, and we have an infant that is vulnerable to a deviation from the normal 
developmental track.    
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1.2.7. Metabolic development in the prenatal and postnatal periods 
All the major maturational processes described thus far are thought to be accompanied by 
metabolic changes in the brain (Robertson and Cox, 2002). Preliminary evidence for this 
comes from studies using proton magnetic resonance spectroscopy (1HMRS). This in vivo 
technique provides a non-invasive method for characterising the cellular biochemistry 
underlying processes such as proliferation, differentiation, migration, and myelination, but also 
cellular energetics, membrane turnover, and neuronal function. In addition, changes in brain 
metabolite concentrations often precede structural brain abnormalities (Fayed et al., 2006). 
1HMRS may thus be a useful tool for identifying early atypical brain features before they can 
be visualised on structural MRI. However, since brain metabolites are both age- and region-
dependent (Huppi et al., 1995; Pouwels et al., 1999), understanding how the concentrations of 
different metabolites change during typical development is a crucial first step, prior to 
exploring the metabolic profile of atypical development. For instance, it is evident even upon 
brief inspection that there are vast differences between typical brain spectra acquired at birth 




Figure 1.8: Differences in typical brain spectra acquired at birth and in adulthood. 
These spectra, sampled from the parieto-occipital cortex, clearly show the difference in the 
metabolic peaks present at (A) birth and in (B) adulthood. It is evident, for instance, that whilst 
N-acetylaspartate increases throughout development, choline decreases. Image adapted from 
Kreis et al., (1993). Abbreviations: Ins = Myo-inositol; Cho = Choline; Cr = Creatine; Glx = 




Although 1HMRS has been widely used in both paediatric and adult settings for some time, 
studies of fetal 1HMRS have only begun to emerge in the last fifteen years. The current 
consensus is that metabolic development begins in the fetal period and continues until around 
the third year of postnatal life. At this point, concentrations stabilise to reach adult levels 
(Figure 1.9), indirectly signalling successful maturation of the human brain (for review see 
Bertholdo et al., 2013; Dezortova and Hajek, 2008; Story et al., 2011).  
 
In typical development, N-acetylaspartate (NAA) can be detected in vivo as early as 18 weeks 
gestation (Evangelou et al., 2016). From there on the NAA signal increases with age 
throughout pregnancy and postnatal life, until it becomes the most dominant spectroscopic 
peak at about 2 years of age (Blüml et al., 2013; Degnan et al., 2014; Evangelou et al., 2016; 
Girard et al., 2006a, 2006b; Heerschap et al., 2003; Kok et al., 2001, 2002; Ross and Bluml, 
2001). In contrast, both myo-inositol and choline dominate the brain spectrum at short echo 
times from 22-28 weeks gestation (Girard et al., 2006a), but decrease with age during the 
prenatal and postnatal periods (Blüml et al., 2013; Cady et al., 1996; Degnan et al., 2014; 
Girard et al., 2006a, 2006b; Kimura et al., 1995; van der Knaap et al., 1990; Kok et al., 2002; 
Kreis et al., 1993; Pouwels et al., 1999; Story et al., 2013).  
 
Until recently, creatine was thought to remain relatively stable throughout development, such 
that it became common practice to use creatine as a reference for calculating other metabolite 
ratios (Bertholdo et al., 2013; Brown et al., 2013; Kousi et al., 2013; Ross and Bluml, 2001). 
However, studies have now begun to report regional increases in creatine levels over the first 
2 years of life, as well as immediately before birth (Blüml et al., 2013; Degnan et al., 2014; 
Evangelou et al., 2016; Girard et al., 2006a; Huppi et al., 1995; Kreis et al., 1993, 2002). 
Differences amongst clinical and control populations have also started to emerge (Suzuki et 
al., 2010). Consequently, this has led to the use of creatine as a reference metabolite being 













Figure 1.9: A representation of how metabolite concentrations vary with age. 
Although the most dynamic changes in brain biochemistry take place immediately before and 
after birth, metabolite concentrations only begin to stabilise at around three years of age. For 
example, while NAA increases in postnatal life, both myo-inositol and choline are found to 
decrease. In addition, recent evidence suggests that creatine increases over the first 2 
postnatal years. This image was adapted from Dezortova and Hajek (2008). Abbreviations: 
NAA = N-acetylaspartate; Cr = Creatine; Cho = Choline; Ins = Myo-inositol. 
 
 
Also unclear are the maturational changes that take place in glutamate and glutamine, 
commonly referred to as Glx. According to a prenatal report, Glx is clearly visible in vivo by 24 
weeks gestation (Girard et al., 2006a), but no major changes in this metabolite have been 
observed with increasing gestational age (Girard et al., 2006a, 2006b). In postnatal studies, 
the majority of evidence suggests that brain maturation is accompanied by increases in Glx or 
glutamate (Blüml et al., 2013; Degnan et al., 2014; Kornhuber et al., 1993; Kreis et al., 2002). 
However, there is at least one report suggesting that Glx does not vary with postnatal age 
(Kreis et al., 1993). Thus, our understanding of how this metabolite changes with age remains 
inconsistent, especially with regards to its prenatal development. Nonetheless, glutamate is 
crucial for a variety of neurodevelopmental processes and so, understanding what happens to 
its concentration during these critical periods is of utmost importance. 
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 N-acetylaspartate (NAA) 
NAA is an essential amino acid found exclusively in the central and peripheral nervous 
system. The NAA peak is detected at 2.0 ppm on a 1HMRS spectrum and is comprised of both 
NAA and N-acetylaspartylglutamate. In the typical brain, NAA is synthesised by L-aspartate N-
acetyltransferase in neural mitochondria. It then diffuses along axons and is transferred to 
oligodendrocytes, where the deacetylation of NAA by aspartoacylase can take place 
(Ariyannur et al., 2008; Moffett et al., 2007; Patel and Clark, 1979). Although its exact function 
remains unclear, NAA is important for both the development and maintenance of the central 
nervous system. It is thought to be involved in processes such as migration, synaptogenesis, 
myelination, energy regulation, cellular signalling, mitochondrial function, protein synthesis, 
and the maintenance of neuronal integrity (Baslow, 2000; Coyle, 1997; Moffett et al., 2007). 
 
Up until recently, NAA was thought to be predominantly present in neurons and therefore it 
was mainly considered as a neuronal marker (Demougeot et al., 2001; Moffett and 
Namboodiri, 2006; Simmons et al., 1991). However, a recent study reported that aside from 
being present in neuronal cell bodies, NAA is also present in high concentrations within 
oligodendrocytes (Nordengen et al., 2015). This suggests that NAA may be a marker for both 
neurons and oligodendrocytes. The increase in NAA evident from prenatal to late postnatal life 
is thus likely to reflect neural maturation, as well as oligodendrocyte proliferation and 
differentiation (Bhakoo and Pearce, 2000).  
 
In the typically developed brain, NAA is present in high concentrations only in ‘normal’ 
neurons, axons, and oligodendrocytes, such that irregular levels are a good indicator of an 
abnormality. For instance, neonates suffering from hypoxic-ischemic encephalopathy (a type 
of brain injury caused by a reduction in the supply of oxygen to the brain), often show low 
levels of NAA (Barkovich et al., 1999). On the contrary, in Canavan’s disease, aspartoacylase 
deficiency leads to an abnormal accumulation of NAA in the brain, which results in myelin 
degeneration and a series of symptoms including loss of motor skills, abnormal muscle tone, 
and seizures (Janson et al., 2006).  
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 Creatine (Cr) 
In 1HMRS, the Cr peak is detected at 3.0 ppm and reflects both Cr and phosphocreatine. 
Synthesised in the liver and transported to the brain, these molecules are involved in the 
cellular energy exchange between adenosine triphosphate and adenosine diphosphate. 
Hence, Cr plays an essential role in the energy metabolism and equilibrium of cells, and is 
present in both neurons and glia (Bertholdo et al., 2013; Rae, 2014; Ross and Bluml, 2001; 
Urenjak et al., 1992). For instance, at birth, high levels of Cr can be found in the basal ganglia 
and thalamus; most likely because the metabolite is required for energy production during 
myelination of both these regions (Brighina et al., 2009; Huppi et al., 1995).  
 
 Choline (Cho) 
Cho is a complex peak comprised of several Cho-containing compounds, including free Cho, 
phosphorylcholine, and glycerophosphorylcholine (Govindaraju et al., 2000; Rae, 2014). The 
Cho peak is evident at 3.2 ppm in a 1HMRS spectrum, but it is representative of only a small 
percentage of the Cho present in brain tissue. This is because the majority of the metabolite is 
incorporated in substances such as myelin, undetectable using 1HMRS. Cho-containing 
compounds are intermediates in the process of phospholipid metabolism. They are therefore 
considered essential components of cell membranes, used as markers for cell membrane 
formation, turnover, density, and integrity (Nelson, 2003; Sibtain et al., 2007; Soares and Law, 
2009). In addition, Cho-containing compounds have been implicated in the process of 
myelination, which explains why Cho is predominantly found in the white matter (Bertholdo et 
al., 2013; Blüml et al., 1999; Pouwels and Frahm, 1998). It also explains why this metabolite is 
most prominent in the fetal spectrum and why, in typical brain development, progressive 
myelination results in the concentration of Cho decreasing with age (Girard et al., 2006b; Kok 
et al., 2002; Story et al., 2011). Once it has decreased, the Cho peak reaches a definite 
plateau, but only after 2 years of age when myelination is assumed to be largely complete 




 Myo-inositol (Ins) 
Ins is a naturally occurring pentose sugar and an essential constituent of all living cells, both 
mature and immature. The metabolite is found in high concentrations throughout the central 
nervous system and can be reliably visualised using 1HMRS at short echo times, with 
resonance at 3.6 ppm. Although primarily synthesised in glial cells and considered as an 
important glial marker (Brand et al., 1993; Kousi et al., 2013; Ross and Bluml, 2001), high 
concentrations of Ins have also been identified in neuronal populations (Novak et al., 1999). 
As a glial marker, increased levels of Ins are indicative of enhanced glial proliferation and/or 
augmented glial cell size, which can be suggestive of an inflammatory response (van der 
Graaf, 2010; Soares and Law, 2009). In addition, Ins plays an important part in the regulation 
of cell growth, neuronal plasticity, and the maintenance of osmolyte homeostasis (Fisher et 
al., 2002; Ross and Bluml, 2001). It is also a main product of myelin degradation, which 
explains why altered levels of Ins are commonly reported in patients with degenerative and 
demyelinating conditions (Lin et al., 2005; Wattjes et al., 2008).   
 
 Glutamate and glutamine (Glx)  
In 1HMRS, glutamate and glutamine resonate as a composite peak between 2.1 and 2.5 ppm. 
Given their similar chemical structures, it is not always possible to differentiate between the 
two metabolites. As a result, they are often measured together and referred to as Glx. 
Glutamate is the most abundant source of excitatory transmission in the nervous system and 
together with glutamine, it forms the important glutamate-glutamine neurotransmitter cycle. In 
this cycle, glutamate (mainly stored in neurons) is released into the synaptic cleft during 
neurotransmission. It is then transported out of the cleft by surrounding glia in order to be 
converted into glutamine. In turn, glutamine (mainly stored in glia) is released and taken up by 
neurons, where it is hydrolysed back to glutamate (Bak et al., 2006). Given that high levels of 
extracellular glutamate are considered to be excitotoxic, not only is this cycle critical for 
normal brain function, it also provides protection against excitotoxicity. Aside from its 
involvement in the redox cycle (van der Graaf, 2010; Soares and Law, 2009), glutamate also 
plays a critical role in a variety of neurodevelopmental processes, including the proliferation 
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and differentiation of oligodendrocytes, synaptogenesis, neural migration, plasticity, and 
cortical development (Gallo and Ghiani, 2000; Huttenlocher et al., 1982; Yuan et al., 1998). 
 
 γ-aminobutyric acid (GABA) 
The measurement of GABA using 1HMRS is technically challenging. Nonetheless, through 
pulse-editing sequences such as MEGA-PRESS, the metabolite can be identified at 1.9 ppm 
in a 1HMRS spectrum (Mullins et al., 2014). GABA will not, however, be examined in this 
thesis, but it is an important metabolite to consider when studying early neurodevelopment.  
 
GABA is synthesised from glutamate via the rate limiting enzyme glutamate decarboxylase 
(Bak et al., 2006). It is also the major inhibitory transmitter of the adult nervous system and 
hence, partly responsible for mediating the excitatory activity of glutamate. In adulthood, the 
inhibitory role of GABA is thought to be involved in both the maintenance and regulation of 
cognition, sleep, motor control, and anxiety (Rae, 2014). However, GABA is not always 
inhibitory; in early infancy it is excitatory. In brief, there is a developmental switch in the 
molecular machinery controlling the intracellular concentration of chloride which changes the 
functional role of GABA from excitatory to inhibitory (Ben-Ari, 2002). This switch is critical for 
normal brain development as it plays an important role in synaptic tuning and neuronal wiring, 
helping to establish appropriate neural connectivity. Thus, it is not surprising that irregularities 
in this developmental switch have been recently implicated in the manifestation of early 
atypical behaviours, as well as in neurodevelopmental disorders such as ASD (Ben-Ari, 2015; 














1.3. Key behavioural milestones 
As highlighted in the previous section, the brain undergoes tremendous development from the 
early prenatal to the late postnatal period. Similarly, the first few years of life are marked by an 
astonishing increase in the amount and variety of skills that a child acquires. These skills tend 
to develop across specific age ranges, and are known as ‘milestones’. Many individuals who 
go on to develop ASD or other neurodevelopmental disorders have delays in reaching specific 
behavioural milestones. Since ASD is a behaviourally defined condition, it is critical that we 
understand what the first observable indicators of future ASD may be. This introductory 
section will, therefore, focus on some of the key behavioural milestones that a child is 
expected to reach from 0-2 years, accompanied by a description of the most common 
departures from these targets reported in individuals who go on to receive an ASD diagnosis.  
 
1.3.1. Birth 
As soon as they are born, infants begin to interact socially, exhibiting a number of skills that 
facilitate engagement with others (Klin et al., 2003). For example, within the first few hours of 
life, newborn infants give preferential attention to people, preferring human faces over shapes 
and human voices over silence (Sheridan, 2008). They also prefer faces with eyes open (Batki 
et al., 2000), and favour their own mother’s face and voice to that of a stranger’s (Bushnell, 
2001; Johnson et al., 1991). In addition, neonates are able to distinguish between a directed 
gaze and an averted gaze, orienting towards and fixating on a directed gaze more frequently 
and for longer periods of time (Farroni et al., 2002). Aside from their ability to engage in eye 
contact, newborn infants display spontaneous and imitative facial gestures, which helps them 
establish an interaction with their parents and/or carers within just a few days of birth 
(Sheridan, 2008). At this time, infants can respond to the emotional cues of others, an ability 
exemplified by ‘contagious’ crying (Geangu et al., 2010), and they are also able to produce 





1.3.2. Infancy: 1 to 6 months 
One of the ways in which typically developing infants begin to respond to social cues in their 
environment is by smiling. Usually, social smiling is manifested over the first 2 months of life 
(Emde and Harmon, 1972), and is accompanied by gaze following, which involves orienting 
attention in response to another person’s shift in gaze (Farroni et al., 2004). At this age, 
infants also begin to produce non-crying noises, such as cooing and gurgling sounds, and by 
as early as 2 months, some infants may begin to make vowel sounds, like “ah-ah” or “ooh-
ooh” (Oller, 1978). Skill co-ordination becomes noticeable at around 3 months, when 
vocalizations become integrated with smiles, and eye contact becomes integrated with hand 
gestures. A little later on, by 6 months of age, infants are able to turn their bodies to the 
source of a sound, including that of a familiar voice across the room (Sheridan, 2008).  
 
During this period of early infancy, typically developing infants begin to display a range of 
gross motor skills. At 1 month of age, infants tend to make jerky and uncontrolled movements 
with their arms and legs. Their hands are mostly kept closed with their thumbs turned in, but 
occasionally, infants will open their hands in order to grasp an adult’s finger (Sheridan, 2008). 
By 3 months of age, the hands are more loosely open, and the body movements are generally 
less jerky and more continuous. When lying on their front in the prone position, infants are 
able to lift their head and upper chest, and they are also able to keep their head erect and 
steady for several seconds at a time. When pulled to sit, at around 4 months of age, infants 
can typically keep their head in line with their body, and by 6 months, head lag is very 
uncommon in typically developing infants (Bly, 1994). Infants also begin to roll over from front 
to back and back to front (Bly, 1994), and as their arm and hand muscles develop, they begin 
to use their hands in order to reach for and grasp objects.  
 
During this period of postnatal life, most of the infants who develop ASD are progressing in 
much the same way as their typically developing peers. Studies comparing high-risk and low-
risk infants, for instance, found no significant differences in the behaviours of each group at 6 
months of age; infants who were later diagnosed with ASD showing typical engagement in 
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social interactions with others, manifested by normal rates of directed gaze, social smiling, 
and vocalization (Ozonoff et al., 2010; Rozga et al., 2011; Zwaigenbaum et al., 2005). There 
are however exceptions, and in a study conducted by Zwaigenbaum et al. (2005), some of the 
infants who later developed ASD were described as being more ‘passive’ than typically 
developing infants, with a marked decrease in their levels of attention and responsiveness to 
others. In a more recent study, similar findings were reported, and 6-month-old infants later 
diagnosed with ASD could be differentiated from age-matched controls by a diminished ability 
to attend spontaneously to social scenes and human faces (Chawarska et al., 2013). This, 
however, is not a consistently reported finding, as others have not identified a significant 
association between an ASD diagnosis and a 6-month-old’s ability to orient or visually attend 
to a face (Elsabbagh et al., 2013a; Ozonoff et al., 2010). In addition, infant siblings who go on 
to develop ASD have been observed to produce significantly fewer vocalizations, including 
fewer cooing, laughing, and imitative sounds, as compared to their typically developing peers 
(Paul et al., 2011). Others have also reported that these infant siblings have limited motor 
control (Bryson et al., 2007), including a more frequent inability to keep their head in line with 
their body by 6 months of age (Flanagan et al., 2012). Although delays in reaching gross 
motor milestones are considered as an important warning sign for a range of 
neurodevelopmental disorders, including ASD, why these motor delays occur and whether 
they cause subsequent problems, is not fully understood.   
 
To summarize, there are already some subtleties in the behaviours of 6-month-old infants who 
go on to develop ASD, as compared to those who do not. However, it is only after 6 months of 
age, that the difference between these groups of infants becomes increasingly noticeable. 
Over the next few months, while typically developing individuals gradually become more social 
and creative, those who are later diagnosed with ASD may acquire socio-communicative skills 
at a rate slower than the typical rate, or in some instances, demonstrate a general loss of 




1.3.3. Infancy: 6 to 12 months 
By 9 months of age, typically developing infants have become very visually attentive to their  
environment, including to the people, objects, and activities around them (Sheridan, 2008). 
They are also able to respond to their name (Fenson et al., 1993) and can recognise the 
meaning of a few familiar words, such as “no” and “bye-bye” (Bergelson and Swingley, 2012). 
At this age, infants enjoy participating in vocal play; they begin to vocalize more deliberately 
with others and to babble loudly and repetitively using strings of syllables, like “adaba” and 
“agaga” (Sheridan, 2008). They also enjoy clapping their hands, and show interest in taking 
part in social games, like peek-a-boo (Hodapp et al., 1984).  
 
As they reach 12 months of age, typically developing infants can produce most vowels and 
many consonants, and are babbling more often and loudly than before (Sheridan, 2008). They 
are now also able to recognise familiar people from a distance, as well as capable of locating 
sounds that originate from various directions. By the time of their first birthday, infants can 
follow the gaze of others (Corkum and Moore, 1998; Gredebäck et al., 2008; Senju et al., 
2008) as well as alternate the direction of their own gaze between a person and an object, for 
instance, in order to initiate episodes of joint attention (Carpenter et al., 1998). Similarly, to 
elicit attention and initiate social interaction, infants begin to improve their skill co-ordination 
and to use a greater variety of gestures. For instance, it is very common for 12-month-old 
infants to point with their index figure at objects of interest, while looking back for a reaction 
from an adult, hoping to engage in shared attention (Bates and Dick, 2002).  
 
Alongside the acquisition of fine motor skills, including the ability to grasp objects with their 
thumb and index finger, the development of gross motor skills continues. For example, at 
around 7-9 months of age, the majority of typically developing infants are crawling, and by the 
age of 12 months, they are able to walk with one or both hands held, and perhaps even 
entirely unassisted. In contrast, infants later diagnosed with ASD may not have the same 
strengths and co-ordination as their typically developing peers, and so can have a delayed 
onset of walking (Iverson and Wozniak, 2007). 
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Other studies have identified additional patterns of delay, with many of the infants who later 
receive an ASD diagnosis presenting with very specific atypical behaviours by the age of 12 
months (Ozonoff et al., 2010; Zwaigenbaum et al., 2005). Deficits in social and visual 
attention, for instance, become apparent around the end of the first year of life, with infants 
having atypical eye contact (Klin et al., 2003; Ozonoff et al., 2010), including a decline in gaze 
and visual tracking (Ozonoff et al., 2010), as well as a delay in the ability to disengage visual 
attention (Elsabbagh et al., 2013b; Zwaigenbaum et al., 2005). Others have reported a poor 
co-ordination of point and gaze (Landa et al., 2007), fewer attempts to show and point (Rozga 
et al., 2011), as well as a general lack of response and interest in interacting with others, 
including a reduced frequency of looking at faces (Gillberg et al., 1990; Hoshino et al., 1987).  
 
Overall, children with ASD tend to engage less in activities requiring joint attention, as 
compared to their typically developing peers (Charman, 2003; Chawarska et al., 2003). The 
ability to engage in joint attention is considered to play a critical role in the development of 
socio-communicative skills (Mundy et al., 1986; Tomasello et al., 2005), and therefore, it is 
possible that abnormalities in joint attention may lead to other difficulties in social cognition 
and language. As an example, 12-month-old infants who later receive an ASD diagnosis 
already have abnormalities in socio-communicative behaviours, including fewer directed 
vocalizations, gestures, social smiles (Landa et al., 2007; Ozonoff et al., 2010; Zwaigenbaum 
et al., 2005), and deficits in initiation and response to social interaction, such as a failure to 
respond to when their name is called (Feldman et al., 2012; Zwaigenbaum et al., 2005). A 
decreased expression of positive affect is also evident by the age of 1, and tends to be 
accompanied by extreme temperaments, ranging from alarming passivity to marked irritability 
(Gillberg et al., 1990; Hoshino et al., 1987). Finally, 12-month-old infants who later develop 
ASD are usually intensely interested in non-social stimuli, fixating on objects and playing with 
them in a stereotyped sensory-oriented manner (Zwaigenbaum et al., 2005). There is thus 
growing evidence to suggest that many of the infants who will eventually be diagnosed with 
ASD, have already started to appear ‘withdrawn’ by the age of 1. 
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1.3.4. Toddlerhood: 12 to 24 months 
This pattern of social atypicality withdrawal amongst high-risk infants who develop ASD 
becomes increasingly more evident with age, particularly as typically developing infants begin 
to show a growing interest in social activities. From the age of 15 months, most toddlers will 
engage in functional play, by pushing a toy car and pretending to drink from an empty cup 
(Sheridan, 2008). A little later at 18 months of age, infants will enjoy simple picture books in 
the company of their parents, and by 24 months, they will spontaneously engage in role-play, 
make-believe, and pretend play. A toddler of similar age who goes on to develop ASD, is 
much less likely to engage in this type of imaginative play, and instead, may prefer to play in a 
more self-stimulatory way. It is not uncommon at this age, for example, for high-risk infants 
who develop ASD to continue fixating on toys, consequently displaying fewer functional and 
more non-functional repetitive behaviours (Christensen et al., 2010; Zwaigenbaum et al., 
2005). 
 
Throughout toddlerhood, infants become more mobile and begin to enjoy climbing onto 
furniture, walking upstairs, and running around unassisted (Sheridan, 2008). The range of 
behaviours that a toddler is able to exhibit increases markedly in the second year of life, as 
toddlers learn at least one novel behaviour a day, mostly through observation and imitation 
(Barr and Hayne, 2003). It is also through imitation that toddlers begin to acquire a more 
comprehensive vocabulary (Masur, 1995; Masur et al., 2002). First words typically emerge 
spontaneously and in the correct context around the first year of life. By 18 months of age, 
toddlers will usually produce between 6-20 recognisable words, although some may already 
be producing 50 words, and by 2 years, they will begin to put two or more words together to 
form simple sentences (Fenson et al., 1994). The auditory comprehension of a typically 
developing child develops even more quickly than the spoken language, as toddlers are able 
to understand many more words than the ones that they produce (Fenson et al., 1994). In 
contrast, toddlers who are later diagnosed with ASD tend to show a decreased 
comprehension of single words and an atypical production of language. In fact, a delay in the 
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production of the first words is one of the earliest ‘red flags’ for ASD (Short and Schopler, 
1988), and one which has also been recently replicated in high-risk samples (Mitchell et al., 
2006; Zwaigenbaum et al., 2005).    
 
In conclusion, infants who later develop ASD tend to show specific deficits and delays in key 
behavioural milestones, from 12 months of age, with some subtle differences already evident 
at 6 months. Despite common areas of impairment, such as socio-communicative skills, 
individuals who go on to develop ASD still show an enormous variability in the expression and 
severity of their behaviours. Perhaps for this reason, no study has yet found a reliable 
predictor of ASD within the first year of life.  
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1.4. Magnetic Resonance Imaging (MRI) 
MRI is a particularly safe, non-invasive, and non-ionising imaging technique, which has been 
increasingly used to examine the fetal, neonatal, and infant brain. In recent years, MRI has 
made it possible to study the anatomy and chemistry of the brain in vivo. As a result, huge 
advances have been made in our understanding of typical and atypical neurodevelopment.  
 
1.4.1. The physics of MRI  
 Nuclear magnetic resonance 
Nuclear magnetic resonance describes the quantum mechanical behaviour of nuclei within a 
magnetic field and provides the fundamental construct for MRI (Rabi et al., 1939). In order to 
obtain information about the anatomy and function of the body in vivo, MRI exploits the 
magnetic properties inherent to hydrogen nuclei – the most abundant nuclei in the human 
body. Hydrogen nuclei are comprised of a single proton (1H) with a corresponding positive 
charge, and since protons are in constant precession (spinning around their own axes); their 
presence contributes to the induction of a magnetic moment. In the absence of a magnetic 
field, hydrogen nuclei are randomly oriented in space. However, as soon as an external 
magnetic field (B0) is applied, the spins of the nuclei align their axis of rotation longitudinally to 









Figure 1.10: The application of an external magnetic field (B0) to hydrogen nuclei. 
(A) In the absence of an external magnetic field (B0=0), the hydrogen nuclei are in random 
orientation. (B) In the presence of an external magnetic field (B0), the nuclei align themselves 
parallel or anti-parallel to the field. 
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Hydrogen nuclei can exist in one of two energy states: in the low-energy state, the nuclei align 
parallel to the field (spin up), whereas in the high-energy state the nuclei possess enough 
energy to oppose the magnetic field and hence, to align anti-parallel to it (spin down). With 
time, the nuclei continuously oscillate between the two energy states, favouring the state that 
requires less energy. Consequently, the number of nuclei aligned parallel to the magnetic field 
usually outnumbers that which are aligned anti-parallel to it. This gives rise to a net 
magnetisation, parallel to the external magnetic field, which is referred to as the longitudinal 
magnetisation. In normal circumstances and irrespective of energy state, the aligned nuclei 
continue to precess about their axes. The frequency of their precession is proportional to the 
applied magnetic field strength and is defined by the Larmor equation:  
 
0 =  0 
Where 0 = precessional or Larmor frequency (MHz),  = gyromagnetic ratio (MHz/T), 
and 0 = magnetic field strength (T) 
 
Nuclei often precess out of phase from one another, except when they are made to precess in 
phase. Nuclei that precess in phase give rise to a net magnetisation that is perpendicular to 
the magnetic field, termed transverse magnetisation. The vector sum of all the magnetic 
moments in a sample of nuclei refers to the net magnetisation vector, which is comprised of 
both longitudinal and transverse magnetisations.  
 
 Excitation, relaxation, and the MR signal detection 
The application of a radiofrequency (RF) pulse, equal to the Larmor frequency, produces an 
overall excitation, which causes the nuclei to absorb energy and move onto a high-energy 
state. With an increased number of nuclei in the high-energy state, the longitudinal 
magnetisation is reduced. Consequently, the net magnetisation vector moves out of alignment 
with the magnetic field and in alignment with the precessing nuclei that are now in phase, and 
hence, inducing transverse magnetisation. The angle to which the net magnetisation vector 
realigns to is called the flip angle, and its magnitude depends on the amplitude and duration of 
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the applied RF pulse, normally 90°. The constant changing of the net magnetisation vector in 
the transverse plane causes an induced current in the coil, which can be measured, and is 
commonly referred to as the MR signal.  
 
After the RF pulse has been applied, the nuclei eventually relax back into their low-energy 
states, realigning with the external magnetic field. In doing so they release the absorbed 
energy back into the surrounding tissue, or lattice, and re-establish thermal equilibrium in a 
process referred to as T1 longitudinal relaxation (or spin-lattice relaxation). In addition, as the 
nuclei relax back to their original energy states, the magnetic fields of the nuclei interact and 
exchange energy with one another. Ultimately, this leads to a loss of phase and a loss of 
signal, in a process known as T2 transverse relaxation (or spin-spin relaxation). In the 
presence of an applied 90° RF pulse, T1 is defined as the time taken for longitudinal 
relaxation to return to approximately 63% of its value, prior to the application of the RF pulse. 
In contrast, T2 is the time taken for transverse magnetisation to fall to approximately 37% of 
its original value after RF pulse application, corresponding to the 63% of transverse 
magnetisation that will be lost.   
 
Multiple RF pulses are applied during a single MR examination. These are often referred to as 
pulse sequences and described in terms of their magnitude and frequency. The time taken 
between each RF pulse application is defined as the repetition time (TR), and it is largely 
responsible for the amount of T1 relaxation that can occur amidst two pulses. In addition, the 
echo time (TE) refers to the time taken between RF pulse application and MR signal 
detection, and controls the amount of T2 decay that occurs before the signal is read.  
 
 Image formation in structural MRI 
Image formation does not occur directly from the MR signal received. Instead, the signal is 
first encoded in an intermediate form, known as the k-space. A Fourier transformation is then 
applied in order to reconstruct the k-space data into an appropriate MR image. The final 
image consists of a matrix of pixels, corresponding to the data previously encoded in the k-
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space, with each pixel allocated to a specific spatial location and a particular shade on the 
grey-scale.  
 
In medical imaging, the tissue contrast (that is, the difference in brightness between grey-
scale shades) is one of the most important characteristics of an image, as it is what helps to 
visualise and delineate anatomical structures. The contrast of an MR image is highly 
dependent on both intrinsic and extrinsic properties. Intrinsic properties, for instance, are 
inherent to the tissue being imaged and depend on factors such as T1 recovery, T2 decay, 
and proton density. Tissues with high proton density (that is, with a large number of protons 
per unit volume of tissue) have a large component of transverse magnetisation and thus a 
high signal. In contrast, tissues with low proton density have a small component of transverse 
magnetisation and a low signal. Moreover, transverse magnetisation may decay faster in 
some tissues relative to others. If a signal takes a long time to decay, a low signal is detected 
in the region being imaged, and therefore, it appears dark in intensity.  
 
Altering some of the extrinsic imaging parameters, such as TE, TR, and flip angle, can also 
produce images with different contrasts. To achieve a T1-weighted image, for example, the 
TR must be short enough so that tissues do not have sufficient time to fully recover before the 
next RF pulse is applied. In contrast, given that TE controls the amount of T2 decay that is 
allowed to occur before a signal is received, to produce a T2-weighted image, the TE must be 
long. MRI sequences can be designed to give images different weightings of T1 and T2, which 
will ultimately produce images of opposing contrasts. In a T2-weighted image, for instance, 
lipids have low signal intensity and appear dark, whereas water has high signal intensity and 
is bright. This explains why cerebrospinal fluid (CSF), which is largely composed of water, 
appears bright in a T2-weighted image, but very dark in a T1-weighted image (Figure 1.11). 
Moreover, in prenatal and postnatal periods when there is still limited myelination, T2-
weighted images provide better tissue contrast and signal to noise ratio (SNR), when 
compared to T1-weighted images. Thus, the studies included in this thesis have only analysed 











Figure 1.11: Tissue contrast in a T1-weighted and T2-weighted image. 
 The brain of a healthy term neonate scanned at an age of 40+1 corrected weeks is displayed 
above. In (A) the T2-weighted image, lipids have a low signal intensity and emerge as dark 
(arrow), but water has high intensity and appears bright in colour (arrowhead). Conversely, in 
(B) the T1-weighted image, lipids have high signal intensity and appear bright (arrow), 
whereas water has low signal intensity and appears dark (arrowhead). Note for instance, the 
difference in intensities between the lateral ventricles (arrowhead) and cortex (arrow).  
 
 
 Spectrum formation in 1HMRS 
1HMRS is based on the same physical constructs as MRI. Instead of generating a structural 
image, however, it produces a chemical spectrum that provides information on the 
biochemistry of the tissue under study. More specifically, the 1HMRS technique relies on the 
fact that hydrogen nuclei will resonate at different frequencies, depending on the tissue in 
which they are incorporated in and on the type of molecules surrounding them. This 
phenomenon is known as the chemical shift and it produces a change in the resonant 
frequency that is reliant on the molecular group attached to the hydrogen nuclei. The 
difference in the resulting frequency can then be used to identify which metabolites are 
present within the tissue being investigated.  
 
The MR signal in 1HMRS is recorded as a function of voltage over time; for a single RF pulse, 
this is denoted as the free induction decay (FID). Much like with the formation of anatomical 
images, a Fourier transformation is applied to the FID in order to reproduce the data in the 
A                 B 
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form of a chemical spectrum. In a 1HMRS spectrum (Figure 1.12), peaks are positioned at 
different radiofrequencies. Each peak represents a different metabolite that can be identified 
by its specific frequency, expressed in parts per million (ppm) on the x-axis. The y-axis depicts 
the signal intensity of each metabolite, which is represented in arbitrary units. The signal 
intensity and the width of the peak are influenced by the spin-lattice and spin-spin relaxation 
times, whilst the area below the peak provides the metabolite concentration of the voxel under 
study. In principle, the area below the peak is proportional to the number of protons 
contributing to the MR signal. However, absolute concentrations cannot be accurately 
obtained without controlling for a series of confounding factors, including the pulse sequence 
and acquisition method. Hence, metabolite concentrations are often presented as relative 
ratios, expressed over what is considered to be a stable metabolite – Cr for example. 
Although commonly used, this technique is limited by the uncertainty of a given metabolite’s 
stability (Jansen et al., 2006). It is also particularly problematic in the developing and atypical 
brain. Still, some argue that relative quantifications are actually more robust than absolute 




Figure 1.12: An example of a 1HMRS spectrum acquired from a healthy neonate. 
The 1HMRS spectrum is described by two axes – the vertical y-axis represents the signal 
intensity of metabolites, whilst the horizontal x-axis describes the frequency chemical shift in 
parts per million (ppm). The metabolite peaks for myo-inositol (Ins; 3.6 ppm), choline (Cho; 3.2 
ppm), creatine (Cr; 3.0 ppm), glutamate/glutamine (Glx; 2.1-2.5 ppm), and N-acetylaspartate 
(NAA; 2.0 ppm) are indicated in red. 
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Metabolic profiles vary according to the brain region under study. However, they are also 
dependent on both pathology and age, which makes 1HMRS an invaluable tool for assessing 
the function of the typical and atypical brain. In recent years, this particular imaging modality 
has been commonly used to assess the neonatal and infant brain, and increasingly so to 
examine the fetal brain. Thus, the studies included in this thesis have also used 1HMRS to 
quantify the neurometabolic profile of the late prenatal and early postnatal periods. In order to 
detect metabolites with short spin-spin relaxation times, such as Glx and Ins, a short TE (55 
ms) acquisition was used. Furthermore and although also visible at short TEs, NAA, Cho, and 
Cr were assessed using a longer TE (144 ms), as their long relaxation times allow for a more 
accurate quantification with this approach.    
 
1.4.2. Imaging the fetal brain 
At present, ultrasound (US) remains standard practice for the in vivo evaluation of fetal 
development in antenatal medicine. This is largely due to its many practical benefits; for 
example, its high safety profile, low cost, easy portability, and real-time use. However, US 
produces poor contrast resolution, which limits accurate anatomical delineations (Gholipour et 
al., 2011; Glenn, 2006; Rutherford, 2009). In addition, it lacks detailed visualisation of specific 
brain structures such as the cerebellum and cortex, particularly in the presence of an 
unfavourable fetal position. Compared to US, MRI has a larger field of view (FOV), which 
enables visualisation of the whole uterus and fetal body throughout gestation. It is also not 
limited by fetal position or maternal habitus, and has far better spatial and contrast resolution 
as well as higher SNR. Hence, MRI has recently been recognised as an invaluable 
complementary tool to US, often used to confirm diagnostic findings, evaluate suspected 
anomalies, monitor the progression of high-risk pregnancies, and provide a more 
comprehensive assessment of the fetal brain (Sévely and Manelfe, 2002).  
 
Ever since its first application to fetal imaging in 1983 (Smith et al., 1984), when MRI was 
limited by long acquisition times and greatly affected by both fetal motion and maternal 
respiration (D’Ercole et al., 1993; Sévely and Manelfe, 2002), huge advances have been 
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made in fetal MRI (Figure 1.13). For example, the development of the single-shot rapid 
acquisition sequence in which each slice is acquired in less than one second, has 
revolutionised the field of fetal MRI, by allowing for good quality images to be produced in the 
presence of inevitable motion. Furthermore, advances in post-processing techniques, such as 
the offline registration and reconstruction of T2-weighted single-shot images, has enabled the 
production of 3D volumetric images with high SNR, high resolution, and relatively free of 
motion artefacts (Jiang et al., 2007).  
 
Taken together, these techniques have greatly enhanced the visualisation and quantification 
of fetal brain development across a range of gestational ages. They have also improved the 
type of imaging analysis that can be accomplished with fetal data (Jiang et al., 2007; 
Rutherford, 2009; Sévely and Manelfe, 2002). As a result, the use of MRI for the in vivo study 
of the developing brain has enabled clinicians and researchers to examine both typical and 












Figure 1.13: Advances in fetal MRI within the past 30 years. 
(A) A T1-weighted image of a 32 week-old fetus acquired from a 0.04-0.08T MR scanner in 
1983 (image obtained from Smith et al., 1984), and (B) a T2-weighted image of a 26+5 week-
old fetus acquired on a 1.5T MR scanner in 2016. 
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 Safety concerns and practicalities 
MRI is considered to be a safe technique for use in pregnancy, despite some animal studies 
having reported an increased risk of developmental abnormalities and offspring mortality, 
subsequent to the use of MRI (Mevissen et al., 1994; Yip et al., 1994). However, these studies 
exposed animals to prolonged periods of MRI lasting up to 6 hours (Yip et al., 1994), and 
therefore, cannot be directly compared to human studies in which scanning times are 
considerably lower. For example, in a human study investigating the effects of MRI on 74 
normal fetuses scanned at 0.5T, there were no reports of any adverse impacts upon fetal 
growth (Myers and Johnson, 2007). Other studies have also found no significant variations in 
fetal heart rates during scanning, and there is no current evidence stemming from human 
work to suggest that there are any adverse effects of fetal MRI on the health of either the 
pregnant woman or the fetus (Michel et al., 2002; Poutamo et al., 1998; Vadeyar et al., 2000). 
Hence, regulatory guidelines state that it is safe to use fetal MRI at 3T or less during the 
second and third trimester, but recommend that the use of MRI be carefully considered during 
the first trimester of pregnancy when the fetus is particularly vulnerable (Patenaude et al., 
2014). However, in a recent study involving over 1.4 million pregnancies, it was reported that 
exposure to MRI during the first trimester of pregnancy was not significantly associated with 
any adverse effects on the fetus or the developing child (Ray et al., 2016). In light of this 
evidence it is therefore expected that future recommendations be made more lenient.   
 
Other safety concerns associated with fetal MRI can easily be overcome, so long as 
precautionary measures are taken. One of the risks associated with fetal imaging, for 
example, relates to temperature. The slightest of increases in maternal body temperature 
could result in adverse effects on the developing fetus, including growth restriction and 
developmental defects (Chambers et al., 1998; Edwards et al., 2003; Kline et al., 1985). 
These adverse effects are thought to be a consequence of alterations in neurodevelopmental 
processes such as cell proliferation, migration, differentiation, and apoptosis. The effects are 
also largely dependent on the extent and duration of the temperature rise, as well as on the 
gestational age at which the insult occurs (Edwards et al., 2003). For instance, it appears that 
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the fetal brain is most sensitive to heat during the embryonic and mid-gestation periods. At 
this time, the fetus has no homeostatic mechanism to control its own body temperature, and 
instead, it is reliant on both maternal temperature and placental blood flow. Fetal temperature 
is assumed to be 0.5°C greater than that of the maternal temperature (Schroder and Power, 
1997). Hence, it is important to ensure that the maternal temperature does not rise by more 
than 0.5°C while in the MRI scanner, and that the fetal temperature is kept under 38°C. As a 
result, it is a rule in some hospitals that whenever a fetal scan takes place, if the maternal 
temperature is ≥ 37.5°C, the scan is postponed. Alternatively, if there is no need to 
reschedule, the temperature in the scanning room is kept cool, and the expectant mother’s 
temperature is monitored once again after the scan.  
 
Another safety concern refers to the level of acoustic noise that is produced by the rapid 
changing of the currents within the gradient coils, and which gives rise to the characteristic 
knocking noise of the MR scanner (Rutherford et al., 2008; Sévely and Manelfe, 2002). 
Furthermore, although it is known that there is at least a 30 dB sound attenuation as noise 
passes through the maternal abdomen and amniotic fluid to the fetus, there is limited 
information regarding the level of noise heard by the fetus. To date, there has been no 
evidence of hearing impairments in children who have undergone MRI examination during 
fetal life (Kok et al., 2004; Reeves et al., 2010). Nonetheless, aside from protecting the 
mother’s hearing with earplugs and headphones, it is also advised that imaging sequences be 
kept to a minimum of 100 dB. As a further precautionary measure, it is suggested that the 
more noisy sequences – for example, those used for diffusion tensor imaging – are acquired 
for only short periods of time.  
 
Aside from this, claustrophobia and discomfort are common complaints during scanning. The 
small diameter of the bore also does not always allow for the imaging of patients with a high 
body mass index (BMI; ≥ 35 Kg m-2). Women that are extremely claustrophobic (incapable of 
entering a lift, for example) are advised to not take part in fetal MRI, unless in cases of clinical 
need. In those circumstances, prism glasses can also be used in order to redirect the 
 72 
women’s line of sight and to make them feel more at ease. With regards to discomfort, 
pregnancy pillows are placed around the women’s body to try and ensure the most 
comfortable position possible. Finally, because MRI is contraindicated in participants that have 
ferrous metal inside their body, anyone entering the MRI scanning room must complete a 
thorough metal check, which then needs to be approved by the designated radiographer.  
 
1.4.3. Imaging the neonatal and infant brain 
MRI has been far more extensively used to visualise and assess the neonatal and infant 
human brain, than it has been to assess the fetal brain. As with fetal imaging, it is commonly 
used to detect lesions, carry out diagnostic assessments, and predict outcomes. However, 
advances in imaging techniques have extended its role beyond visual assessments to allow 
for more robust analyses of volumetric data, metabolic profiles, connectivity, and function 
(Arichi, 2012; Ball et al., 2010; Counsell and Rutherford, 2002; Makropoulos et al., 2015; 
Malamateniou et al., 2013; Ramenghi et al., 2009; Varela et al., 2012; Xue et al., 2007). 
Importantly, the purpose of this thesis extends beyond the assessment of brain development 
during prenatal life, such that neurodevelopment will also be studied during neonatal and 
infant timepoints.  
 
Similar safety precautions to those just highlighted for fetal imaging – regarding temperature, 
acoustic noise, and metallic implants – also need to be considered when scanning a neonate 
or infant. Hence, before entering the scanning room, it is necessary that a thorough metal 
check be complete to ensure that the individual is free of any ferrous metal. Special attention 
should be paid to neonates and infants that are being scanned for clinical reasons, as medical 
devices such as intravenous access lines and electroencephalograms are not always MR 
compatible. Aside from this, exposure to acoustic noise is also minimised by insulating the 
scanner bore with sound attenuating foam. The infant’s ears are also protected with 
mouldable silicone-based dental putty and MiniMuff noise attenuators. In addition, an 
experienced clinician supervises the MR examination to monitor the infant’s physiological 
parameters, including heart rate, oxygen saturation, and body temperature.  
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1.5. Autism Spectrum Disorder (ASD) 
ASD is a heterogeneous neurodevelopmental condition, characterised by difficulties in 
reciprocal social communication and social interaction, as well as restricted and repetitive 
patterns of behaviour (American Psychiatric Association, 2013). The disorder affects 
approximately 1% of the general population (Baird et al., 2006; Baron-Cohen et al., 2009) and 
is more commonly diagnosed in males, with the most recent prevalence recorded at a ratio of 
2-5:1 (Lai et al., 2015). In recent years there has been a tremendous increase in the number 
of ASD diagnoses, from an incidence of 0.04% in the 1990’s to the current 1%. This rise may 
be explained, at least partly, by a broadening of the diagnostic criteria, improved service 
availability, and increased public awareness (Charman, 2002; Fombonne, 2005; Wing and 
Potter, 2002). Nonetheless, whether the current figure also reflects a true increase in the 
incidence of the disorder remains to be determined.   
 
Currently, ASD is diagnosed exclusively based on its behavioural phenotype. Moreover, whilst 
initial symptoms have been identified as early as 12 months (Ozonoff et al., 2010; Volkmar 
and Chawarska, 2008; Zwaigenbaum et al., 2013), clinical diagnoses are not typically given 
before 2-3 years of age. Even then, diagnosis involves a lengthy clinical assessment with no 
biomarkers available to facilitate the process. In addition to the core deficits described, as 
many as 70% of individuals with ASD also suffer from co-occurring conditions. These include 
intellectual disability, ADHD, motor abnormalities, epilepsy, sleep disruptions, and affective 
difficulties such as anxiety and/or depression (Joshi et al., 2013; Matson and Nebel-Schwalm, 
2007; Simonoff et al., 2008). Therefore, it is crucial that these conditions be carefully screened 
for and routinely evaluated as well as treated if possible. 
 
Although some adults with ASD are able to live independently, the majority (58-78%) are 
described as having poor to very poor outcomes in terms of independent living, educational 
achievement, employment, and the establishment of meaningful relationships (Billstedt et al., 
2011; Howlin et al., 2014). From a public health perspective, ASD’s early onset, lifelong 
persistence, and associated co-morbidities, can cause considerable health and financial 
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burden to the individuals and their families (Howlin et al., 2004; Knapp et al., 2009; 
Woolfenden et al., 2012). Recent studies have also identified a 2.56-fold increase in the odds 
of premature mortality amongst individuals with ASD, relative to those in the general 
population (Hirvikoski et al., 2015; Schendel et al., 2016). This increase in likelihood of 
premature mortality does not appear limited to a specific cause of death, as it was found 
elevated for almost all of the ICD categories analysed (Hirvikoski et al., 2015). Despite this, 
evidence suggests that low-functioning individuals (that is, those with a co-existing intellectual 
disability) are more likely to die from neurological conditions such as epilepsy, whilst 
premature death in those that are high-functioning (with average or above average intellectual 
ability) will most likely be due to suicide (Hirvikoski et al., 2015).  
 
1.5.1. Treatment and management 
At present, there are no pharmacological treatments for the core symptoms of ASD (Ecker et 
al., 2013a), and even if they were to become available, it is uncertain whether they would be 
suited for young children. Therefore, the majority of work regarding the treatment and 
management of childhood ASD has mainly focused on developing behavioural therapies. 
Symptoms are thought to be particularly malleable in early infancy (Lord et al., 2005), most 
probably due to the heightened neuroplasticity at this time. In addition, this may partly explain 
the considerable progress made in recent years to develop interventions targeted at very 
young children (aged < 3 years). Some of these interventions have been designed by 
adapting existing treatments for older individuals, whilst others have attempted to incorporate 
aspects of the early infant environment, including parent-infant interactions (Dawson et al., 
2010; Green et al., 2015; Oono et al., 2013; Rogers and Vismara, 2008; Volkmar and Pauls, 
2003). Perhaps more importantly though, there is now evidence to suggest that early 
behavioural interventions are effective in decreasing core symptoms and improving outcomes 
(Zwaigenbaum et al., 2015).  
 
As has been proposed with pharmacotherapy, it is unlikely that the treatment and 
management of ASD is possible with a “one-size-fit-all” approach (Ecker et al., 2013a). 
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Instead, as the field progresses towards targeted pharmacotherapies, it is likely that the 
development of stratified behavioural interventions will also emerge, particularly once we have 
understood which individuals respond best to which therapies. For early behavioural 
interventions to be successful, however, prompt referrals to appropriate services are required. 
Hence, the early identification of ASD has become a priority.   
  
1.5.2. Aetiology 
The exact aetiology of ASD remains unknown. Nonetheless, there is now considerable 
evidence to suggest that it is one of the most genetically determined psychiatric conditions 
(Sandin et al., 2014). While the estimated concordance rates in monozygotic twins is 60-99%, 
the rates in dizygotic twins range from 14-36% (Colvert et al., 2015; Hallmayer et al., 2011; 
Lichtenstein et al., 2010; Rosenberg et al., 2009). These figures highlight the importance of 
genetic influences on the pathogenesis of ASD; however, the incomplete concordance in 
monozygotic twins also indicates the significant role that is played by environmental factors 
(Hallmayer et al., 2011). Consequently, the current consensus is that ASD is caused by a 
complex interplay between both genetic and environmental risk factors (Hallmayer et al., 
2011; Mandy and Lai, 2016; Rutter, 2005). In addition, ASD is largely viewed as a 
multifactorial condition with a highly heterogeneous phenotype. Some even suggest that there 
are probably many different kinds of “autisms”, each with distinct developmental pathways 
(Abrahams and Geschwind, 2008).  
 
 Genetic risk factors 
Most ASD cases are idiopathic, and recent advances in the field of genetics have identified 
over a thousand susceptibility genes (Abrahams and Geschwind, 2008). Nevertheless, clues 
to the molecular pathways implicated in the disorder come from the association of ASD with 
specific genetic syndromes and copy number variants (CNVs).  For instance, syndromic forms 
of ASD such as fragile X syndrome (Hagerman et al., 2005), tuberous sclerosis (Shafali, 
2015), Rett syndrome (Moretti and Zoghbi, 2006), and Phelan-McDermid syndrome (Durand 
et al., 2007) account for about 5% of all ASD cases (Miles, 2011). For the most part, the 
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functions of the genes involved in these conditions implicate synaptic dysfunction as a unifying 
cause in the pathogenesis of ASD (for review see Zoghbi and Bear, 2012). However, a 
substantial proportion of the ASD risk has been found to reside in high impact CNVs, involving 
microscopic deletions or duplications of DNA fragments. These variants have been associated 
with genes that code for proteins involved in various roles, including cell adhesion, 
neurotransmitter synthesis, and synaptic function, as well as neuronal differentiation and 
migration (Iossifov et al., 2012; Levy et al., 2011; O’Roak et al., 2012; Sanders et al., 2012). 
CNVs are responsible for 10-20% of all ASD cases (Miles, 2011). However, no single locus 
has been found to account for more than 1% (Abrahams and Geschwind, 2010), despite the 
fact that some loci have been more commonly implicated than others – perhaps especially 
those on chromosomal regions 7q11, 15q11-13, 16p11, and 22q11.2 (Jonas et al., 2014; 
Kumar et al., 2008; Sanders et al., 2011; Szafranski et al., 2010; Weiss et al., 2008). In 
addition, although some CNVs are dominantly inherited, the majority arise from de novo 
mutations, meaning that not all genetic causes of ASD are of familial origin – i.e. some arise 
for the first time in a new family member, as a result of a mutation in a germ cell or in the 
fertilised egg itself. Thus, a significant proportion of genetic risk arises de novo.  
 
 Environmental risk factors  
As previously mentioned, genetic heritability is not thought to be the only cause of ASD, 
particularly since environmental risk factors have recently been found to play an important part 
in the emergence of the disorder (for review see Mandy and Lai, 2016). In fact, there is now 
evidence to suggest that some of the environmental factors implicated in ASD can impact 
neurodevelopmental outcome prior to birth, during the fetal period (Bale et al., 2010; Szatmari, 
2011). For instance, there is an association between ASD and fetal exposure to gestational 
diabetes (Gardener et al., 2009), vitamin D deficiency (Cannell, 2008), and the presence of a 
viral or bacterial infection such as congenital rubella (Atladóttir et al., 2010; Chess, 1977). 
Maternal use of medication during pregnancy – specifically anticonvulsants such as sodium 
valproate (Williams et al., 2001), but also thalidomide (Strömland et al., 1994) and 
paracetamol (Liew et al., 2015) – has also been found to correlate with a higher incidence of 
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ASD, especially if ingested within the first trimester. Furthermore, there is now a growing body 
of evidence to suggest that women who are depressed or stressed during pregnancy, 
including those who take antidepressant medication, may also be at an increased risk 
(Boukhris et al., 2015; Croen et al., 2011; Kinney et al., 2008; Rai et al., 2013).  
  
In addition to the impact of the prenatal environment, postnatal complications can also play a 
contributory role in the development of ASD. Associated factors include a breech 
presentation, caesarean delivery, induced labour, preterm birth, as well as a low Apgar score 
and low birth weight (Gardener et al., 2011; Glasson et al., 2004; Guinchat et al., 2012; 
Hultman et al., 2002; Johnson et al., 2010; Kuzniewicz et al., 2014; Landrigan, 2010). Specific 
congenital abnormalities such as ventriculomegaly and cerebellar anomalies, have also been 
linked to poor neurodevelopmental outcomes, often present in individuals with ASD, ADHD, 
and learning difficulties (Courchesne et al., 1994; Gilmore et al., 2001; Limperopoulos et al., 
2007; Palmen et al., 2005). Furthermore, advanced paternal and/or maternal reproductive age 
has also been considered a risk factor (Croen et al., 2007; Hultman et al., 2011; Reichenberg 
et al., 2006), possibly due to the higher rate of de novo mutations and epigenetic alterations 
associated with older gametes (Crow, 2000; Reichenberg et al., 2006).  
 
 Gene-environment interactions 
Many of the environmental factors thus far identified are unlikely to be sufficient in isolation to 
cause ASD. However, the emerging field of epigenetics has identified a number of gene-
environment interactions, in which exposure to a given environmental insult can result in the 
manifestation of the disorder, if the exposed individual is already genetically susceptible (Bale 
et al., 2010; Rutter et al., 2006). Gene-environment interactions are mediated by epigenetic 
modifications of the genome, which result in altered gene expression, and may involve DNA 
methylation, histone modification, and non-coding RNAs (Borrelli et al., 2008; Franklin and 
Mansuy, 2010; Sweatt, 2009). Epigenetics may also help to explain the extensive 




Despite an increase in studies using a range of investigational techniques, including genetic, 
animal, post-mortem, and neuroimaging work, the neurobiology of ASD remains unclear. The 
majority of studies investigating brain anatomical differences in individuals with ASD, 
compared to unaffected controls, have generated a series of inconsistent results. Partly 
accounting for these inconsistencies are demographic differences in cohorts, particularly with 
regards to age, gender, handedness, and ethnicity (Courchesne et al., 2011). In addition, 
there is significant diagnostic heterogeneity in the individuals who have been studied. Some 
groups have only included participants with high-functioning ASD, whereas others have 
studied more severe forms of the disorder, including individuals that suffer from associated co-
morbidities such as intellectual disability and ADHD. Since it is likely that ASD subgroups 
have distinct neurobiological underpinnings, studies that include different behavioural 
phenotypes will probably confound results (Johnson and Myers, 2007). Moreover, 
neuroimaging studies can vary in terms of the scanning equipment used, imaging protocol 
run, and the analyses conducted. These factors are therefore all likely to explain, at least in 
part, the inconsistencies in the findings reported so far.   
 
An additional significant complication is the age of subjects who are investigated.  Age may be 
especially important in a disorder of brain maturation, as the dynamic changes that take place 
with time will be even more pronounced for individuals suffering from neurodevelopmental 
conditions (Courchesne et al., 2007). For instance, findings from observational studies 
including individuals from broad age-ranges (of 8-55 years, for example) cannot be restrained 
to a specific developmental timepoint. Moreover, most studies investigating structural brain 
differences in ASD, relative to age-matched typically developing controls, have been cross-
sectional in design – restricting our understanding of the disorder’s neurodevelopmental 
trajectory. In addition, the majority of these studies have been carried out in adults, 
adolescents, and children who already have ASD and so it is unknown if the brain differences 
that are detected underpin, or result from, having ASD. Consequently, very little is currently 
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known about early brain development in ASD, and there is limited knowledge on the brain 
biology of infants who go on to develop the disorder.  
 
 Studies of children, adolescents, and adults with ASD 
Cross-sectional studies comparing brain volumes in children, adolescents, and adults with and 
without ASD, generally reveal a pattern of inconsistent findings. For example, whilst some 
have reported smaller-than-normal brain volumes in ASD (Lotspeich et al., 2004), others have 
observed larger volumes (Piven et al., 1995, 1996), and some have detected no significant 
differences in individuals with ASD compared to age-matched controls (Herbert et al., 2003; 
Kates et al., 2004). Partly driven by these discrepancies, recent reports have employed 
longitudinal designs in order to better understand the neurodevelopmental trajectory of ASD in 
later life. So far, these studies have revealed that after early adolescence, brain development 
in ASD is dominated by an accelerated age-related decline in total brain volume (Lange et al., 
2015). Aside from an accelerated reduction of total grey matter in individuals with ASD 
(Hardan et al., 2009; Lange et al., 2015), the overall decline in total brain volume also appears 
to be accompanied by an unusually slow pattern of white matter growth, particularly evident in 
the temporal, parietal, and occipital lobes (Hua et al., 2013; Lange et al., 2015). Recent 
longitudinal studies in children, adolescents, and adults with ASD, therefore, provide initial 
evidence for an arrest in total brain volume growth, followed by a potentially accelerated 
decline from adolescence onwards.    
 
Aside from this generalised difference in total brain growth, there is also evidence to implicate 
regional brain abnormalities in ASD. For example, neuroimaging studies of ASD have 
observed smaller volumes of the cerebellum (Courchesne et al., 1988; Levitt et al., 1999; 
McAlonan et al., 2002; Rojas et al., 2006), with differences in cerebellar morphometry 
identified as one of the key markers for classifying adults with ASD (Ecker et al., 2010). Post-
mortem evidence corroborates these findings, particularly since cerebellar hypoplasia and a 
reduced size, packing density, and number of Purkinje cells, have been commonly reported in 
studies of adults and adolescents with ASD (Courchesne, 1997; Fatemi et al., 2012; Skefos et 
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al., 2014). Purkinje cell loss, for example, has been identified in 95% of the ASD post-mortem 
studies carried out between 1980 and 1997 (Courchesne, 1997). Since then, this finding has 
been replicated in other ASD samples, and appears prominent in both the cerebellar 
hemispheres and the vermis of affected individuals (Allen, 2005; Bailey et al., 1998; Palmen et 
al., 2004; Skefos et al., 2014). Indeed, the vermis is one of the most affected regions of the 
cerebellum, with numerous studies reporting hypoplasia of vermal lobules VI-VII (Allen, 2005; 
Courchesne et al., 1988, 1994, 2001, 2011; Kaufmann et al., 2003; Stanfield et al., 2008). 
Vermal hypoplasia has also been found to correlate with some ASD symptoms, namely 
stereotyped behaviours and repetitive movements (Kaufmann et al., 2003; Pierce and 
Courchesne, 2001), indicating that there may be a relationship in adulthood between vermal 
size and autistic symptoms.   
 
Besides the cerebellum, other brain regions have been reported as significantly different 
between ASD and control groups. For example, the subcortical region has been frequently 
implicated in studies of ASD, with caudate overgrowth commonly reported in children, 
adolescents, and adults affected by the disorder (Haznedar et al., 2006; Herbert et al., 2003; 
Hollander et al., 2005; Langen et al., 2007; Rojas et al., 2006; Sears et al., 1999). Other 
subcortical regions such as the globus pallidus and putamen, have also been reported to be 
enlarged in older individuals with ASD (Herbert et al., 2003; Hollander et al., 2005; Langen et 
al., 2007; Sato et al., 2014; Turner et al., 2016). However, these studies are limited by their 
cross-sectional designs and the inclusion of participants from broad age-ranges. Thus, just as 
differences in total brain volume between ASD and control groups have started to be analysed 
longitudinally, so have differences in regional brain volumes.  
 
In a recent longitudinal study focussed on the striatum (encompassing caudate and putamen), 
different growth trajectories were identified in children and adolescents with ASD, compared to 
typically developing controls (Langen et al., 2014). Specifically, ASD individuals demonstrated 
a significantly increased growth rate of the caudate nucleus, which was disproportional to 
overall brain growth and significantly associated with more rigid behaviours in autistic 
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individuals (Langen et al., 2014). Adding to this, others have also noted that the volume of the 
putamen and anterior cingulate cortex increases at an abnormally rapid rate in children and 
young adolescents with ASD, compared to controls (Hua et al., 2013). Taken together, these 
findings stand in stark contrast to the accelerated decline identified in total brain volume at 
similar ages, and suggest that different brain regions show distinct age-related volumetric 
trajectories in ASD.  
 
In summary, although there has been progress in our understanding of brain anatomy in older 
individuals with ASD, more work is needed to further understand how the different regions 
implicated in the disorder, develop and change in later life. Moreover, it remains to be 
determined whether these atypical developmental trajectories are primary to ASD 
pathogenesis, or secondary to having the disorder (for example, in association with disease-
related factors or as a consequence of treatment). Studying younger individuals at and around 
the time of clinical diagnosis may therefore inform us more about the potential biological 
underpinnings of the disorder. 
 
 Studies of toddlers and pre-school aged children with ASD  
Prior studies of head circumference at birth suggest that the head (and therefore perhaps 
brain) size of infants who go on to develop ASD, is of either average (Dawson et al., 2007; 
Hazlett et al., 2005; Surén et al., 2013) or reduced size (Courchesne et al., 2003; Redcay and 
Courchesne, 2005), when compared to that of typically developing controls. However, some 
studies have reported that individuals with ASD subsequently show a sudden increase in head 
circumference (Courchesne et al., 2003; Dawson et al., 2007; Hazlett et al., 2005). For 
instance, in infants who were later diagnosed with ASD, head circumference increased 
between 1 to 2 months, and then again between 6 to 14 months, such that individuals with 
ASD already had larger head sizes by 6 months of age, when compared to controls 
(Courchesne et al., 2003). Importantly though, this pattern of accelerated head growth in the 
first postnatal year has not been observed by all (Surén et al., 2013; Zwaigenbaum et al., 
2014). Early head overgrowth may therefore not necessarily reflect a pathological mechanism 
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that is common to all individuals with ASD. Rather, it may reflect a specific neurobiological 
subtype of the disorder (Zwaigenbaum et al., 2014). 
 
Having said that, cross-sectional neuroimaging studies that directly measure brain volume as 
opposed to head circumference, have consistently shown that toddlers with ASD (aged 2-4 
years) have larger total brain volumes than typically developing controls of similar ages 
(Carper and Courchesne, 2005; Courchesne, 2002; Courchesne et al., 2001; Hazlett et al., 
2005; Sparks et al., 2002). Furthermore, recent evidence suggests that deviations in brain 
growth may begin before the age of 2. Longitudinal studies in toddlers, for example, have 
shown that affected individuals already have significantly larger brain volumes by 2.5 years of 
age, compared to those without ASD (Schumann et al., 2010). In addition, toddlers with ASD 
have enlarged cerebral cortices by 2 years of age (Hazlett et al., 2011) and thus, it is likely 
that there is accelerated brain growth in ASD prior to this age.  
 
During the first few years of life there therefore appears to be an accelerated brain growth in 
young affected individuals, rather than an arrest or decline in brain growth, as evident in older 
individuals with ASD. However, as with findings from ASD studies in later life, affected 
toddlers also have specific regional abnormalities. That is, early overgrowth in ASD does not 
appear to be proportional throughout the brain, with neuroimaging evidence suggesting that 
enlargement may be localised to specific regions. For instance, multiple studies have 
observed significant overgrowth in the frontal, temporal, and cingulate cortices, but not in 
other brain regions, such as the occipital lobe (Carper and Courchesne, 2005; Carper et al., 
2002; Schumann et al., 2010). The amygdala (located deep within the temporal lobes) has 
also been implicated in neuroimaging studies of young individuals with ASD. For example, in 
studies of toddlers (aged 1-5 years) who later received an ASD diagnosis, the volume of the 
amygdala was reported to be significantly enlarged and disproportional to total brain volume, 
when compared to that of toddlers who did not receive a diagnosis (Schumann et al., 2009). 
More recently, a longitudinal study reported similar results. Relative to typically developing 
children, the amygdala of children with ASD was significantly enlarged at both 3 and 4 years 
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of age. The growth of the amygdala between these two timepoints was also significantly 
greater in some, but not all children with ASD (Nordahl et al., 2012). Moreover, the size of the 
amygdala in toddlers with ASD has been found to positively correlate with overall symptom 
severity (Sparks et al., 2002), as well as social and communication impairments (Munson et 
al., 2006; Schumann et al., 2010) and joint attention scores (Mosconi et al., 2009). Thus, not 
only is there evidence that the amygdala is enlarged in young individuals with ASD, but also 
that it is associated with core autistic symptoms, and that increased growth rates may be 
present in only a subset of affected individuals. 
 
 Conclusions from structural studies of ASD 
In conclusion, considerable progress has been made in recent years, with perhaps the most 
notable discovery being that (at least some) individuals with ASD appear to undergo a pattern 
of abnormal early brain development (Courchesne et al., 2007; Lange et al., 2015). Although 
this was originally proposed based on findings from cross-sectional investigations, it has now 
been confirmed by longitudinal studies. Taken together, prior work suggests that at birth, the 
head size of infants who go on to develop ASD is of either normal or small size, when 
compared to typically developing controls. However, there then appears to be a period of early 
brain overgrowth in toddlerhood and early childhood. This is followed by an arrested growth 
during adolescence and adulthood, which in some cases may lead to smaller-than-normal 
brain volumes in later life (Figure 1.14). 
 
Based on the findings from a recent longitudinal study, the intersection between overgrowth 
and arrested growth in ASD has been proposed to occur between 10-15 years of age, when 
the growth curves of affected and unaffected individuals appear to converge (Lange et al., 
2015). Nonetheless, it is not yet known when brain overgrowth in ASD begins, and in order to 
investigate this, future studies would benefit from inclusion of even younger populations. In 
line with this, more research is needed to investigate whether deviation from the normal 
trajectory is already evident in prenatal life, or whether disrupted growth is largely a postnatal 











Figure 1.14: The aberrant neurodevelopmental trajectory of ASD. 
Some individuals with ASD undergo an accelerated period of postnatal brain growth, which is 
followed by a period of arrested growth during adolescence, and a possible degeneration in 
later adulthood. In this figure, adapted from Courchesne et al., (2007), the blue line represents 
individuals with ASD, whilst the red represents those with typical development. 
 
  
This thesis will also attempt to examine which brain regions (if any) are implicated from early 
on. As mentioned earlier, there is evidence that the neurodevelopmental trajectory of ASD is 
not proportional, with particular regions showing a significantly greater deviation in volume 
from the established norm. For instance, there is extensive evidence implicating the frontal, 
temporal, and cingulate cortices, as well as the cerebellum, amygdala, and subcortical 
regions, including components of the basal ganglia such as the caudate and putamen. These 
are also brain regions that mediate motor and high-order skills. Therefore, if their development 
is disrupted, this could result in a variety of social, emotional, cognitive, and motor 
dysfunctions – all of which are recognised areas of ASD deficit – and constitute an important 
direction for future research.  
 
In addition, the underlying cause(s) of the putative and aberrant neurodevelopmental 
trajectory in ASD have yet to be established. A potential way forward is to study the in vivo 




Further insight into the underlying development of ASD has come from studies using 1HMRS. 
However, here too there are inconsistencies in the literature (for review see Ford and 
Crewther, 2016), which can be explained by many of the same factors that affect structural 
studies, including differences in sample characteristics and imaging protocols.  
 
 NAA 
To date, the majority of 1HMRS studies carried out in children with ASD, support the notion 
that there are low levels of NAA across the brain (Aoki et al., 2012; DeVito et al., 2007; Ipser 
et al., 2012). For example, lower NAA has been identified in both grey and white matter brain 
regions (Corrigan et al., 2013; DeVito et al., 2007; Friedman et al., 2006; Levitt et al., 2003b), 
as well as in the cerebellum and the anterior cingulate cortex of autistic children (Chugani et 
al., 1999; DeVito et al., 2007; Fujii et al., 2010; Otsuka et al., 1999). In contrast, the NAA 
literature on adults with ASD is less clear, with autistic individuals exhibiting both lower 
(Suzuki et al., 2010; Tebartz Van Elst et al., 2014) and higher NAA levels (Brown et al., 2013; 
Murphy et al., 2002), as well as no significant differences (Bernardi et al., 2011; Hashimoto et 
al., 1997; Kleinhans et al., 2009; Page et al., 2006) when compared to age-matched controls. 
 
Amongst its many roles (noted earlier in section 1.2.7.1 on page 51), NAA is considered to be 
a marker of neuronal integrity (Clark, 1998; Kleinhans et al., 2007). Lower levels of NAA are 
thus likely to indicate loss, dysfunction, or immaturity of neurons (Aoki et al., 2012; DeVito et 
al., 2007; Horder et al., 2013), as well as decline in axon count (Levitt et al., 2003b). These 
findings, therefore, do not support the hypothesis of increased neural and synaptic density as 
the basis for an early brain overgrowth in children with ASD. However, since the majority of 
1HMRS studies conducted in children have been carried out within, or shortly after 2-4 years 
of age, it could be that the low levels of NAA correspond to the period of arrested brain growth 
that follows early overgrowth. In addition, since NAA is cycled between neurons and 
oligodendrocytes, low levels of NAA in the young autistic brain may also signal errors in 
myelination and not in neurons per se (Moffett et al., 2007).    
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The abnormal levels of NAA identified in these studies might also contribute to the 
manifestation of some of the core symptoms of ASD. Lower NAA in the hippocampal-
amygdala complex, for instance, has been linked with repetitive behaviours in adults with ASD 
(Kleinhans et al., 2009). Moreover, others have found NAA levels to correlate with deficits in 
communication (Fujii et al., 2010; Horder et al., 2013; Kleinhans et al., 2009), social 
responsiveness and functioning (Fujii et al., 2010; Kleinhans et al., 2009), and directed eye 
gaze (Levitt et al., 2003b). 
 
 Cr  
Low levels of Cr have been identified in the cortex of ASD children (Corrigan et al., 2013; 
DeVito et al., 2007; Friedman et al., 2003; Hardan et al., 2008; Levitt et al., 2003b). In 
contrast, adult studies of ASD have reported elevated levels of Cr in the auditory and medial 
prefrontal cortex, as well as in the hippocampal-amygdala complex (Brown et al., 2013; 
Murphy et al., 2002; Page et al., 2006; Suzuki et al., 2010). Cr is present in both neurons and 
glia, and plays a critical role in the energy metabolism and equilibrium of cells (Bertholdo et 
al., 2013; Rae, 2014; Ross and Bluml, 2001; Urenjak et al., 1992). Hence, these findings 
suggest that there may be abnormalities in the energy metabolism and homeostasis of cells 
amongst individuals with ASD (Turner and Gant, 2014).  
 
Cr levels have also been found to correlate with some of the core ASD symptoms, including 
impairments in social and repetitive domains (Kleinhans et al., 2009; Turner and Gant, 2014). 
In addition, they have been linked with associated symptoms, such as atypical motor learning 
and intellectual disability (Turner and Gant, 2014). Thus, it is possible that Cr may be involved 
in both the underlying pathophysiology of ASD, as well as in the development of co-morbid 
symptoms. 
 
 Cho  
In ASD studies assessing Cho levels in children, evidence is inconsistent at present. For 
example, children with ASD have been reported to exhibit both lower (Corrigan et al., 2013; 
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DeVito et al., 2007; Fayed and Modrego, 2005; Friedman et al., 2003, 2006; Hardan et al., 
2008; Levitt et al., 2003b) and higher Cho levels (Gabis et al., 2008; Levitt et al., 2003b; 
Vasconcelos et al., 2008), when compared to age-matched controls. By adulthood, however, 
results consistently report elevated levels of Cho in ASD individuals relative to controls 
(Bertholdo et al., 2013; Gabis et al., 2008; Murphy et al., 2002; Suzuki et al., 2010). 
 
As mentioned earlier (please see section 1.2.7.3 on page 51), Cho is predominantly found in 
the white matter and has been largely implicated in the process of myelination. Thus, the 
abnormal levels of Cho observed in studies of ASD imply that there may be a dysfunction in 
myelination, which could underlie some of the developmental delays associated with the 
disorder (Baruth et al., 2013; Corrigan et al., 2013; Vasconcelos et al., 2008). Also, given that 
cholinergic pathways play a vital role in the development of cognition, an aberrant maturation 
of the cholinergic system may explain some of the behavioural abnormalities apparent in ASD; 
specifically, the deficits in attention orientation and sensory processing (Lam et al., 2006). 
 
 Ins 
Thus far, the majority of ASD studies point towards low levels of Ins in both children and 
adults affected by the disorder, relative to typically developing controls (Bernardi et al., 2011; 
Friedman et al., 2003, 2006). However, there have been two studies reporting elevated levels 
of Ins in the hippocampal-amygdala complex, cerebellum, anterior cingulate cortex, and 
striatum of children with ASD (Gabis et al., 2008; Vasconcelos et al., 2008). In addition, aside 
from being considered as a glial marker, Ins also plays an important role in the regulation of 
cell growth and cell signalling (Fisher et al., 2002; Ross and Bluml, 2001). Evidence 
implicating low levels of Ins in ASD, therefore suggests that abnormalities in glial proliferation 
and cell signalling, may be present in affected individuals.   
 
 Glx 
There has been a recent surge in the number of ASD studies either examining Glx or 
glutamate. This is mainly due to increasing evidence that the balance between excitatory 
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glutamate (E) and inhibitory GABA (I) – the E/I balance – is altered in individuals with ASD (for 
review see Rubenstein and Merzenich, 2003). However, spectroscopic findings remain 
inconsistent at present. For example, children with ASD have been reported to exhibit lower 
(Corrigan et al., 2013; DeVito et al., 2007; Kubas et al., 2012), higher  (Bejjani et al., 2012; 
Doyle-Thomas et al., 2014), and no significant differences in Glx levels (Friedman et al., 2003, 
2006; Hardan et al., 2008), when compared to typically developing controls. In addition, 
studies focussing on adult populations are similarly inconclusive (Aoki et al., 2012; Bernardi et 
al., 2011; Brown et al., 2013; Horder et al., 2013; Page et al., 2006; Tebartz Van Elst et al., 
2014). Nonetheless, there is evidence that abnormalities in Glx may underlie some of the 
symptoms associated with ASD. For example, Glx levels have been found to correlate with 
deficits in motor and sensory regulation, as well as social interaction (Doyle-Thomas et al., 
2014; Hardan et al., 2008; Tebartz Van Elst et al., 2014).  
 
 Conclusions from spectroscopic studies of ASD 
Although many of the spectroscopic studies here reported have focussed on paediatric 
populations, no study has examined the neurochemistry of ASD in early infancy, prior to 3 
years of age. In addition, not all studies in children are independent of medication; some have 
included participants on stimulants, antidepressants, anticonvulsants, and/or antipsychotics, 
further confounding the interpretation of results. Nonetheless, and despite discrepancies in the 
literature, the overall evidence points towards low levels of NAA, Cr, and Ins in young children 
with ASD relative to typically developing controls. Evidence from ASD studies assessing Cho 
and Glx is less clear. More research is therefore needed to fully understand if, and how, these 
brain metabolites differ in affected individuals, as well as in those at risk of developing the 
disorder.   
 
1.5.5. Studying infants at risk of ASD 
Studies from children, adolescents, and adults point toward differential maturation processes 
in both the neuroanatomy and neurochemistry of individuals with ASD, and highlight that the 
first years of life are key. In addition, and as alluded to throughout this introductory chapter, 
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both prenatal and early postnatal periods are crucial for normal brain development. More 
specifically, these critical periods play an important role in the appropriate establishment of the 
neural circuitry, which makes possible the development of the very skills that are impaired in 
ASD. It is thus highly probable that a neurodevelopmental disorder like ASD will be vulnerable 
to abnormal processes occurring during these early periods of development. Indeed, although 
the pathology of ASD remains unknown, its signature is most likely to be evident during fetal 
and/or early postnatal life, when clinical symptoms first begin to emerge.  
 
To date, very few imaging studies have focused on these critical first years. However, there is 
now an increased recognition that ASD needs to be studied from a very early age and tracked 
throughout development. In order to study brain development in ASD prior to symptom 
manifestation, research has turned to ‘infants at risk’ who already have an older sibling with a 
diagnosis of the disorder. Given the disorder’s genetic liability, infant siblings of diagnosed 
children have a considerably higher chance than the general population of developing ASD, or 
the BAP, with up to 20% developing ASD and perhaps a further 15-20% developing the BAP 
(Constantino et al., 2010; Georgiades et al., 2013; Ozonoff et al., 2011). In addition, many 
individuals at risk of ASD have early deficits in joint attention and delays in communication, 
neither of which are specific to ASD (Bedford et al., 2012). Therefore, prospective studies of 
infants at risk of ASD may help to identify neural markers that predate the emergence of 
symptoms, and provide novel insights into the neurodevelopmental processes underpinning 
risk and resilience for ASD and other behavioural difficulties common to many developmental 
problems.  
 
The first MRI study using an infants at risk design to compare brain volume in 6 month-old 
siblings of infants with ASD, relative to those with typically developing siblings, reported no 
significant differences in intracranial, cerebellar, or lateral ventricular volumes, and no 
difference in head circumference (Hazlett et al., 2012). However, since then, other volumetric 
MRI studies have found evidence to suggest that enlarged corpus callosum (Wolff et al., 2012, 
2015) and ‘extra’ CSF volume in the subarachnoid space (Shen et al., 2013), is present in 
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high-risk siblings by as early as 6 months of age. Increased area and thickness of the corpus 
callosum, as well as volume of subarachnoid CSF, also correlated with subsequent ASD 
symptom severity at 24 months – and these measures were proposed by the researchers as 
potentially predictive biomarkers of the disorder (Shen et al., 2013; Wolff et al., 2015). In 
addition, high-risk infants who later developed ASD had significantly larger total cerebral 
volumes at both 12-15 and 18-24 months, when compared with infants who did not develop 
ASD (Shen et al., 2013).   
 
Alternative imaging modalities, such as diffusion tensor imaging and functional MRI, have 
proven useful in establishing other brain differences in infants at risk of ASD. For instance, 
there have been preliminary reports of differences in the development of white matter 
microstructure (Jin et al., 2015; Wolff et al., 2012). In line with this, connectivity abnormalities 
have enabled the differentiation of 6 month-old infants at high-risk of ASD, from those at low-
risk, with a 76% accuracy (Jin et al., 2015). Moreover, prior to 6 months of age, irregularities in 
both brain function and behaviour can already be observed in infants at risk of ASD. For 
example, there are reports of high-risk infants aged 4-6 months showing a lack of early 
specialisation for human voice processing (Blasi et al., 2015; Lloyd-Fox et al., 2013) and a 
reduced sensitivity to social visual stimuli (Lloyd-Fox et al., 2013). Consistent with this, 
differences in the interaction of high-risk infants with their early caregivers, is evident by 6 
months of age, with high-risk infants reported to be less lively than their low-risk peers 
(Doussard-Roosevelt et al., 2003; Wan et al., 2012, 2013).  
 
Altogether, these studies have made critical first steps in advancing our understanding of 
atypical brain development within the context of infants at risk of ASD. However, as far as I 
am aware, there have not yet been any studies using 1HMRS to examine neurochemical 
differences in these infants, nor have there been any structural studies investigating total and 
regional brain volumes in infants younger than 6 months. It is therefore not yet known whether 
there are any differences in brain structure and chemistry, present in individuals at risk of ASD 
prior to 6 months of age. 
 91 
 
1.6. Aims and hypotheses 
The over-arching aim of this thesis, therefore, was to investigate very early brain 
development, and to identify potential deviations from typical maturation that may be 
associated with a genetic risk of ASD. To do this, MRI measures of brain volume and 
chemistry were acquired in late prenatal and early postnatal life, from a sample of individuals 
at low and high-risk of ASD. Participants were considered to be at low-risk if they did not have 
a first-degree family relative with ASD, and at high-risk if they had a biological sibling with a 
diagnosis of the condition. 
 
In the first study of this thesis (chapter 3), I worked with others to examine the association 
between observational measures of normative mother-infant interactions and regional brain 
volumes, in a typical sample of infants aged 3-6 months. The tested hypothesis was that there 
would be a significant association between brain and behaviour, and that this would be 
stronger in males.  
 
In the next study (chapter 4), the objectives were to (i) compare total and regional brain 
volumes in 4-6 month-old infants with and without a familial risk of ASD; (ii) examine whether 
any early differences in brain volume were associated with ASD symptom severity and/or 
clinical diagnostic status at 36 months; and (iii) explore whether early mother-infant 
interactions moderated the extent of differences in brain volume and/or subsequent severity of 
symptoms. Given that larger volumes of extracerebral CSF in 6 month-old infants at risk of 
ASD have been reported in comparison to infants at low-risk (Shen et al., 2013), a group 
difference in CSF volume was predicted. In addition, it was hypothesised that mother-infant 
interactions would moderate the association between risk group and infant brain volume. No a 
priori hypothesis regarding the direction of these differences was made.   
 
To build on the results of this previous study, subsequent studies examined brain 
development in individuals of even younger ages. The first of these studies focused on the 
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fetal period (chapter 5). It aimed to characterise volumetric brain growth across risk groups 
between 28-38 gestational weeks, and to compare volumes between groups. The next study 
(chapter 6) examined the neonatal period. Here, the goal was to characterise volumetric brain 
development across risk groups in the first month of life, as well as to compare brain volumes 
between groups. Both studies tested the hypothesis that there would be early brain 
differences in individuals at high-risk of ASD, relative to those at low-risk.  
 
Finally, given that neurochemical abnormalities often precede and/or accompany structural 
brain differences (Fayed et al., 2006), the last study of this thesis (chapter 7) used 
spectroscopic data to examine key brain metabolites. By selecting the basal ganglia as the 
region-of-interest, this study aimed to characterise metabolic maturation from fetal to early 
infant life, and to compare brain metabolite ratios in 4-6 month-old infants with and without a 
familial risk of ASD. This was the first study to examine brain metabolites in infants genetically 
predisposed to ASD and therefore, no definite a priori hypotheses were made. However, given 
the current evidence suggesting that there is E/I imbalance in ASD (Nelson and Valakh, 2015; 
Rubenstein and Merzenich, 2003), it was proposed that if group differences did exist, these 
would be manifested by differences in Glx.  
 
At this point, it is important to emphasise the exploratory nature of this research, as well as to 
highlight that the immediate results of this thesis will not inform outcome prediction, given that 
most of the studies set out below are not designed to examine categorical outcomes. 
Nonetheless, long-term follow-up studies will be conducted to specifically examine dimensions 
of cognition and behaviour that may be associated with ASD risk factors, as it is now known 
that children at risk of ASD who do not go on to receive an ASD diagnosis may still show 
signs of other difficulties that may require further support.  
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Chapter 2: Methodology  
This thesis includes data collected as part of two distinct research projects: project 1 – an 
infant MRI study carried out at 1.5T, and project 2 – a serial MRI study conducted at 3T, 
incorporating fetal, neonatal, and infant data. Both projects were prospective in design, aimed 
at gaining a better understanding of very early typical and atypical brain development.  
 
The first two experimental chapters of this thesis (chapters 3-4) are based on data acquired 
from project 1, while the final three chapters (chapters 5-7) report on findings from project 2.  
 
2.1. Defining age: a brief note on terminology 
For consistency, and to allow for easy comparisons between timepoints, the age of the 
participants included in this thesis has been reported in weeks. Moreover, given that some of 
the data incorporated in this thesis was collected at the fetal timepoint, participant age was 
defined based on the expected date of delivery (EDD). Initially, the EDD is determined based 
on the start of the last menstrual period, with an estimated 280 days (or 40 weeks) between 
these two dates. However, it is common for the EDD to be changed slightly subsequent to the 
first US scan, as this allows for a more direct measurement of fetal development. In this 
thesis, age was therefore defined based on the EDD obtained at US. The terms ‘gestational’ 
and ‘corrected’ age were used, as appropriate.  
  
2.1.1. Gestational age 
The term gestational age was used to describe the age of the fetus or the baby at birth; it was 
calculated according to this formula:  
 
Age (in weeks) = (280 – (EDD – RD)) / 7 
 
Where EDD = expected date of delivery, RD = reference date, and (EDD – RD) is 
calculated in days.   
 94 
In these circumstances, the reference date could either refer to the date of the fetal scan 
(used to calculate the gestational age at scan), or the date of delivery (used to calculate the 
gestational age at birth). Fetal scans were conducted from 28 weeks on (that is, 28 weeks ≤ 
Gestational Age < Birth) and only babies born at or over 34 gestational weeks were included.  
 
2.1.2. Corrected age  
Corrected (or adjusted) age was used to describe the postnatal age of a neonate or infant. 
Since the measure was also based on the EDD, it ensured that the baby’s prematurity was 
accounted for, even if minor; for example, when referring to a baby born at 38 weeks 
gestation. This was important as it allowed for a fair developmental comparison between 
infants born at different gestational ages. 
 
Corrected age was calculated according to the formula shown in the previous page; but in this 
case, the reference date referred to the date of examination, be it a scan or a behavioural 
assessment. For the purpose of the studies included in this thesis, the neonatal timepoint 
spanned the first month of life, with babies scanned from birth up to a corrected age of 47 
weeks (that is, Birth ≤ Corrected Age ≤ 47 weeks). The infant timepoint included individuals 
that were a little older, aged between 50-75 corrected weeks (or 4-6 months of age).  
 
Note: In this thesis, the majority of experimental chapters have reported age in weeks. 
However, since the first study is presented in the form of a published paper (chapter 3), infant 
age is referred to in terms of months, as this is what was originally submitted to the journal. In 
addition, there are other times in which age has been reported in months; however, this was 







2.2. Project 1: prospective infant imaging study at 1.5T 
2.2.1. Ethical approval 
This project received ethics approval from the UK National Research Ethics Service (REC 
08/H0718/76, 06/MRE02/73, and 12/LO/2017). Written informed consent was obtained from 
parents on behalf of themselves and their child.  
 
2.2.2. Recruitment strategy 
Infants were eligible if they were aged between 50-75 corrected weeks (or between 
approximately 4-6 months of age). Recruitment was therefore conducted at any stage 
between pregnancy and the first few months of postnatal life. Infants in the high-risk group 
were recruited via the British Autism Study of Infant Siblings (BASIS), while those in the 
typical or low-risk group were recruited from the local community. 
 
2.2.3. Study population 
 Typical community sample 
Participants in this sample were assumed to be typically developing and representative of the 
general population. However, information on familial ASD risk was not collected. For logistical 
reasons, the age of participants in this sample ranged between 3-6 months.  
 
 Low-risk group 
Participants were considered to be at low-risk if they had no family history of a first-degree 
biological relative with a diagnosis of ASD.   
 
 High-risk group 
Participants were characterised as high-risk if they had one full sibling with a clinical diagnosis 
of ASD, confirmed by two expert clinicians with reference to the DAWBA (Development and 
Well-being Assessment; Goodman et al., 2000) and the SCQ (Social Communication 
Questionnaire; Rutter et al., 2003).  
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 Exclusion criteria 
Initial exclusion criteria prior to enrolment in the study included: (i) preterm infants (born < 36 
weeks gestation), with (ii) contraindications for MRI (for example, metallic implants or 
pacemakers), (iii) clinically identified structural brain abnormalities, (iv) major antenatal or 
obstetric complications potentially altering infant development (such as perinatal asphyxia or 
seizures), (v) born to mothers with any current or past major psychiatric illness, and (vi) with a 
poor working knowledge of the English language (precluding informed consent for the study). 
 
2.2.4. Experimental design 
As part of this research project, all participants were assessed at 3/4-6 months of age. Those 
in the high-risk group were also followed-up at 36 months (Figure 2.1). During their first visit, 
participants underwent a structural MRI scan (which was part of a larger functional imaging 
study) and were video-recorded during a mother-infant interaction assessment. Basic 
demographic data on both the infant and the parents was also collected at this time. Then, at 
36 months of age, participants in the high-risk group were behaviourally assessed using the 
Mullen Scales of Early Learning (MSEL; Mullen, 1995) and the Autism Diagnostic Observation 
Schedule (ADOS-2; Lord et al., 2012). The infants’ parents were also interviewed using the 










Figure 2.1: Schematic diagram illustrating the experimental design of project 1. 
At 3/4-6 months, participants were assessed using both imaging and behavioural measures. 
Then, only participants in the high-risk group were followed-up for an outcome assessment at 
36 months. Abbreviations: MSEL = Mullen Scales of Early Learning; ADOS-2 = Autism 









• Behavioural measures:                
- MSEL                                   
- ADOS-2  
- ADI-R
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2.2.5. Imaging procedures 
Infants were scanned during natural sleep at the Centre for Neuroimaging in the Institute of 
Psychiatry, Psychology and Neuroscience at King’s College London. Image acquisition took 
place on a 1.5T General Electric TwinSpeed MRI scanner (GE Medical Systems, Milwaukee, 
WI, USA), equipped with an 8-channel head radiofrequency coil.  
 
 Participant preparation  
Prior to the MRI appointment, each family was given an information sheet detailing the 
purpose of the project and what to expect on the day of the scan. Given that all infants were 
scanned in natural sleep, without the use of sedation, appointment times were scheduled 
around the infant’s usual naptime. On the scanning day, families were invited to come to the 
research facility an hour before the scheduled appointment. This allowed sufficient time for the 
infant to become familiar with the experimental setting, and to be fed, if necessary. The infant 
was then changed into metal-free clothes and weighed on a medical balance. Written 
informed consent was obtained from the parent on behalf of the infant, and a detailed metal 
check was conducted to ensure that the infant was safe to scan. Subsequently, the parent and 
infant were transferred into a dark, quiet room, to allow for the infant to fall asleep on a 
portable MR table.  
 
Once asleep, the infant was swaddled in a cotton sheet and comfortably positioned in a Med-
Vac Infant Immobilisation Bag (CFI Medical Solutions, Fenton, MI, USA), which provided neck 
support and restricted head movement during scanning. In order to minimise acoustic noise, 
the scanner bore was insulated with sound attenuating foam (Ultra Barrier, American Micro 
Industries, Chambersburg, PA, USA) and the infant’s ears were protected with mouldable 
silicone-based dental putty (President Putty, Mahwah, NJ, USA). To further minimise any 
residual noise, MiniMuff noise attenuators (Natus Medical Inc., San Carlos, CA, USA) were 
used to cover the dental putty, and a set of paediatric MR-compatible piezoelectric 
headphones (MR Confon, Magdeburg, Germany) were placed on top. As soon as the infant 
was fully prepped (Figure 2.2), the MR table was moved into the scanning room and the infant 
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was transferred from the portable table onto the scanning bed. A pulse oximeter was secured 
on the infant’s toe, to enable monitoring of the heart rate and blood oxygen saturation levels 
during the scan. Furthermore, both a researcher and parent (if willing) remained inside the 
scanning room to observe the infant’s behaviour throughout. If the infant awoke or showed 










Figure 2.2: A 4 month-old infant prepped for scanning. 
(A) The infant is comfortably swaddled in a cotton sheet and wrapped in an infant 
immobilisation bag. (B) The infant’s ears are protected with dental putty, MiniMuffs, and 
headphones, with a headband used to secure these in place. As shown in image (A), 




The entire scanning protocol lasted for approximately 40 minutes, and involved the acquisition 
of structural and functional sequences. For the purpose of this thesis, analysis was based 
solely on the structural T2-weighted sequence. However, analyses of the functional datasets 
have already been published (Blasi et al., 2011, 2015). 
 
 Image acquisition 
A T2-weighted fast spin echo sequence (T2w) with the following imaging parameters was 
acquired: TR = 3000/4500 ms, TE = 115 ms, slice thickness = 4 mm, slice gap = 2 mm, FOV = 
180 mm, flip angle = 90°, and a 256 x 224 matrix. 
 
 A                B 
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 Radiologic review 
A neuroradiologist who was unaware of risk group reviewed all scans to screen for any 
obvious incidental abnormalities. In the eventuality of an identified anomaly, the 
neuroradiologist contacted the participant’s general practitioner to inform them of the concern. 
 
 Image post-processing and volumetric segmentation 
The T2w images (Figure 2.3A) were volumetrically segmented following an automated 
protocol, developed-in-house. First, the T2w images were skull-stripped using label 
propagation and decision fusion of three manually segmented brain masks (Heckemann et al., 
2006). Subsequent to this, volumetric segmentations of the masked images were performed 
using an atlas-based approach, which adapted the Statistical Parametric Mapping software 
(SPM version 8), and used a 4D probabilistic neonatal brain atlas (Kuklisova-Murgasova et al., 
2011) as the input. SPM’s segmentation model unified tissue classification, image bias 
correction, and non-linear atlas registration (Ashburner and Friston, 2005). An Expectation-
Maximisation algorithm (Dempster et al., 1977) and a Levenberg-Marquardt algorithm 
(Marquardt, 1963) were used to estimate the Gaussian Mixture Model (GMM) parameters. 
Then, in order to optimise these GMM parameters for tissue intensity distribution, bias field, 
and atlas deformation, Iterated Conditional Modes were employed. As a final step, the CSF 
segmentation was refined. This was done by thresholding the masked T2w image based on 
the mean intensity of the CSF, as calculated by SPM’s posterior probability map. Partial 
volume misclassifications were particularly prominent at CSF boundaries. As a result, these 
misclassifications were corrected using second-order Markov Random Fields, which enabled 
spatial constraints to be imposed (Ledig et al., 2012).   
 
Once the automated protocol had been applied to all T2w images, any errors of the 
automated segmentation were manually corrected by a single rater, who used the ITK-SNAP 
tool (version 2.2; Yushkevich et al., 2006) and a pen-tablet interface (Intuos Pro, Wacom, 
Japan) to produce the final segmentations (Figure 2.3B). All segmentations were carried out 
by investigators who were blind to infant risk group, and when necessary, blind to any relevant 
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behavioural measure. The final segmentation produced brain volumes (in cm3) of the following 
regions: total grey and white matter tissue, extracerebral CSF (including third and fourth 
ventricles), lateral ventricles, subcortical region (including caudate nucleus, putamen, globus 
pallidus, thalamus, and internal capsule), midbrain (including cerebral peduncle, substantia 
nigra, brainstem, and pons), and cerebellum. Due to ongoing myelination, tissue contrast in 3-
6 month-old brains does not easily allow for a reliable differentiation of grey and white matter. 
Therefore, similar to others (Hazlett et al., 2012), grey and white matter tissue classes were 
not further segmented.  
 
In addition, the following global measures were calculated: intracranial volume (the sum of all 
regions), total brain tissue (including all brain matter but excluding CSF-filled spaces), and 
total CSF (comprising extracerebral CSF and lateral ventricles). 
Figure 2.3: Volumetric segmentation of a 4-month infant brain acquired at 1.5T 
(A) A transverse T2-weighted fast spin echo sequence acquired from a 4 month-old brain.  
(B) The output of the final segmentation, obtained after manual editing of the automated 
segmentation. Abbreviations: CSF = cerebrospinal fluid. 
 
 Validation of the automated technique, and reliability of the manual editing 
The validity of the automated segmentation protocol was assessed by comparing its output 
with the output of manually segmented (‘gold standard’) brains, randomly selected from n=10 
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individuals (mean age = 60.00 corrected weeks; n = 3 male). All of the manual segmentations 
were completed on ITK-SNAP and performed by the same rater. The inter-rater intraclass 
correlation (ICC) for the total intracranial volume was 0.989 (p < 0.001), suggesting negligible 
variability between the two methods of segmentation. Similar results were obtained for the 
individual ICCs of each brain region, with values as follows: total grey and white matter (0.981, 
p < 0.001), extracerebral CSF (0.976, p < 0.001), lateral ventricles (0.953, p < 0.001), 
subcortical region (0.903, p < 0.001), midbrain (0.823, p < 0.001), and cerebellum (0.932,          
p < 0.001).   
 
Intra-rater reliability of the manual corrections applied to the automated segmentations was 
also excellent, with ICC values ranging between 0.918 and 0.998. For the total intracranial 
volume, the ICC of the intra-rater variability was 0.998 (p < 0.001), indicating excellent 
reproducibility. Similar results were found for the individual correlations of each brain region: 
total grey and white matter (0.984, p < 0.001), extracerebral CSF (0.989, p < 0.001), lateral 
ventricles (0.965, p = 0.001), subcortical region (0.923, p < 0.001), midbrain (0.918, p = 
0.001), and cerebellum (0.948, p < 0.001). 
 
2.2.6. Clinical and behavioural procedures 
 Mother-infant interactions at 3/4-6 months 
Within two weeks of the MRI scan, but usually on the same day, observed mother-infant 
interactions were video-recorded using a standard assessment protocol that can be applied to 
infants aged 2-6 months (Murray et al., 1996a). In a face-to-face play session that lasted for 5 
minutes, mothers were asked to play with and talk to their infant as they normally would, but 
without the use of any toys or objects, and with the infant seated facing towards the mother. 
Maternal and infant behaviours were coded by two trained raters, experienced with the Global 
Rating Scales (GRS; Murray et al., 1996) and blind to infant risk group.  
 
According to the GRS, maternal and infant behaviours are coded on a 5-point rating scale (1-
5), with higher scores indicating more positive behaviours (for example, increased levels of 
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maternal sensitivity) and lower scores indicating inadequate interactions (for example, low 
levels of infant communication). Once the items have been scored, an average of the 
individual scores that constitute a given behavioural dimension is calculated in order to 
generate a composite score, also ranging from 1-5. The dimensions examined in this thesis 
were based on those commonly reported in the current parent-infant literature (Halligan et al., 
2013; Stein et al., 2012), and comprised: maternal sensitivity, maternal affect, infant 
communication, and infant fretfulness (Table 2.1). 
 
Table 2.1: A description of the behavioural dimensions examined as part of the mother-
infant interaction assessment  
Note: Individual items are scored on a rating scale of 1-5, with higher scores indicating more 
positive behaviours. Composite dimension scores comprise an average of the individual items 
that make up each dimension, and hence, also range from of 1-5. 
 
 
Dimensions Individual Items  Definition 
Maternal 






Maternal response to the infant’s 
communication cues; the extent 
to which it is contingent and 
appropriate to the infant’s needs 
and experiences. Includes 
attitudes and feelings towards 
the infant. 
 
Affect • Happy/Sad 
• Much energy/Low energy 
• Absorbed in the Infant/Self-
Absorbed 
Maternal display of affective 
state, including positive and 




Communication • Attentive/Avoidant 
• Active communication/No 
communication 
• Positive vocalisations/No 
positive vocalisations 
 
Infant’s level of engagement and 
communication, including 
positive vocal and non-vocal 
behaviour directed towards the 
mother. 
 
Fretfulness • Happy/Distressed 
• Non-fretful/Fretful 
Infant’s affective state, including 
positive and negative affectivity.  
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Inter-rater ICCs were measured on a randomly selected 20% of the interactions, and ranged 
between 0.741-0.993, indicating very good inter-rater reliability. In cases where there were 
discrepancies between raters, these were discussed, and final consensus ratings were 
obtained in collaboration with members of the research unit who helped develop the scale. 
 
The reason for choosing the GRS over any other measure was partly a logistical one, as the 
scale was already being used in the department and by collaborators. However, the GRS is 
reliant on only a brief 5-minute mother-infant interaction, which may limit its generalizability. In 
addition, although it provides global measures of maternal and infant interactive behaviours, 
there are some aspects of early interactions that are not captured with the GRS, but that may 
have been relevant to study. These include aspects of tactile stimulation and verbal content, 
as well as dimensions that may be more relevant to a population at risk of ASD; for example, 
features which tap into the social behavioural deficits potentially present in the dyad. Finally, 
because the GRS is based on a face-to-face play session where participants are not allowed 
to use any toys or objects, the scale is not able to pick up on other dimensions of play which 
are dependent on the use of toys. For example, in a floor mat play session conducted with 
toys, a range of different behaviours would have been elicited, hence requiring a coding 
scheme which is able to capture maternal control and negativity, as well as the infant’s ability 
to share.  
 
Despite some of these weaknesses, there are many more reasons that make the GRS both a 
valid and reliable tool for assessing mother-infant interactions in the context of infants at risk 
of ASD. First, the GRS is sensitive to impaired interactions even amongst low-risk samples 
(Cohn et al., 1986; Gunning et al., 2004; Murray et al., 1996a), which suggests that it may be 
equally sensitive to interactions involving infants with and without a familial risk of ASD. 
Second, the GRS has been applied cross-culturally, in Africa, South America, and Europe 
(Cooper et al., 1999; Gunning et al., 2004; Sepulveda et al., 1999), which suggests that it is 
reliable for use in this study, which encompasses families from a range of distinct cultures and 
ethnicities. Third, the scales have good discriminant validity, having already been used with a 
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range of clinical groups, including mothers with depression (Murray et al., 1996a, 1996b), 
schizophrenia (Riordan et al., 1999), and borderline personality disorder (Crandell et al., 
2003). The scale has also been recently used with mothers of infants at risk of ASD (Blasi et 
al., 2015), and although other studies examining this population have chosen to use an 
alternative measure (Wan et al., 2012), there is substantial overlap between the two. In fact, 
the measure used by Wan et al., (2012) was built on the fundamentals of the GRS, and 
modified to suit the study’s sample population in terms of age and ASD risk-status. Although 
this would have been an interesting approach to use, it was felt that the modified measure 
was not necessarily as well-validated and reliable as the GRS; therefore, and also due to 
limited time and resources, the GRS was chosen instead. Fourth, maternal and infant ratings, 
as acquired using the GRS, have been shown to predict infant and child cognitive outcomes at 
a later stage in development (Murray et al., 1996b), and as such, were suited for the 
objectives of this study. The scale was also chosen for use in this study because it is not 
overly time-consuming to administer or to rate, and yet, allows for very sensitive data to be 
acquired with high levels of reliability and perceptiveness.  
 
Finally, the mother-infant interactions obtained in this study also complement the brain 
measures used. While information on brain volume and chemistry may provide details on a 
potential biological basis for behaviours observed, they do not in themselves reveal anything 
about behaviour. For that, we need other measures such as observed mother-infant 
interactions, especially since these measures provide a window into the parenting 
environment of the infant, which may itself shape brain biology.   
 
 Outcome assessments at 36 months  
At 36 months of age, all infants in the high-risk group were invited back for a follow-up 
behavioural assessment, which included the ADOS-2, the ADI-R, and the MSEL. The MSEL is 
a standard instrument for the evaluation of cognitive ability and development; it is 
administered directly with the child and is appropriate for use between birth and 68 months of 
age. The assessment yields a standardised score (mean = 100, SD = 15) of overall 
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intellectual ability (Early Learning Composite; ELC). The ADOS-2 is a standard and semi-
structured play-based assessment, used to examine autism-related behavioural 
characteristics. For the ADOS-2, either module 1 (designed for non-verbal children or children 
with only single words) or module 2 (designed for children with consistent phrase speech) was 
administered at 36 months of age. However, to facilitate comparisons of symptom severity 
across different modules and ages, total algorithm scores were converted into standardised 
calibrated severity scores, which range from 1 to 10 (Gotham et al., 2009). The observations 
from the ADOS-2 were complemented with a parent-report of the infant’s behaviours, 
administered by a standard structured interview – the ADI-R.  
 
In common with other research groups studying infants at risk of ASD (Zwaigenbaum et al., 
2007), a ‘best estimate clinical consensus’ approach to diagnosis was taken. That is, outcome 
classifications were defined by a group of experienced clinical researchers (TC, GP, CC), who 
took into account all available information (the MSEL, ADOS-2, ADI-R, and any informal 
observations), and agreed on a consensus ASD outcome. Children were characterised as 
‘high-risk ASD’ if they met the DSM-5 criteria for ASD (American Psychiatric Association, 
2013); in contrast, they were considered as ‘high-risk non-ASD’ if they did not meet the 
specified criteria.  
 
2.2.7. Work done by others 
The infant imaging data was acquired with the help of researchers (AB, VS, and MG) and 
radiographers at the Institute of Psychiatry, Psychology, and Neuroscience. In addition, SW 
completed the image post-processing and automated segmentation steps. Behavioural 
assessments were administered and coded by members of the BASIS team (TC, GP and 
CC), with the exception of the mother-infant interactions, which were conducted by VLS, VS, 





2.2.8. Power considerations and sample size estimation 
The design of this project was based on evidence suggesting that approximately 20% of 
infants who have a sibling with ASD, will themselves be diagnosed with the condition 
(Constantino et al., 2010; Ozonoff et al., 2011; Sandin et al., 2014). Moreover, previous MRI 
studies using the infants at risk design to examine differences in infants as young as 6 
months, have reported significant results with sample sizes of less than 20, but up to at least 
30, per group (Blasi et al., 2015; Lloyd-Fox et al., 2013; Shen et al., 2013). A minimum sample 
size of 25 participants per group was therefore thought to provide sufficient power for the 
identification of preliminary differences (p ≤ 0.05).  
 
Post-hoc power calculations for the main finding(s) of each study are included in Appendix 1. 
Effect sizes are also reported, using partial eta squared (p2), which measures the proportion 
of variance of the dependent variable that is accounted for by the independent variable 
(Portney et al., 2009). The effect sizes were interpreted using Cohen’s (1988) criteria, where 
p2  0.01, 0.06, and 0.14 are respectively considered small, medium, and large effects. For 
further details on the results of these calculations, please refer to Appendix 1 on page 255.   
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2.3. Project 2: prospective serial imaging study at 3T 
This research project built upon the pilot findings of project 1. Besides having access to 
optimised infant MRI protocols, acquired at 3T, this project was also able to accommodate for 
scanning at even younger ages. 
 
2.3.1. Ethical approval 
This project was granted ethical approval by the UK National Research Ethics Service 
committee of Dulwich and Riverside (REC 12/LO/2017 and 14/LO/1169). Written informed 
consent was obtained from all participants, and when appropriate, parents consented on 
behalf of their infants.   
 
2.3.2. Recruitment strategy 
Participants were referred to this project from antenatal US departments and postnatal wards 
in hospitals across South London. The following hospitals were actively involved in the 
recruitment process: King’s College Hospital, St. George’s Hospital, St. Thomas’ Hospital, 
Medway Maritime Hospital, Croydon University Hospital, and the South London and Maudsley 
Trust. Some participants were recruited from the local community (for example, from 
breastfeeding cafes and prenatal yoga classes), and some contacted the team voluntarily, 
having heard of the study from family, friends, and colleagues. Alternatively, participants with 
a familial risk of ASD were recruited more strategically from ASD charities, special needs 
schools, and the BASIS network. 
 
Prior to enrolment in the project, all participants who had given permission for their contact 
details to be passed to the research team were contacted for an initial screening interview. 
The objective of this interview was to determine eligibility, as well as to safety screen for any 
MRI contraindications. Only then and if eligible to take part, did participants become formally 
enrolled. In order to accommodate for as many participants as possible, there was flexibility 
with the timing of enrolment; participants were allowed to enrol at any stage between 
pregnancy and up until early infancy, around 3-4 months of age.  
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2.3.3. Study population 
 Low-risk group 
Participants were considered to be at low-risk if they did not have a first-degree biological 
relative with a diagnosis of ASD and/or a known genetic risk of ASD (for example, the 22q11.2 
deletion syndrome).  
 
 High-risk group 
Participants were characterised as high-risk if they had at least one biological (full or half) 
sibling with a clinical diagnosis of ASD. The diagnostic status of the sibling was verified by a 
copy document of the clinical diagnosis or any other relevant medical correspondence. 
 
 Inclusion criteria 
The classification of participants into low-risk and high-risk groups was based solely on the 
presence of a familial risk of ASD. Therefore, participants with additional risk factors were 
included in both groups. For example, infants with cerebellar abnormalities and/or 
ventriculomegaly, which are commonly but not only associated with ASD outcome, were 
incorporated into either group (Courchesne et al., 1994; Gilmore et al., 2001; Limperopoulos 
et al., 2007; Palmen et al., 2005). Furthermore, since there is now a growing body of evidence 
to suggest that antenatal depression may be an important environmental risk factor for ASD 
(Rai et al., 2013), infants born to mothers with a clinical diagnosis of major depressive 
disorder were allowed to remain in the study. Similarly, late-preterm infants, classified as born 
between 34-37 gestational weeks, were also included. Indeed, preterm infants are currently 
being involved in other early ASD studies (Padilla et al., 2015; Ure et al., 2015), since they too 
provide an additional risk factor for a later diagnosis (Goldin and Matson, 2016; Guy et al., 
2015; Pritchard et al., 2016).  
 
This approach, of including participants with additional risk factors to both risk groups, 
ensured that the groups were fairly equally matched for risks of ASD other than familial. Thus, 
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if there were any significant differences between groups, these would more confidently be 
attributed to the genetic risk, present only in the high-risk group.  
 
 Exclusion criteria 
The exclusion criteria for both low-risk and high-risk groups included: (i) preterm infants born 
at < 34 gestational weeks, with (ii) structural brain abnormalities identified at a routine 
antenatal US (with the exception of mild cerebellar abnormalities and/or mild to moderate 
ventriculomegaly), and (iii) contraindications for MRI (for example, metallic implants). 
Participants were also excluded if there was a (iv) major complication in pregnancy (such as 
perinatal asphyxia) and/or delivery (resulting in abnormal neurological signs as evidenced by 
an Apgar score of < 7 at five minutes), as well as any (v) serious incidental findings (such as 
cystic infarcts) on fetal, neonatal, and/or infant MRI examinations. Finally, infants born to 
mothers (vi) with serious medical conditions (such as epilepsy), (vii) any current or past major 
psychiatric illness (with the exception of major depressive disorder), (viii) exposed to illicit 
drugs and/or alcohol consumption (of more than 7 units per week) during pregnancy, and (ix) 
with poor working knowledge of the English language (precluding informed consent), were 
also excluded.  
 
2.3.4. Experimental design 
As part of this research project, all participants were offered the opportunity to take part in 
fetal, neonatal, and infant assessments (Figure 2.4). MRI acquisition occurred at all three 
timepoints, and in each scanning session the data acquired comprised of structural, 
functional, diffusion, and spectroscopic sequences. However, for the purpose of this thesis, 
only the structural and spectroscopic datasets were analysed. Specifically, spectroscopy was 
analysed at all three timepoints, while the structural data was only analysed at fetal and 
neonatal timepoints. In addition, basic demographic data on both the infant and the parents 
was collected. Physical measures including head circumference and body weight were also 




















Figure 2.4: Schematic diagram illustrating the experimental design of project 2. 
Low-risk and high-risk participants were assessed at several timepoints. At fetal, neonatal, and infant timepoints, all participants underwent an MRI scan, with 
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2.3.5. Imaging procedures 
Fetuses, neonates, and infants were scanned at the Centre for the Developing Brain at St. 
Thomas’ Hospital. All image acquisition took place on a 3T Phillips Achieva MRI scanner 
(Philips Healthcare, Best, The Netherlands).  
 
 Fetal imaging 
Expectant mothers enrolled in the research project and willing to take part in fetal MRI were 
screened, to ensure that they were safe to be scanned. At this stage, the main concern was to 
determine whether the participant had a metallic implant and/or a BMI ≥ 35, as either of these 
conditions would prohibit the scan from taking place. Once eligibility had been established, a 
fetal MRI appointment was scheduled after 28 weeks gestation. This limit on gestational age 
was chosen since it ensured that fetuses were large enough that there was a restricted 
amount of fetal motion (Hayat et al., 2011), allowing for images of better quality to be 
acquired. Prior to their appointment, expectant mothers were also provided with an 
information sheet detailing the purpose of the research project and the practicalities of the 
scanning procedure.  
 
On the day of the scan upon arrival to the centre, the maternity records of the expectant 
mother were checked to ensure that the correct EDD was known. Subsequently, written 
informed consent was obtained from the mother, and the possibility of incidental findings was 
discussed. The participant was then asked to remove all jewellery and to change into hospital 
scrubs, so as to ensure optimal comfort and metal-free clothing. A detailed metal check was 
also conducted to safety screen for any MRI contraindications. Prior to entry in the scanning 
room, the expectant mother’s body temperature and weight were recorded. In instances 
where the maternal temperature was ≥ 37.5°C, the scan was postponed. Alternatively if all 
was well, the mother’s temperature was measured at the end of the scan, to ensure that both 
maternal and fetal body temperatures had remained within a normal range during the MR 
examination. As a precautionary measure, the temperature inside the scanning room was set 
to 18°C, with air-conditioning inside the bore of the magnet providing additional cooling. 
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Once in the scanning room, the participant was asked to lie on the MRI table, feet first, in a 
lateral tilt position to avoid compression of the inferior vena cava. A 32-channel cardiac-
thoracic coil was placed around the abdominal area proximal to the fetal head, and pregnancy 
pillows were placed around the mother to position her as comfortably as possible. Earplugs 
and headphones were provided to protect maternal hearing, allow for the radiographers to 
communicate with the mother, and enable her to listen to music. In addition, the expectant 
mother was given a “buzzer”, which she was advised to use if feeling unwell or uncomfortable. 
Once pressed, this would alert the radiographers and depending on the issue of concern, a 
consensus was reached on whether to stop or continue scanning. A pulse oximeter was also 
attached to the mother’s toe in order to enable monitoring of heart rate and blood oxygen 
saturation levels throughout the scan. 
 
In total, the entire scanning procedure lasted for approximately 60 minutes. Due to fetal 
motion, image acquisition was intermittent throughout, with each imaging sequence requiring 
some geometrical pre-planning.  
 
 Image acquisition 
The fetal MRI assessment involved a set protocol of sequences. Initial sequences were run for 
radiologic reporting purposes and to ensure that normal brain appearances could be 
confirmed, while subsequent sequences were acquired solely as part of the research protocol. 
Irrespective of this, all sequences have been described in detail below, with imaging 
parameters included in Table 2.2.  
 
Survey: The survey is a quick 48-second acquisition, which enables the radiographers to 
identify the fetus’s presentation; that is, whether cephalic or breech. Depending on this, the 
mother’s positioning within the scanner and/or the position of the coil may need to be 
adjusted, so that the fetal brain is placed as close to the overlying coil as possible, to allow for 
maximum SNR.  
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Balanced Fast Field Echo Cine Soft Tone Sequence (BBFE Cine): The cine is a balanced fast 
field echo sequence; it is based on a cardiac sequence and is effective in observing fetal 
movement with near full-body coverage (Hayat et al., 2011). The sequence has proven to be 
particularly useful in research studies designed to assess fetal movement patterns. For this 
study, it was mainly obtained as a visual acknowledgement to the parents, and as a 
confirmation that their baby was healthy and mobile.  
 
T2-weighted Single Shot Turbo Spin Echo of Uterus (T2ssTSE UTERUS): This is another 
rapidly acquired sequence, mainly used for the radiologic reporting of the intrauterine 
environment, including the placenta and the amniotic fluid. Each image is acquired in less 
than a second, and therefore, it is usually free from any motion artefacts. These sequences 
were acquired in the transverse, coronal, and sagittal planes.   
 
T2-weighted Dynamic Single Shot Fast Spin Echo (T2ssFSE): This sequence was designed 
and optimised in the department to allow for a snapshot to volume reconstruction, used to 
overcome motion artefacts (Jiang et al., 2007). Multiple single shot acquisitions (4 transverse, 
2 coronal, and 2 sagittal) with overlapping thin slices were obtained (Figure 2.5). Then, the 
T2ssFSE sequences were processed offline to enable production of a dataset suitable for 









Figure 2.5: A T2-weighted dynamic single shot fast spin echo sequence (T2ssFSE) 
This T2ssFSE sequence was acquired from an expectant mother at 31+6 gestational weeks. 
The image shows the T2ssFSE sequence acquired in the (A) sagittal, (B) coronal, and (C) 
transverse plane. As is evident there is a slight inhomogeneity in the contrast of the image, 
likely due to 3T heterogeneity artefacts, but which can be improved with image reconstruction. 




T1-weighted Snapshot Inversion-Recovery (SNAPIR): In contrast to conventional T1-weighted 
sequences, this SNAPIR sequence (Figure 2.6), designed and developed in the department 
(Malamateniou et al., 2011), provides a much better delineation of the fetal brain, even in the 
presence of motion. The sequence was acquired in the transverse plane and mainly used for 







Figure 2.6: T1-weighted snapshot inversion-recovery 
(SNAPIR) sequence. This is an image of a SNAPIR sequence 
acquired in the transverse plane from an expectant mother at 
34+1 weeks gestation. 
 
 
Point Resolved Spectroscopy (PRESS): Spectroscopic 1HMRS was obtained using the 
PRESS sequence. To enable quantification of different metabolites, the sequence was 
acquired at two distinct echo times: 55 ms and 144 ms. Prior to data acquisition, a 
20x20x20mm voxel was placed in the region of the left basal ganglia, avoiding any CSF-filled 








Figure 2.7: Voxel placement in a fetal 1HMRS PRESS sequence.  
This image was acquired from a fetus at 31+6 gestational weeks. The 20x20x20 mm voxel, 
indicated by the green box, was placed in the fetal brain region of the left basal ganglia. Voxel 
placement is shown in the (A) transverse, (B) coronal, and (C) sagittal planes.  
A      B                 C 
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Table 2.2: Fetal imaging parameters 
Note: The Survey is a rapidly acquired sequence, which ensures that the fetal brain is within field of view. The T2-weighted single shot Turbo Spin Echo of the 
Uterus (T2ssTSE UTERUS) and the T1-weighted Snapshot Inversion-Recovery (SNAPIR) are mainly used for radiologic reporting. The Balanced Fast Field 
Echo Cine Soft Tone (BBFE Cine) sequence is useful for confirming fetal and cardiac motion, but here, it was mainly acquired for the parents. As part of this 
thesis, volumetric analysis was completed using a 3D reconstruction of the transverse, coronal, and sagittal T2-weighted dynamic single shot Fast Spin Echo 
(T2ssFSE) sequences. Spectroscopic analysis was based on the point resolved spectroscopy (PRESS) sequences acquired at 55 ms and 144 ms, with a 
20x20x20 mm voxel placed in the fetal region of the left basal ganglia. Abbreviations: TE = echo time; TR = repetition time; FOV = field of view; SAR = specific 
absorption weight.  
 










 TE (ms)            87 2.4 140 180 12 55 144 
 TR (ms) 8000 4.9 1022 35000 35000 1500 1500 
 Flip angle (deg.) 90 60 90 90 180 90 90 
 Acquisition voxel size (mm) 3.03x3.01x10 2.19x2.21x30 1.08x1.98x4 1.25x1.25x2.50 1.00x1.01x4 - - 
 Slice gap (mm) 3 0 0 -1.25 0 - - 
 Reconstructed voxel size (mm) 0.93x0.93x10 1.25x1.25x30 0.84x0.84x4 1.18x1.18x2.50 0.96x0.97x4 - - 
 FOV (mm) 400x400 500x500x30 430x430x160 320x340x100 320x340x128 - - 
 SAR (W/Kg) 0.4 0.7 0.7 0.7 0.6 0.4 0.4 
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 Radiologic review 
At the end of each scanning session, a neuroradiologist (MR, OC, KP, and SA) reviewed all of 
the acquired images in order to assess fetal development and to screen for any potential 
incidental findings. The radiologic review included assessment of brain structures, but also of 
the orbits (including the lenses and optic nerve), teeth, ears, and pituitary stalk. Apart from 
assessing the general appearance of these regions, the following measurements were also 
taken: biparietal diameter, transcerebellar diameter, vermis height, pons diameter, post horn 
diameter of lateral ventricles, cavum septum pellucidum width, and globe diameter. Normal 
measurements were considered to be between the 5th and 95th centile for any given 
gestational age (to access the Departmental fetal centile calculator, please visit 
https://www.developingbrain.co.uk/fetalcentiles/). In cases where abnormalities were 
identified, the expectant mother was informed; her general practitioner and/or obstetrician was 
also contacted directly by the clinician responsible for the case.  
 
 Spectroscopic analysis 
1HMRS data was analysed in precisely the same manner for all three imaging timepoints, and 
therefore, it will be described in detail later on (please see section 2.3.5.4 on page 142).  
 
 Structural analysis 
2.3.5.1.4.1 Image post-processing 
Before the structural T2ssFSE images could be segmented, a 3D volumetric reconstruction of 
the acquired scans was produced using the Snapshot MRI with Volume Reconstruction (SVR) 
technique, developed in the department (Kuklisova-Murgasova et al., 2012). Since fetal 
motion poses a major challenge in imaging, the acquisition time of the T2ssFSE images was 
set at less than one second per slice. This allowed for the freezing of motion in time and 
ensured, as much as possible, that movement could only be observed between slices. In 
addition, acquisition was also performed with overlapping slices, in order to oversample and 
ensure full coverage of the fetal brain. In total, a series of eight T2ssFSE sequences were 
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acquired across all three orthogonal planes (Figure 2.8A), with imaging parameters as 
previously described (see Table 2.2). 
 
Once acquisition was complete, an automated script split the acquired sequences into their 
constituent loops, with each sequence typically comprised of two loops. Then, in order to 
ensure adequate image quality, all individual loops were manually reviewed on the Image 
Registration Toolkit (IRTK). Image loops that had been seriously corrupted by motion artefacts 
or where the anatomical detail had been lost were removed from subsequent post-processing 
steps. For each of the remaining loops, four landmarks were manually selected on IRTK; 
these included the top of the brainstem, bottom of the brainstem, left eye, and right eye. 
Subsequent to this, an image loop with full brain coverage and with the least motion corruption 
was selected as a template. Transformations that adjusted the orientation of the individual 
loops to the template loop were calculated using the previously selected landmarks. Then, the 
region of the fetal brain was manually segmented on the template loop using ITK-SNAP, to 
create a brain mask that excluded most of the maternal tissue.  
 
Next, the selected loops, transformations aligning these loops to the template loop, and the 
fetal brain mask, were used as an input to the reconstruction software (Kuklisova-Murgasova 
et al., 2012). Registration was performed under the assumption that the fetal brain underwent 
unknown motion during scanning, but did not change in shape or size, and so could only 
experience rigid body motion. Initially, a volumetric registration of the individual loops to the 
template loop was performed, so that the manually created template mask could be used to 
crop the loops and remove the maternal tissue. At this time, an initial estimate of the volume 
was also reconstructed.  
 
Although T2ssFSE sequences tend to freeze fetal motion in time, it is possible that a few 
slices may exhibit artefacts due to sudden fetal motion. This is evident especially at earlier 
gestations when the fetus is still able to move freely because of a disproportionate amount of 
amniotic fluid relative to fetal size. Hence, the reconstruction algorithm ensured that all slices 
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with motion artefacts were automatically identified using robust statistics, and excluded from 
the reconstruction process. Then, the algorithm interleaved slice-to-volume registration with 
volumetric reconstruction for a fixed number of iterations, while increasing the number of free 
registration parameters at each iteration. This meant that motion correction was performed by 
slice-to-volume registration of the acquired slices to the latest estimate of the reconstructed 
volume. During the last iteration, each acquired slice was registered to the reconstructed 
volume separately, in order to fully recover inter-slice motion. Altogether, the algorithm 
performed interleaved motion-correction, rejection of slices corrupted by motion, intensity 
correction, and volumetric reconstruction of fetal brain T2ssFSE images.  
 
At times, the final reconstruction result was not perfectly orientated. In these instances, 
manual input using IRTK was required to minimally orientate the fetal brain, so that the final 
volume was appropriately displayed in the orthogonal plane – with transverse, coronal, and 
sagittal projections (Figure 2.8B). Ensuring a correct orientation was particularly important in 
order to achieve high reproducibility and homogeneity between subjects.  
 
The final step in post-processing was to resample the reconstructed brain. The voxel size of 
the final reconstructed brain (0.75x0.75x0.75 mm) was far too large for an accurate volumetric 
segmentation, mainly because the analysis would be prone to errors driven by partial volume 
misclassifications. Therefore, the voxel size of the reconstructed and oriented image was 
converted from 0.75x0.75x0.75 mm to 0.20x0.20x1.00 mm (Figure 2.8C). This specific voxel 
size was chosen as it provided high image resolution and a feasible number of slices for 
manual segmentation (that is, approximately 100 slices in the transverse plane).  
 
Image post-processing of a single participant (including registration, reconstruction, 
orientation, and resampling) took, on average, two hours to complete. The final product of the 
volumetric reconstruction yielded a 3D fetal brain of full coverage, with high resolution and 
SNR. This allowed for the fetal brain to be viewed with equal detail and quality in all three 




Figure 2.8: Post-processing of fetal T2-weighted images 
Section (A) presents a single loop of a T2ssFSE sequence acquired in the sagittal plane from 
a fetus at 31+4 gestational weeks. Notice how the slices are corrupted by fetal motion, with 
missing data represented by a series of dark lines in both the transverse and coronal planes 
(see arrowheads). In (B) the panel below, a reconstructed image of a 3D fetal brain, oriented 
in the orthogonal plane, is shown. The final panel (C) illustrates the oriented brain, which has 
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2.3.5.1.4.2 Volumetric segmentation 
Once the full reconstruction was complete (Figure 2.9), volumetric segmentations were 
performed on ITK-SNAP (Yushkevich et al., 2006), which enables all three orthogonal planes 
to be segmented simultaneously. Although the software was originally designed for adult 
medical images, an analysis protocol was developed-in-house to ensure that the fetal brain 
would be segmented reliably (Kyriakopoulou et al., 2014, 2016; Vatansever et al., 2013).  
Figure 2.9: The 3D reconstructed brain of a fetus at 34+1 gestational weeks. 
 
 
Manual segmentations are still the ‘gold-standard’ in fetal brain imaging; however, by making 
use of ITK-SNAP’s semi-automated technique, the developed protocol attempted to minimise 
manual labour as much as possible. This was feasible through the active contour evolution of 
ITK-SNAP, which relies on the fact that different brain structures have different contrast 
intensities. First, by visually assessing the image, upper and lower intensity thresholds were 
established and manually defined for each region-of-interest. Once the threshold parameters 
had been set, active ‘bubbles’ were placed on strategic location within the region. Then, by 
making use of the active contour evolution, it was possible to visualise the automatic 
expansion of the bubbles evolve from a rough estimate to a very close approximation of the 
region-of-interest.  
 
Contour evolution is governed by the velocity of expansion, which depends on the shape and 
size of the bubbles created, as well as on the intensities of the neighbouring voxels. The ITK-
SNAP software allows for the user to define the velocity of the contour evolution. It also 
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enables for the process to be viewed in real-time, which ensures a greater control of the 
segmentation, compared to more fully automated techniques in which only the end-result is 
available to the user. According to the fetal segmentation protocol, once the process of 
contour evolution had been stopped, any errors of the semi-automated technique were 
corrected in order to optimise accuracy. Editing of the segmentation was performed manually 
using a pen-tablet interface (Intuos Pro, Wacom, Japan), with the rater amending any 
erroneously segmented voxels in order to arrive at the final segmentation (Figure 2.10).  
 
The entire segmentation process was conducted on the transverse plane by investigators who 
were blind to infant risk group. More details on workload distribution and rater reliability are 
provided later on (please see pages 126-127). The transverse plane was chosen because it 
provided the highest image quality and contrast resolution, as well as the best delineation of 
the anatomy. Accuracy of the segmentations was confirmed on both sagittal and coronal 
planes. Once complete, the volume of the region-of-interest was automatically calculated in 
cm3 on ITK-SNAP, through multiplication of the segmented area by the thickness of each 
slice. The following regions were segmented: lateral ventricles, third ventricle, fourth ventricle, 
cerebellum, pons, extracerebral CSF, supratentorial brain tissue, and cortex (see Table 2.3 for 
a detailed description of the anatomical boundaries).  
 
As was done at the infant timepoint, some additional measures were also calculated. These 
included: intracranial volume (defined as the sum of all regions), total brain tissue (which 
included all brain matter but excluded CSF-filled spaces), and total CSF (comprising 
extracerebral CSF and ventricles). Moreover, since the subcortical region (including basal 
ganglia and thalami) is consistently implicated in ASD (Calderoni et al., 2014; Estes et al., 
2011), but was not segmented at the fetal timepoint, I subtracted the volume of the cortex 
from the volume of the supratentorial tissue, to calculate a composite measure of the 
supratentorial white matter and subcortical grey matter tissue. Although not perfect, this index 
was used as an approximation of the subcortical volume, to try and assess the development 
of the subcortical region.  
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Table 2.3: A description of the anatomical boundaries used for fetal segmentation 
Brain region Description of anatomical boundaries  
Lateral ventricles Aside from both right and left lateral ventricles, the volume of this 
region also included the choroid plexuses. It excluded the cavum 
septum pellucidum and cavum vergae, which are anatomically 
separated from the lateral ventricles by the septal leaves.  
 
Third ventricle This region was delimited longitudinally by the anterior and 
posterior commissures, laterally by the thalami, and superiorly by 
the cavum septum pellucidum.  
 
Fourth ventricle The fourth ventricle was defined superiorly by the superior 
medullary velum, and inferiorly by the obex. The circumferential 
boundaries of the fourth ventricle were defined anteriorly by the 
pons, laterally by the middle cerebellar peduncles, and posteriorly 













The CSF surrounding the cerebellum defined its posterior, inferior, 
and lateral boundaries, while the superior boundary was 
determined by the inferior extent of the cerebrum. The cerebellar 
hemispheres and the vermis were included in the segmentation. 
 
The pons was anteriorly defined by the pre-pontine cistern, and 
posteriorly by the inferior cerebellar peduncles and fourth ventricle. 
The superior and inferior boundaries were based on visualisation of 
the pontine bulge, most easily identified on the sagittal plane.  
 
This region included all of the intracranial CSF space surrounding 
the supratentorial brain tissue and cerebellum; it also included the 
interhemispheric fissure space. It excluded the cavum septum 
pellucidum and the cavum vergae. The CSF borders were marked 
by the difference in intensity between the CSF and the skull, as 
well as the CSF and the cortex. The cisterna magna (included in 
the segmentation) and the spinal cord canal defined the inferior 
boundary of this region. 
 
Supratentorial tissue The volume of this region included grey and white matter brain 
tissue, but it excluded the intracerebral CSF, choroid plexuses, 
cerebellum, and brainstem structures below that of the pons.   
 
Cortex All cortical grey matter between the outer cortical border (at the 
boundary of the CSF and cortex) and the inner cerebral cortex (at 





































Figure 2.10: Volumetric segmentation of a 3D reconstructed fetal brain at 34+1 
gestational weeks. (A-F) Volumetric segmentations of the (A) lateral ventricles, (B) third 
ventricle, (C) posterior fossa, including cerebellum (in green), pons (in yellow), and fourth 
ventricle (in pink), (D) extracerebral CSF, (E) supratentorial brain tissue, and (F) cortex. 


























The region of the cortex was the hardest to segment, largely due to its convoluted 
appearance. Furthermore, not all cortical areas were clearly visualised in all fetal images, 
either due to the reconstructed image quality, or because the limits surrounding the 
developing structures were unclear. As a result, a specific segmentation protocol was 
designed to ensure consistent segmentations, irrespective of the reconstructed image quality 
and fetal gestational age. Specifically, the protocol defined strict rules of what to do when 
dealing with uncertain cortical areas.  
 
The following rules were applied:  
(i) The cingulate gyrus was segmented up until the first convolution from the corpus 
callosum (Figure 2.11A). 
(ii) The cortical regions surrounding the interhemispheric fissure were segmented, even 
in the presence of low-signal intensity (Figure 2.11B). 
(iii) The parieto-occipital sulcus was segmented up until the medial aspect of the 
hippocampus isthmus (Figure 2.11C). 
(iv) The calcarine sulcus was segmented in its entirety, including the deep convolutions 
present in fetuses of older gestational ages (Figure 2.11D). 
(v) The cortex surrounding the inferior part of the frontal lobes was not included in the 
segmentation due to a consistently compromised visualisation of this region, driven 
by partial volume of the frontal lobes, orbits, and nasal cavity (Figure 2.11 E and F). 
 
Owing to the design of this segmentation protocol, some cortical areas had to be excluded 
despite being visualised. As a result, the cortical volumes provided in this thesis are most 
likely an underestimation of the true value. Nonetheless, whatever underestimation error does 



















Figure 2.11: A representation of the cortical segmentation rules used when segmenting 
a reconstructed fetal brain. (A) The cingulate gyrus (arrow) was segmented up until the first 
convolution from the corpus callosum (arrowhead). (B) The cortical regions surrounding the 
interhemispheric fissure (arrow) were segmented. (C) The parieto-occipital sulcus (arrow) was 
segmented up until the medial aspect of the hippocampus isthmus (arrowhead). (D) The 
calcarine sulcus (arrow) was segmented in its entirety. (E) The cortex surrounding the inferior 
part of the frontal lobes was not included in the segmentation (arrow), due to partial volume 
from the orbits (arrowhead); however, (F) slices with no partial volume, such as those 




Duration of volumetric segmentations:  
The duration of the volumetric segmentations varied and was largely dependent on the 
gestational age of the fetal brain, as well as the quality of the reconstructed image. For 
example, a reconstruction of poor image quality, involving a fetus of advanced gestational 
age, resulted in longer segmentation times. On average, the time required to segment each 
brain region was as follows: lateral ventricles = 30 minutes, third ventricle = 10 minutes, 
posterior fossa (including pons, cerebellum, and fourth ventricle) = 2 hours, extracerebral CSF 
= 3 hours, supratentorial tissue = 5 hours, and cortex = 6-8 hours. 
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Inter-rater and intra-rater reliability of volumetric segmentations:  
Manual segmentation is an extremely laborious task. As a result, the fetal segmentations were 
performed with the help of research assistants (AD and AN) and students that I supervised 
(AF, CDR, JM and JS). In total there were 7 raters, including myself (IP). Some regions were 
segmented by a single rater while others, particularly those encompassing larger volumes, 
were split between two. IP segmented the lateral and third ventricles, JM and AN segmented 
the posterior fossa, CDR and AF segmented the supratentorial brain tissue, AD and JS 
segmented the cortex, and CDR and AD segmented the extracerebral CSF.  
 
Volumetric segmentations were validated to ensure both reliability and accuracy. Hence, each 
rater obtained inter-rater reliability with the team, and intra-rater reliability with themselves. For 
inter-rater reliability, volumetric results from a test series of n = 5 cases (mean gestational age 
= 30.49 weeks), completed by the rater in question, were compared to the measurements 
obtained by an experienced member of the team. The inter-rater ICCs of each brain region 
suggested negligible variability between the raters and the team, with individual values as 
follows: lateral ventricles (IP: 0.999, p < 0.001), third ventricle (IP: 0.905, p < 0.001), fourth 
ventricle (JM: 0.823, p = 0.001; AN: 0.803, p = 0.001), cerebellum (JM: 0.985, p < 0.001;           
AN: 0.986, p = 0.001), pons (JM: 0.863, p < 0.001; AN: 0.934, p = 0.016), extracerebral CSF 
(CDR: 0.988, p < 0.001; AD: 0.999, p < 0.001), supratentorial tissue (CDR: 0.999, p < 0.001; 
AF: 1.000, p < 0.001), and cortex (AD: 0.999, p < 0.001; JS: 0.982, p < 0.001).  
 
Then, intra-rater ICCs were also calculated from a random selection of n = 5 cases, with 
values confirming excellent reproducibility of segmentation by the same rater. The intra-rater 
ICC values of each brain region were as follows: lateral ventricles (IP: 0.987, p < 0.001), third 
ventricle (IP: 0.975, p < 0.001), fourth ventricle (JM: 0.983, p < 0.001; AN: 0.995, p < 0.001), 
cerebellum (JM: 0.981, p < 0.001; AN: 0.999, p < 0.001), pons (JM: 0.977, p < 0.001;                
AN: 0.976, p = 0.001), extracerebral CSF (CDR: 0.993, p < 0.001; AD: 0.997, p < 0.001), 
supratentorial tissue (CDR: 0.999, p < 0.001; AF: 0.989, p < 0.001), and cortex (AD: 0.997,         
p < 0.001; JS: 0.982, p < 0.001). 
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 Other data collected at this timepoint 
During the fetal timepoint, either prior to or after the MRI scan, mothers were interviewed to 
obtain the family’s demographic information as well as the expectant mother’s obstetric, 
medical, and psychiatric history. With permission from the mother, antenatal notes were also 
reviewed to confirm details.   
 
 Work done by others 
Fetal imaging was only possible with help from the BIBS team, the radiographers at the 
Centre for the Developing Brain (MF and JA), and the research nurses (JK and DH). 
Volumetric segmentations were performed with the support of research assistants and 
students (AD, AN, AF, CDR, JM, and JS).  
 
 Neonatal imaging  
All participants enrolled in this project by the time of the neonatal timepoint were offered an 
MRI scan. Eligible families who agreed to take part were booked in for an appointment within 
the infant’s first postnatal month, and at less than 47 corrected weeks. Prior to their 
appointment, families were sent an information sheet re-iterating the purpose of the research 
and providing specific details on the practicalities of scanning at this time. On the day of the 
scan upon arrival to the centre, written informed consent was obtained from one of the parents 
on behalf of the child, and the possibility of incidental findings was discussed. A detailed metal 
check was also conducted to safety screen for any MRI contraindications. Then, to ensure 
that the infant was fit for scanning, an experienced clinician (usually a paediatrician or 
neonatologist) conducted a physical examination. At this point, the neonate was also weighed 
and his head circumference measured. He was then changed into a metal-free gown and left 
to feed in a darkened quiet room with his parents. Electrocardiogram electrodes were also 
placed on the infant’s chest and a pulse oximeter was attached to his toe. These devices 
allowed for the heart rate, oxygen saturation, and body temperature to be recorded throughout 
the scan. In addition, both a research nurse and experienced clinician were present to 
supervise the examination at all times (Pennock, 2002).  
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Although neonatal scanning as part of this research project began on August 2014, due to the 
start of the developing Human Connectome Project (dHCP), all neonatal imaging protocols at 
the Centre for the Developing Brain – including that of this project – were changed in May 
2015. Consequently, this thesis includes neonatal imaging data acquired from both the pre-
dHCP and dHCP protocols. Moreover, since implementation of the dHCP also included 
optimisation of pre-scan patient preparation, two distinct preparation processes were used. 
Both are outlined below.  
 
Neonatal scanning was conducted during natural sleep. If the baby awoke or showed any 
signs of distress, the session was immediately stopped. The entire scanning protocol lasted 
for approximately 60-90 minutes, and involved the acquisition of structural, spectroscopic, 
functional, and diffusion sequences. For the purpose of this thesis, however, only the 
structural and spectroscopic sequences were analysed and therefore only those will be 
discussed.   
 
 Pre-dHCP pre-scan preparation 
Once asleep, neonates were swaddled in a cotton sheet and comfortably positioned in a Med-
Vac Infant Immobilisation Bag (CFI Medical Solutions, Fenton, MI, USA), which provided neck 
support and ensured that the head was immobilised during scanning. In addition, to ensure 
ear protection, all neonates were fitted with mouldable earplugs made of silicone-based dental 
putty (President Putty, Mahwah, NJ, USA) and adhesive MiniMuff noise attenuators (Natus 
Medical Inc., San Carlos, CA, USA). Preparation took place on a portable MR table, and as 
soon as the baby was fully prepped, the table was moved into the scanning room and the 
neonate was transferred onto the scanning bed. In order to minimise further acoustic noise, 
the scanner bore was also insulated with sound attenuating foam (Ultra Barrier, American 
Micro Industries, Chambersburg, PA, USA). As part of the pre-dHCP, all neonates were 
scanned with a 32-channel adult head coil.  
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 dHCP pre-scan preparation 
The objective of the dHCP protocol was to obtain the best possible neonatal imaging data. 
Adult coils are suboptimal for scanning the neonatal brain and therefore a dedicated imaging 
system was developed-in-house (Hughes et al., 2016). This imaging system included a 32-
channel neonatal head coil and a baby transport/positioning device (Figure 2.12). The device 
was designed to withstand vibrations from high gradient scans but also to be light, safe, and 
permitting of acoustic protection, immobilisation, and appropriate physiological monitoring.   
 
Once asleep, neonates scanned under dHCP were placed on the transport/positioning device, 
which consisted of a V-shaped base (Figure 2.12A) attached to a headpiece (Figure 2.12B). 
Neonates were wrapped in a specially designed cotton sheet that incorporated a head 
extension and pull tag. The attached tag was passed through a designated hole in the 
headpiece and pulled to guide the head into position, with minimal disruption to the baby 
(Figure 2.12C; red arrow). As before, in order to ensure acoustic protection, all neonates were 
fitted with mouldable earplugs (President Putty, Mahwah, NJ, USA) and adhesive MiniMuffs 
(Natus Medical Inc., San Carlos, CA, USA). Then, three immobilisation cushions conforming 
to the shape of the baby’s head were positioned over the ears and under the base of the 
head, in order to reduce further motion (Figure 2.12D).  
 
Once the baby’s head was securely positioned as confirmed by visual inspection through the 
two additional holes in the headpiece (Figure 2.12B), the Med-Vac Immobilisation Bag (CFI 
Medical Solutions, Fenton, MI, USA) was adjusted to the baby’s body using vacuum air 
removal. To prevent lateral movement of the body independent of the head, the Med-Vac was 
locked into the V-shaped base. Finally, the 32-channel neonatal head coil was slid over the 
baby’s head. An acoustic hood (Ultra Barrier, American Micro Industries, Chambersburg, PA, 







Figure 2.12: The dHCP neonatal imaging system. The system includes a 32-channel 
neonatal head coil and a transport/positioning device, consisting of (A) a V-shaped base and 
(B) a headpiece. Neonates are wrapped in a specialised cotton sheet, which is attached to a 
pull tag. The pull tag is passed through a hole in the headpiece and (C) pulled to guide the 
neonatal head into position, as shown by the red arrow. (D) Three immobilisation cushions are 
positioned to ensure minimal head movement. Image adapted from Hughes et al., (2016). 
 
 
 Image acquisition 
A detailed description of the structural and spectroscopic sequences, for both pre-dHCP and 
dHCP protocols, are included below.  
 
T1- and T2-weighted Structural Sequences: A T1-weighted inversion recovery turbo spin echo 
(T1 IR-TSE) and a T2-weighted multishot turbo spin echo (T2 TSE) sequence was acquired 
for both pre-dHCP and dHCP protocols. These sequences were obtained in both transverse 
and sagittal planes – with the exception of the T1 IR-TSE sequence, which when conducted 
under pre-dHCP, was only acquired in the transverse plane. Imaging parameters also differed 
slightly between the two protocols and therefore these have been provided in separate tables 
(Table 2.4 and 2.5). The T2-weighted sequences were reconstructed and used for volumetric 
segmentation, whilst the T1-weighted sequences were mainly used for radiologic assessment.  
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Table 2.4: Neonatal pre-dHCP structural imaging parameters 
Note: The T2-weighted sequences were reconstructed and used for volumetric segmentation, whereas the T1-weighted sequences were mainly used for 
radiologic assessment. Abbreviations: T1 IR-TSE IR = T1-weighted inversion recovery turbo spin echo; T2 TSE = T2-weighted multishot turbo spin echo; TE = 




Parameters T1 IR-TSE (transverse) T2 TSE (transverse) T2 TSE (sagittal) 
TE (ms) 8.0 156 156 
TR (ms) 4795 10000 10000 
Flip angle (deg.) 90 90 90 
Acquisition voxel size (mm) 1.01x1.01x2.00 1.01x1.01x2.00 1.01x1.01x2.00 
Slice gap (mm) 




















SAR (W/Kg) 0.1 0.2 0.2 
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Table 2.5: Neonatal dHCP structural imaging parameters 
Note: The T2-weighted sequences were reconstructed and used for volumetric segmentation, whereas the T1-weighted sequences were mainly used for 
radiologic assessment. Abbreviations: T1 TSE IR = T1-weighted inversion recovery turbo spin echo; T2 TSE = T2-weighted multishot turbo spin echo; TE = echo 
time; TR = repetition time; FOV = field of view; SENSE = SENSitivity Encoding; TSE = turbo spin echo; SAR = specific absorption rate.   
Parameters T1 IR-TSE (transverse) T1 IR-TSE (sagittal) T2 TSE (transverse) T2 TSE (sagittal) 
TE (ms) 
TR (ms) 
Flip angle (deg.) 
Acquisition voxel size (mm) 
Slice gap (mm) 
Number of slices 
Reconstructed voxel size (mm) 
FOV (mm3) 
















































Point Resolved Spectroscopy (PRESS): To enable quantification of different metabolites and 
to allow for comparison with data acquired at the fetal timepoint, neonatal 1HMRS was 
obtained with PRESS sequences acquired at two separate echo times: 55 ms and 144 ms. 
Prior to data acquisition, a 20x20x20 mm voxel was placed on the region of the left basal 
ganglia, avoiding any CSF-filled spaces (Figure 2.13). Imaging parameters were exactly the 
same for both pre-dHCP and dHCP protocols, as follows: TR = 1500 ms, TE = 55 or 144 ms, 








Figure 2.13: Voxel placement in a spectroscopic neonatal PRESS sequence. 
This image was acquired from a neonate scanned at 43+4 corrected weeks. The 20x20x20 
mm voxel, indicated by the red box, was placed on the region of the left basal ganglia. Voxel 
placement is shown in the (A) transverse and (B) sagittal planes, with the neonate lying in a 
(C) fixed supine orientation. 
 
 Radiologic review 
At the end of each scanning session, a neuroradiologist (MR, OC, KP, and SA) reviewed all of 
the acquired images to assess brain development and screen for any potential incidental 
findings. The neonatal review was conducted in much the same way as the fetal one, but due 
to the timepoint in question, there was a greater focus on assessing the progress of 
myelination. If any incidental findings were identified, the participant’s parents and general 
practitioner were contacted directly by the clinician responsible for the case.  
 
 Spectroscopic analysis 
A full description of the 1HMRS data analysis will be provided later on (please see section 
2.3.5.4 on page 142).  
 
A            B             C 
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 Structural analysis 
2.3.5.2.6.1 Image post-processing and volume reconstruction 
Although neonatal imaging was conducted during natural sleep, it was common for sporadic 
movements to occur, even if the neonate was deeply settled. Moreover, multislice multishot 
imaging as was acquired at this timepoint, tends to be particularly vulnerable to motion 
artefacts (Andre et al., 2015). In an uncorrected image (Figure 2.14A), for example, motion 
artefacts and signal variations are frequently observed from slice-to-slice. Therefore, before 
the structural T2 TSE images could be segmented, a 3D motion corrected reconstruction was 
applied to the acquired images (Cordero-Grande et al., 2016). This reconstruction process 
estimated the motion states corresponding to the acquired shots and slices to ensure that 
both within-plane and through-plane motion were dealt with (Cordero-Grande et al., 2016). As 
part of the methodological pipeline, motion corrected reconstructions were first applied to the 
transverse and sagittal views independently. Upon successful reconstruction, artefacts tended 
to be fully or almost fully resolved, and the quality of the overall image was substantially 














Figure 2.14: Applying motion corrected reconstruction to a sagittal T2 TSE neonatal 
volume. (A) Uncorrected versus (B) motion corrected reconstruction of a T2 TSE sagittal 
volume, with all three orthogonal views (transverse, coronal, and sagittal) shown from left to 













Once each view had been independently reconstructed, the two views were assembled by 
slice-to-volume registration (Kuklisova-Murgasova et al., 2012), based on the methodology 
applied at the fetal timepoint. By correcting for rigid motion within structural scans, the final 
result yielded a motion-free reconstruction with high resolution and SNR (Figure 21.5), 
allowing for optimal tissue segmentation. The reconstruction process was conducted in the 
exact same way for both pre-dHCP and dHCP images. Depending on the extent of motion 
present in the original images, the process could take between 30 minutes to 3 hours of 
computational time. 
 
Figure 2.15: Final reconstruction of a neonatal brain acquired at 42+2 corrected weeks. 
Once the transverse and sagittal views had been independently reconstructed, the two views 
were assembled by slice-to-volume registration. The final reconstruction is displayed above, 
with all three orthogonal views (transverse, coronal, and sagittal) shown from left to right. 
 
 
2.3.5.2.6.2 Volumetric segmentation 
Once the 3D motion corrected reconstruction was complete, the neonatal images were 
segmented. Segmentation was performed using Draw-EM (Developing Brain Region 
Annotation with Expectation-Maximisation; https://github.com/MIRTK/DrawEM) – an open-
source software for neonatal brain segmentation developed-in-house based on methods 
proposed by Makropoulos et al. (2014).  
 
As part of the segmentation process, the first step was to conduct a brain-extraction of the T2 
reconstructed image to remove any non-brain tissue (Smith, 2002). Only then was the 
reconstructed image corrected for intensity inhomogeneity (Tustison et al., 2010). After this, in 
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order to compute a GMM probability map of the image, initial tissue segmentation was 
performed. Then, predefined atlases were registered to the subject’s target image by using a 
multi-channel registration that incorporated the image intensity and the GMM probability map. 
The atlas labels were transformed and averaged according to the similarity between the atlas 
and the target image. Draw-EM utilises manually segmented atlases (Gousias et al., 2012), 
incorporating multiple labels and spanning an age-range of 36 to 44 corrected weeks. After 
registering theses atlases to the individual target images, a spatial prior probability of the 
different brain structures was computed, based on the local similarity of the transformed 
atlases and the input target image. The final segmentation was performed with an 
Expectation-Maximisation algorithm, which included a spatial prior term and an intensity 
model of the image. The intensity model of the image was approximated with a GMM, and the 
spatial dependency between the brain structures was modelled with Markov Random Field 
regularisation. The Draw-EM pipeline also incorporated model averaging, to limit the influence 
of intensity in the delineation of structures with very similar contrasts. In addition, the pipeline 
corrected for any partial volume misclassifications, particularly prominent at CSF boundaries.  
 
After the Draw-EM pipeline had been applied, two different segmentation outputs (with grey 
and white matter parts merged) were produced: the ‘label’ segmentation and the ‘tissue’ 
segmentation. In order to examine similar brain regions to those obtained at fetal and infant 
timepoints, a decision was made to focus on the tissue segmentation output, which consisted 
of 8 labels: white matter, cortex, subcortical grey matter (encompassing the thalamus, caudate 
nucleus, subthalamic nucleus, lentiform nucleus, and internal capsule), hippocampi and 
amygdala (segmented together), brainstem, cerebellum, lateral ventricles, and extracerebral 
CSF (including third and fourth ventricles) (Figure 2.16). However, since the neonatal 
segmentation software also produced a more detailed segmentation (the ‘label’ 
segmentation), specific brain structures commonly implicated in ASD were also selected for 
analysis. These included the hippocampus, amygdala, insula, thalamus, subthalamic nucleus, 
lentiform nucleus, caudate nucleus, and corpus callosum (Figure 2.17). 
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Figure 2.16: Volumetric tissue segmentation of a 3D reconstructed neonatal brain. 
The panel on the left includes the T2-weighted reconstructed volume, and the panel on the 
right includes the corresponding tissue segmentation. As we move from the anterior to the 
posterior brain (A-E), only transverse sections are shown. (A) Shows extracerebral CSF, 
cortex, and white matter, while (B) exhibits the lateral ventricles and (C) the subcortical grey. 
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Figure 2.17: Volumetric segmentation of selected structures obtained from a 3D 
reconstructed neonatal brain. In this image, transverse, coronal, and sagittal views are 
shown. (A) Comprises the corpus callosum, caudate nucleus, lentiform, insula, and thalamus. 




These segmentations were utilised to extract volumetric measures (in cm3) of the tissues and 
specified structures of interest. As before, additional brain measures were calculated, 
including the volume of the intracranium, total brain tissue, and total CSF. These calculations 
were based on the values obtained from the tissue segmentation output. The intracranium 
was defined as the sum of all regions, while the total brain tissue included all brain matter but 
excluded CSF. The measure for total CSF included extracerebral CSF and lateral ventricles. 
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 Comparison between pre-dHCP and dHCP measures 
Volumetric measures: T2 image reconstruction and segmentation was performed using the 
exact same pipelines, for both pre-dHCP and dHCP protocols. The original images, however, 
were acquired using slightly different imaging parameters and different coils. As a result, small 
differences in volumetric measures could have arisen from the distinct methodologies. 
Therefore, once these measures had been quantified, an independent samples t-test was run 
to compare the values obtained from n = 5 neonates scanned under pre-dHCP (mean age = 
43.20 corrected weeks; 2 male) and n = 5 scanned under dHCP (mean age = 43.32 corrected 
weeks; 3 male), with both groups matched for age (t = -0.18, p = 0.864). Since no differences 
were found between the regional brain volumes obtained from the two protocols (all p > 0.05), 
the results were merged and analysed together. 
 
Spectroscopic measures: Despite equal pre-dHCP and dHCP PRESS parameters, the 
different coils used for the separate protocols meant that small differences could have arisen 
in the acquired spectra. Therefore, once spectroscopic analysis had been conducted (please 
see section 2.3.5.4 on page 142 for a detailed description of the process), an independent 
samples t-test was run to compare the metabolite ratios obtained from n = 5 neonates 
scanned under pre-dHCP (mean age = 43.23 corrected weeks; 4 male) and n = 5 scanned 
under dHCP (mean age = 43.20 corrected weeks; 3 male), with both groups matched for age 
(t = 0.05, p = 0.963). As with the volumetric measures, there were no significant differences 
between the metabolite ratios obtained from the two protocols (all p > 0.05). Consequently, 
the results from both protocols were merged and analysed together. 
 
 Other data collected at this timepoint 
Prior to the neonatal scan, delivery summaries were reviewed to obtain more specific details 
not always known to the mother, but of relevance to the research. These measures included 
Apgar scores at 1 and 5 minutes, mode of delivery, as well as body weight and head 
circumference at birth.  
 
 140 
 Work done by others 
Neonatal imaging data was acquired with the help of the BIBS team, radiographers at the 
Centre for the Developing Brain (MF, JA, and EH), research nurses (JW, MS, JBC, and PW), 
and specified clinicians (NT, CK, MK, DC, and MB). LC completed the volumetric 
reconstructions, whilst the automated segmentations were conducted by AM.  
 
 Infant imaging 
All participants enrolled in the research project by the time of the infant timepoint were offered 
an MRI scan. Eligible families who agreed to take part were booked in for an appointment 
when the infant was aged between 50-75 corrected weeks (or at approximately 4-6 months). 
At this age infants are very aware of their surroundings, which makes it incredibly difficult to 
get them to settle down in a new environment. Therefore, the usual protocol for imaging these 
infants at the Centre for the Developing Brain, involves the optional use of a low dose of 
chloral hydrate – a very mild sedative which helps to promote sleep. To ensure that the 
families were given sufficient time to consider this, research nurses discussed the use of 
sedation prior to booking. On the day of scanning, the assigned paediatrician also discussed 
this option with the parents yet again. Nonetheless, as part of this study, all of the families who 
participated in infant imaging agreed to the use of sedation. 
 
As at other timepoints, families were sent an information sheet re-iterating the purpose of the 
research and providing specific details on the practicalities of scanning at the infant timepoint. 
Then, upon arrival to the centre on the day of the scan, written informed consent was obtained 
from one of the parents on behalf of the child, and the possibility of incidental findings was 
discussed. A detailed metal check was also conducted to safety screen for any MRI 
contraindications. At this time, the parents were once again briefed on how the sedation would 
be administered. Although chloral hydrate has an extremely safe profile, side effects can still 
occur; therefore, parents were informed of the potential adverse effects, which include 
nausea, vomiting, and mild respiratory depression (Delgado et al., 2014; Finnemore et al., 
2014). Afterwards, a routine physical examination was conducted by the case assigned 
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clinician, who ensured that the infant was fit for scanning and for administration of chloral 
hydrate. The infant was also weighed and his head circumference measured. He was then 
changed into a metal-free gown and left to feed with his parents.  
 
Once ready, usually 1 hour after feeding, chloral hydrate was orally administered to the infant 
in a weight-dependent dose of 30-50 mg/kg. Since the medication has a bitter aftertaste, 
which infants find unpleasant, it was always administered alongside sucrose. Importantly, 
chloral hydrate is classified as a sedative rather than an anaesthetic, meaning that it merely 
predisposes infants to fall into natural sleep more easily. Usually, this takes approximately 15-
20 minutes to take effect; therefore, as soon as the medication was administered, the parents 
were given some time alone to let the infant settle. Once asleep, the infant was prepped 
according to pre-dHCP guidelines (please refer back to section 2.3.5.2.1 on page 128). This 
included the fitting of electrocardiogram electrodes and a pulse oximeter, which allowed for 
the infant’s heart rate, oxygen saturation levels, and body temperature to be monitored 
throughout the scan. As was done at the neonatal timepoint, both a research nurse and a 
clinician were present to supervise the examination. In addition, because the effect of chloral 
hydrate usually only lasts for 40-60 minutes, there was a chance that the infant could wake up 
during the scan. If this occurred, the scanning session was immediately stopped.  
 
The entire scanning protocol lasted for approximately 60 minutes and involved the acquisition 
of structural, spectroscopic, and functional sequences. Post-scan, infants were monitored for 
30 minutes. Parents were given a post-sedation care leaflet and were contacted 24 hours 
after the administration of the sedative to ensure that all was well.  
 
For the purposes of this thesis, only the infant spectroscopic sequences were analysed and 
therefore only the imaging parameters of those sequences will be provided.  
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 Image acquisition 
Infants were scanned with a 32-channel adult head coil. Spectroscopic data was acquired in 
the exact same manner as it was done at the neonatal timepoint, with PRESS sequences 
obtained at two separate echo times: 55 ms and 144 ms. All acquisitions were performed 
using water suppression, and with a 20x20x20 mm voxel placed in the region of the left basal 
ganglia. Imaging parameters were as follows: TR = 1500 ms, TE = 55 or 144 ms, flip angle = 
90°, and SAR = 0.0 W/Kg.  
 
 Radiologic review 
Radiologic review of the acquired images was conducted in much the same way as was done 
at the neonatal timepoint (please refer back to section 2.3.5.2.4 on page 133 for more details). 
In the case of an incidental finding, the infant’s’ parents and general practitioner were 
contacted.  
 
 Other data collected at this timepoint 
If the infant under examination had not participated in the neonatal timepoint, delivery 
summaries were reviewed here, to obtain all relevant information pertaining to the birth.  
 
 Work done by others 
The imaging data collected as part of the infant timepoint would not have been possible 
without the help of the BIBS team, the radiographers at the Centre for the Developing Brain 
(MF, JA, and EH), the research nurses (JW, MS, JBC, and PW), and the relevant clinicians 
(NT, CK, MK, DC, and MB).  
 
 Spectroscopic analysis 
Irrespective of the timepoint of acquisition (that is, fetal, neonatal, or infant), all 1HMRS spectra 
were acquired using identical imaging parameters. This allowed for all spectroscopic data to 
be analysed and processed in the exact same manner, which rendered the comparisons 
between timepoints more accurate. The first step was to visually assess each 1HMRS 
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spectrum in order to ensure adequate SNR and no obvious artefacts. Then, the data was 
analysed in a fully automated manner using the TARQUIN software version 4.3.6 (Wilson et 
al., 2011).  
 
TARQUIN is a novel algorithm used to quantify 1HMRS data; it is particularly suitable for the 
analysis of sequences acquired at short echo times. The algorithm uses a least squares 
approach to estimate signal amplitudes, and imposes a method of soft constraints on the 
projection to reduce errors associated with overfitting. In addition, baseline interference is 
reduced by point truncation and water peak removal in a fully automated process. Point 
truncation eliminates the very early points of the free induction decay, which contain very 
broad signals that are difficult to model; it also removes the last few points, which tend to only 
contain noise. Given its automated quantitation, TARQUIN ensures that user variability is 
eliminated (Scott et al., 2016), which made it a particularly useful tool for the analysis of the 
1HMRS data acquired in this thesis. Another important aspect of the TARQUIN software is that 
it is a robust tool for the analysis of clinical data of variable quality, having been compared 
favourably to other automated processes such as LCModel (Wilson et al., 2011). 
 
When defining the quantitation settings, TARQUIN asks that a reference metabolite be chosen 
in order to produce appropriate phase adjustments of the data. Since the 1HMRS spectrum 
changes considerably between the prenatal and early postnatal periods, these settings were 
therefore input in a slightly different manner depending on the timepoint in question. For 
example, given that Cho is the most abundant peak at the fetal timepoint, it was selected as 
the reference metabolite when analysing fetal spectra. Conversely, when analysing neonatal 
and infant spectra, a combination of metabolites was chosen as the reference, including NAA, 
Cho, and Cr. TARQUIN also provides basis sets of predefined models; however, for this 
analysis, the same internal basis set was used to analyse data collected at different timepoints 
and using different echo times.  
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After the automated quantitation has been concluded, TARQUIN produces a processed signal 
of the 1HMRS spectra. A residual line is also created, with visual inspection of the line allowing 
for adequate SNR to be confirmed; ideally, the residual should represent a fairly homogenous 
line. In addition, the 1HMRS signal is superimposed with a model signal from which the 
metabolite peaks are fitted (Figure 2.18). Only metabolites that met a reliable fit, with a 
standard deviation of < 25%, were included in further analyses.  
 
Figure 2.18: Spectroscopic analysis performed using the TARQUIN software. 
In this example, a 55 ms PRESS sequence acquired at the infant timepoint has been 
analysed. As is shown, TARQUIN has created a processed signal from the original spectra 
and superimposed it with a model signal, allowing for metabolites to be reliably fitted. The 
residual line created also enables visual inspection of SNR. Abbreviations: Ins = myo-inositol; 
Cho = choline; Cr = creatine; Glx = glutamate and glutamine; NAA = N-acetylaspartate. 
 
As part of the spectroscopic analysis, the following metabolites were assessed: N-
acetylaspartate and N-acetylaspartylglutamate (NAA); creatine and phosphocreatine (Cr); free 
choline, glycerophosphocholine, and phosphocholine (Cho); myo-inositol (Ins); and glutamate 
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and glutamine (Glx). Since all 1HMRS acquisitions were performed using water suppression, 
metabolite concentrations were reported as relative ratios, expressed in relation to Cho and 
Cr, as follows: Cho/Cr, Ins/Cho, Ins/Cr, Glx/Cho, Glx/Cr, NAA/Cho, and NAA/Cr. 
 
2.3.6. Power considerations and sample size estimation   
As with project 1, the design of research project 2 was based on evidence suggesting that 
there is a 20% chance that individuals born to a sibling with ASD will themselves be 
diagnosed with the condition (Constantino et al., 2010; Ozonoff et al., 2011; Sandin et al., 
2014). Previous studies using MRI to examine brain volume differences in 6 month-old infants 
at risk of ASD have reported significant results with sample sizes of 20-30 subjects per group 
(Blasi et al., 2015; Lloyd-Fox et al., 2013; Shen et al., 2013). However, the data acquired as 
part of project 2 included individuals of younger ages, scanned at fetal and neonatal 
timepoints. Project 2 also included 1HMRS data, which has not been previously used in 
studies of individuals at risk. Therefore, the issue of sample size estimations was a difficult 
one to address here. Nonetheless, based on other studies carried out at the fetal and neonatal 
timepoints, examining different clinical groups (such as individuals with intrauterine growth 
restriction and isolated ventriculomegaly), significant group differences in brain volume and 
chemistry were identified with approximately 20 subjects per group (Damodaram et al., 2012; 
Lockwood Estrin et al., 2016). In a study more akin to the present, significant differences were 
identified in the brain volumes of preterm neonates with and without a later ASD diagnosis, 
and there were only 11 and 22 subjects in each group respectively (Padilla et al., 2015). 
Consequently, a minimum sample size of 15 participants per group was deemed sufficient to 
identify preliminary differences (p ≤ 0.05).  
 
Post-hoc power calculations for the main finding(s) of each study are included in Appendix 1. 
Effect sizes are also reported, using partial eta squared (p2), and interpreted using Cohen’s 
(1988) criteria, where p2  0.01, 0.06, and 0.14 reflect small, medium, and large effects. For 
further details on the results of these calculations, please refer to Appendix 1 on page 255. 
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2.4. Analytic approach 
All statistical analyses were performed using IBM SPSS (Statistical Package for the Social  
Sciences) Software Package version 21 (IBM Corp, Armonk, NY). Unless otherwise stated, 
the statistical threshold was set at p ≤ 0.05. In cases where transformations were utilised, 
statistical analysis was run on the transformed data. However, for ease of interpretation, both 
descriptive and visual displays depict untransformed data.  
 
A detailed description of the analytic approach carried out in each study is described in the 
individual experimental chapters to come.  
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Chapter 3: Mother-infant interactions and regional 






































Aside from what was mentioned in the concluding remarks of this paper, the findings of this 
study also have implications for understanding the relative vulnerability of males to 
neurodevelopmental problems, and for considering potential (possibly parent-mediated) 
interventions.  
 
Based on these results, the next study incorporated observational measures of mother-infant 
interactions in the analysis of infants genetically predisposed to ASD. The objective of the 
study was to compare total and regional brain volumes in infants with and without a familial 
risk of ASD, and to explore whether any differences in brain volume were associated with 
subsequent ASD severity and/or clinical diagnostic status. Finally, the study also sought to 
examine whether mother-infant interactions moderated the extent of differences in brain 




Chapter 4: Regional brain volumes and behavioural 
outcomes in infants with a familial risk of 
ASD 
 
Part of this study is currently under review with Psychological Medicine: Pote et al., “Familial 
risk of autism alters brain anatomy in infants and predicts the emergence of autistic 
behaviours in early childhood”. 
 
4.1. Introduction 
As outlined in the main introduction of this thesis, the majority of studies investigating 
structural brain differences in ASD, relative to unaffected controls, have been carried out in 
adults, adolescents, and older children. Among the most consistently observed findings in 
studies of younger ASD populations, is that affected individuals may undergo a pattern of 
abnormal early brain development (Lange et al., 2015). For instance, a number of groups 
have reported a postnatal period of accelerated brain growth, leading to an increase in total 
brain volume (of up to 10%) by the age of 2 (Courchesne et al., 2001; Hazlett et al., 2011; 
Redcay and Courchesne, 2005; Schumann et al., 2010; Sparks et al., 2002). Also, evidence 
for larger head sizes at 4-6 months in children who later developed ASD has been reported by 
some (Courchesne et al., 2003; Dawson et al., 2007; Lainhart et al., 1997; Nordahl et al., 
2011), but not all (Surén et al., 2013; Zwaigenbaum et al., 2014), and suggests that underlying 
differences in brain structure may precede the onset of clinical symptoms.  
 
In recent years, prospective studies of infants at risk of ASD have made some crucial first 
steps in understanding the early biological signs of the disorder. As more of these studies 
arise, they may help to identify neural markers that predate the emergence of symptoms. 
Thus far, MRI studies comparing brain structure in 6 month-old siblings of infants with ASD, 
relative to those with typically developing siblings, have reported differences in white matter 
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microstructure as well as extracerebral CSF and corpus callosum (Shen et al., 2013; Wolff et 
al., 2012, 2015). Specifically, increased area and thickness of the corpus callosum (Wolff et 
al., 2015), as well as increased volume of subarachnoid CSF (Shen et al., 2013) correlated 
with subsequent ASD symptom severity at 24 months (Shen et al., 2013; Wolff et al., 2015). 
There is therefore preliminary evidence to suggest that infants at high-risk of ASD have early 
differences in brain structure by 6 months, which are associated with the subsequent 
development of ASD symptoms. However, it is still unclear whether differences in brain 
volume can be identified in high-risk infants at younger ages and/or in other brain regions. 
 
Moreover, as reported in the first experimental study of this thesis (chapter 3), variations in 
early mother-infant interactions are associated with differences in brain volume. Hence, the 
early caregiving environment may have the ability to impact upon later behavioural and 
cognitive outcomes (Cabrera et al., 2011; Lugo-Gil and Tamis-LeMonda, 2008). In addition, 
prior studies of infants at risk of ASD have reported that differences in early parent-infant 
interactions are evident by 6 months of age. For instance, parents of high-risk infants have 
shown increased directiveness and lower levels of sensitive responding, compared to low-risk 
controls. High-risk infants also appear less lively (Doussard-Roosevelt et al., 2003; Wan et al., 
2012, 2013). To date, however, no studies of infants at risk of ASD have related variations in 
parenting style to differences in infant brain volume. It is therefore unknown whether any 
putative differences in brain development are influenced by early mother-infant interactions. 
Nonetheless, just as early identification of ASD has become a priority, so has the search for 
how parent-infant interactions can modulate outcome. 
 
In summary, there is initial evidence that infants at high-risk of ASD have early differences in 
brain development and in parent-infant interactions. However, it is not yet known if infants with 
a familial risk of ASD have differences in brain volume that can be detected before 6 months 
of age. Neither is it known whether the early caregiving environment influences any such 
putative differences.  
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As a result, this prospective longitudinal study used MRI to (i) investigate total and regional 
brain volume differences in 4-6 month-old infants at high familial risk of ASD, relative to a 
group of infants at low-risk. Since larger volumes of extracerebral CSF in 6 month-old infants 
at risk of ASD have been reported in comparison to infants at low-risk (Shen et al., 2013), the 
CSF was specifically examined. Next, (ii) I examined whether any observed group differences 
were associated with subsequent ASD symptom severity and/or clinical diagnostic status at 
36 months. Finally, (iii) the possibility that early mother-infant interactions moderated the 
extent of differences in brain volume and/or severity of ASD symptoms was also explored.  
 
Given the pre-existing evidence implicating extracerebral CSF in ASD, a group difference in 
CSF volume was predicted. All other brain regions remained exploratory. In addition, based 
on the findings from the prior study (chapter 3), it was hypothesised that mother-infant 
interactions would moderate the association between risk group and infant brain volume. 
However, as no previous volumetric study has examined high-risk infants younger than 6 
months of age, no a priori hypothesis regarding the direction of these differences was 
constructed.  
 
4.2. Materials and methods 
4.2.1. Participants 
For this particular study, both high-risk and low-risk infants were included, and participants 
were categorised based on the criteria previously described in the methodology section of this 
thesis (please see section 2.2.3 on page 95). A total of 59 infants originally participated in this 
study. Of the 59 cases, 9 were excluded from the main analysis: 8 due to poor image quality 
and motion artefacts, and 1 low-risk participant because they subsequently received an ASD 
diagnosis. Hence, the final sample size consisted of 50 infants: 26 low-risk (n = 12 male; 
mean corrected age at scan = 60.54 corrected weeks, SD = 4.17) and 24 high-risk (n = 11 




4.2.2. Experimental procedures 
Infants were scanned within an age-range of 50-70 corrected weeks (between approximately 
4-6 months of age). Within two weeks of the MRI acquisition, but usually on the same day, 
mother-infant interaction dimensions were obtained. Behavioural measures of observed 
mother-infant interactions were available for only n = 23 of the 26 infants in the low-risk group, 
and n = 21 of the 24 infants in the high-risk group. At 36 months of age, all infants in the high-
risk group were invited back for a follow-up behavioural assessment; n = 23 of the 24 infants 
scanned returned. All experimental procedures were conducted as described earlier in the 
main methodology of this thesis (see sections 2.2.4-2.2.6, starting on page 96). By the time of 
analysis, however, the segmentation protocol had been further refined, so that the volumetric 
measure for lateral ventricles included here did not incorporate the cavum septum pellucidum.  
 
4.2.3. Statistical analysis 
Normality of data distribution was assessed visually using box-plots, and statistically using the 
Shapiro-Wilk Test. Group differences in infant characteristics and mother-infant interaction 
dimensions were tested using the Independent Samples t-test, the Mann-Whitney U-test, and 
the Pearson’s Chi-Square test, as appropriate.  
 
 Baseline differences in regional brain volumes  
Brain volumes were not normally distributed; hence, logarithmic transformations were 
performed on all volumes to adjust for skew and achieve normal distribution. An analysis of 
co-variance (ANCOVA) on the log-transformed data was used to examine cross-sectional 
differences in regional brain volumes between the two risk groups (low-risk vs. high-risk). The 
dependent variables of interest included: total grey and white matter, subcortical region, 
midbrain, cerebellum, total brain tissue, lateral ventricles, extracerebral CSF, total CSF, and 
intracranial volume. The proportion of extracerebral CSF over total CSF volume was also 
compared between risk groups. Infant age and intracranial volume were included as co-
variates, and sex was included as a (between subjects) fixed factor, mainly because males 
and females are known to have different developmental trajectories (Lenroot et al., 2007),  
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 Regional brain volumes and outcome measures within the high-risk group  
In regions where the high-risk group had shown significant differences in brain volumes at 4-6 
months, the associations between these early volumes and ASD outcome measures at 36 
months were examined. Dimensional analyses were run using non-parametric (Spearman’s 
rank) correlations. These analyses explored the association between regional brain volumes 
at 4-6 months and observable autistic behaviours at 36 months, as assessed using the 
ADOS-2 calibrated severity scores. Statistical significance was set at p ≤ 0.05 (one-tailed).  
 
Following assessment at 36 months, n = 4 male infants in the high-risk group received a 
diagnosis of ASD. Analyses were thus repeated to determine if the results were representative 
of the high-risk group as a whole, or whether driven by individuals with an ASD diagnosis.  
 
 Moderation by mother-infant interactions 
Moderation analyses were conducted to examine whether mother-infant interactions (that is, 
maternal and/or infant behaviours) influenced brain regions with significant group differences 
in volume at 4-6 months of age. The PROCESS macro tool (Hayes, 2012) was applied to test 
whether the interaction between risk group and maternal behaviour (Group x Maternal 
Behaviour) predicted infant brain volume. This was then repeated to test the interaction 
between risk group and infant behaviour (Group x Infant Behaviour). In this analysis, infant 
age, sex, and intracranial volume were included as co-variates. PROCESS applies bias 
corrected bootstrapping intervals to probe the interaction term and make inferences about 
indirect effects, rather than relying on the normality assumption. The number of bootstrap 
samples used to determine 95% bias-corrected bootstrap confidence intervals was 1000. For 
continuous moderators, PROCESS produces the conditional effects of the independent 
variable at the sample mean of the moderator, and at plus and minus one standard deviation 
from the mean. A Bonferroni correction for multiple comparisons was applied to these results. 
Where a significant interaction term emerged, the association between behaviour and brain 
volume was further examined using simple correlations within each risk group.   
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Finally, further moderation analyses were conducted within the high-risk group only, to 
examine whether the behaviours found to moderate the association between risk group and 
brain volume at 4-6 months (that is, the impact of maternal sensitivity on the subcortical 
region), moderated the association between brain volume and infant outcome at 36 months. 
Again, the PROCESS macro tool was applied to test whether the interaction between 
maternal sensitivity and early brain volume (Subcortical Volume x Maternal Sensitivity) 
predicted infant outcome at 36 months. Infant outcome was assessed by both the ADI-R and 
the ADOS-2, but since the scores were not normally distributed, logarithmic transformations 
were performed to obtain normality, and the transformed values were used instead. As before, 
infant age, sex, and intracranial volume were included as co-variates. A Bonferroni correction 
for multiple comparisons was also applied to the results.  
 
4.3. Results 
4.3.1. Sample characteristics 
The characteristics of the total sample, and split by risk group, are presented in Table 4.1. 
Infants (n = 50; 26 low-risk, 24 high-risk) were scanned at a mean age of 60.63 corrected 
weeks (SD = 3.70, range = 53.00-68.00 corrected weeks; Figure 4.1), and risk groups did not 
differ significantly in age (at birth and at MRI), body weight (at birth and at MRI), head 
circumference (at MRI), or sex. There were also no significant group differences in observed 
mother-infant interactions for any of the dimensions examined at 4-6 months. The range in the 




































A histogram of the participants’ corrected age at the time of the infant MRI is shown.  
The total sample comprised of 50 infants, with 26 low-risk (in black) and 24 high-risk (in red). 
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Table 4.1: Infant characteristics stratified by risk group 






(N = 50) 
Low-Risk Group 
(n = 26) 
High-Risk Group 
(n = 24) 
Group Difference 
Statistic (p-value) 
Gestational age at birth (weeks); mean (SD) 39.63 (1.45) 39.68 (1.72) 39.59 (1.18) U = 281.00, p = 0.537 
Corrected age at MRI (weeks); mean (SD) 







t = -0.18, p = 0.857  
χ2 = 0.00, p = 0.982 
Body weight at birth (kg); mean (SD) 
Body weight at MRI (kg); mean (SD) 










t = -1.40, p = 0.167 
t = -1.32, p = 0.195 
t = 0.39, p = 0.700 
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Table 4.2: Maternal and infant interaction dimensions stratified by risk group 
Note: Interaction dimensions are scored on a scale from 1-5; low scores indicate poor interactions (for example, lower levels of sensitivity, increased depressive 








Total Sample (N = 44) 
 
Low-Risk Group (n = 23) 
 












































































Following assessment at 36 months, infants in the high-risk group were subdivided by 
outcome classification as follows: high-risk non-ASD (n = 19), and high-risk ASD (n = 4). 
When stratified by outcome group, participants did not differ significantly in age (p = 0.896) or 
MSEL (p = 0.105); but please see Table 4.3 for a complete description of behavioural scores. 
 
4.3.2. Group differences in total brain matter and intracranial volume at 4-6 months 
There was no significant difference in the volume of total brain matter [F(1,45) = 0.36,                   
p = 0.549] or intracranium [F(1,45) = 0.33, p = 0.569], between infants in the high-risk and low-
risk groups (Table 4.4). 
 
4.3.3. Group differences in regional brain volumes at 4-6 months 
Infants in the high-risk group had a significantly larger volume of the cerebellum [F(1,44) = 
6.92, p = 0.012] and the subcortical region [F(1,44) = 4.64, p = 0.037], when compared to 
those in the low-risk group (Table 4.4, Figure 4.2). Results did not differ when the analysis 
was co-varied for total brain tissue, as opposed to intracranial volume. No other brain region 




Figure 4.2: Mean cerebellar and subcortical volumes in 4-6 month-old infants at low and 
high-risk of ASD. Infants in the high-risk group had a significantly larger volume of the         
(A) cerebellum and (B) subcortical region, when compared to low-risk controls. Error bars 
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Table 4.3: Infant clinical and behavioural measures stratified by outcome group 
 High-Risk Non-ASD Group (n = 19) High-Risk ASD Group (n = 4) 
Measure Mean SD Mean SD 
Age at Assessment Visit (months) 38.97 1.54 38.86 0.89 
Mullen ELC SS* 107.89 22.66 81.00 34.07 
ADOS-2 Domains  









Restricted & Repetitive Behaviours CSS 3.53 2.57 7.25 1.71 











Communication 2.37 2.97 13.50 3.70 
Repetitive Behaviours & Interests 0.53 0.96 6.00 0.82 
Note: *Mullen and ADI-R measures were only available for n = 3 of the 4 infants in the high-risk ASD group. Abbreviations: Mullen ELC SS = Mullen Scale of 
Early Learning Composite Standard Score; ADOS-2 = Autism Diagnostic Observation Schedule – Second Edition; CSS = Calibrated Severity Score; ADI-R = 
Autism Diagnostic Interview – Revised; SD = standard deviation.  
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Table 4.4: Group differences in infant brain volumes and proportions of volumes, between low-risk and high-risk groups 
 
Low-Risk Group (n = 26) High-Risk Group (n = 24) Group Difference 
  Mean SD Mean SD F p-value 
Brain Volumes (cm3) 
      
Total Grey & White Matter 584.47 61.47 590.02 59.30 0.29 0.593 
Subcortical Region 33.59 2.99 35.27 3.34 4.64 0.037 
Midbrain 13.35 1.89 13.17 1.57 0.84 0.364 
Cerebellum 71.15 8.91 75.83 8.09 6.92 0.012 
Total Brain Tissue 702.56 71.55 714.29 69.03 0.36 0.549 
Lateral Ventricles 14.22 5.67 13.34 3.73 0.59 0.448 
Extracerebral CSF  122.90 27.23 125.30 31.75 0.03 0.857 
Total CSF 137.12 29.21 138.64 33.34 0.12 0.727 
Intracraniuma 839.68 86.23 852.93 80.05 0.33 0.569 
       
Brain Proportions (au.) 
      
Extracerebral CSF/Total CSF 0.90 0.04 0.90 0.03 0.50 0.483 
Note: In this analysis of co-variance, infant age and intracranial volume were included as co-variates, and sex was included as a fixed factor; hence, F = F(1,44). 
aIn this analysis, only infant age and sex were corrected for; hence, F = F(1,45). Significant results are shown in bold. Abbreviations: CSF = cerebrospinal fluid; 
F = F-statistic; SD = standard deviation. 
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When the 4 participants who received a diagnosis of ASD were excluded from the analyses, 
the cerebellum remained significantly larger in the high-risk group [F(1,40) = 8.79, p = 0.005]. 
However, there was no significant difference in cerebellar volume between high-risk infants 
who received an ASD diagnosis, relative to those who did not [F(1,18) = 1.07, p = 0.315]. In 
contrast, the subcortical region was no longer significantly enlarged in the high-risk group 
[F(1,40) = 1.60, p = 0.213], most likely because the high-risk infants who received an ASD 
diagnosis had significantly larger subcortical volumes than the high-risk group without a later 
diagnosis [F(1,18) = 8.39, p = 0.010]. Results did not differ when co-varied for total brain 
tissue, as opposed to intracranial volume.  
 
4.3.4. Associations between regional brain volumes at 4-6 months and ASD symptoms 
at 36 months 
Within the high-risk group, there was a significant positive correlation between the volume of 
the subcortical region at 4-6 months and restricted and repetitive autistic behaviours at 36 
months (r = 0.52, p = 0.011) (Figure 4.3A). There was also a strong trend to significance in 
social affect (r = 0.38, p = 0.071) and total autistic symptoms (r = 0.40, p = 0.061). When the 4 
children who received a diagnosis of ASD at 36 months were excluded from the analyses, the 
correlation between subcortical volume and the ADOS-2 score for repetitive behaviour still 
approached, but did not reach, significance (r = 0.36, p = 0.066).  
 
There was a significant correlation between cerebellar volume at 4-6 months and restricted 
and repetitive behaviours at 36 months, as measured by the ADOS-2 (r = 0.44, p = 0.017) 
(Figure 4.3B). Correlations between cerebellar volume and social affect (r = 0.347; p = 0.052), 
as well as total ADOS-2 score (r = 0.315; p = 0.071) also approached significance. When the 
4 children who received a diagnosis of ASD at 36 months were excluded from the analyses, 
correlations between cerebellar volume and ADOS-2 scores remained highly significant 
across all behavioural domains (restricted and repetitive: r = 0.64, p = 0.001; social affect: r = 












































Figure 4.3: Scatter plots of the correlations between infant regional brain volumes at 4-
6 months of age, and restricted and repetitive behaviours at 36 months in high-risk 
infants. (A) Subcortical and (B) cerebellar volumes are shown. The linear trendline indicates 
the correlation for all high-risk infants, but those who received an ASD diagnosis at 36 months 
are highlighted in clear circles. Abbreviations: ADOS-2 = Autism Diagnostic Observation 


















4.3.5. Moderation of regional brain volumes by mother-infant interactions at 4-6 months  
Maternal sensitivity moderated the association between infant risk group and volume of the 
subcortical region, suggesting that there was an interaction between risk group and maternal 
sensitivity [Group x Maternal Sensitivity: Unadjusted (β = -0.05, p = 0.016, CI = -0.08, -0.01)] 
(Figure 4.4). This interaction term (Group x Maternal Sensitivity) survived Bonferroni 
correction (p = 0.032), and remained significant at trend level after adjusting for infant age, 
sex, and intracranial volume [Group x Maternal Sensitivity: Adjusted (β = -0.03, p = 0.059,         
CI = -0.06, 0.00)].  
 
 
Figure 4.4: A representation of the interaction between maternal sensitivity and risk 
group on infant subcortical volume. High-risk infants are shown in red, whilst low-risk 
infants are shown in black. However, high-risk infants who received a diagnosis of ASD at 36 
months are highlighted in yellow. Note: linear trendlines have been fitted to the risk groups, 
and not the outcome groups. 
 
 
In light of this finding, the association between subcortical volume and maternal sensitivity 
was examined within each risk group separately. In the high-risk group, there was a significant 
negative correlation between the degree of sensitivity displayed by mothers and the infants’ 
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subcortical volume (r = -0.45, p = 0.045). In contrast, maternal sensitivity was not significantly 
correlated with infant subcortical volume in the low-risk group (r = 0.29, p = 0.187). The 
difference between these correlation coefficients was significant (z = 2.37, p = 0.018). Thus, 
infants in the high-risk group whose mothers demonstrated higher levels of ‘sensitivity’ tended 
to have subcortical volumes more similar to those of the low-risk (‘typical’) infants.  
 
No other maternal or infant behaviour moderated the association between risk group and 
infant subcortical volume. In addition, no maternal or infant behaviour moderated the 
difference in cerebellar volume. 
 
4.3.6. Moderation of infant outcome at 36 months by maternal sensitivity at 4-6 months  
Within the high-risk group, maternal sensitivity moderated the association between subcortical 
volume at 4-6 months and infant outcome at 36 months, as assessed by the ADI-R score on 
social affect [Subcortical Volume x Maternal Sensitivity: Adjusted (β = -37.55, p = 0.032, CI = -
71.31, -3.79)]. The interaction term survived Bonferroni correction at trend level (p = 0.096). 
This suggests that there was an interaction between subcortical volume and maternal 
sensitivity, which was predictive of ASD symptom severity at a later timepoint. The model 
explained 53.0% of the outcome and of this, 23.0% was explained by the interaction term 
(Subcortical Volume x Maternal Sensitivity). In addition, 33.1% was explained by the 
subcortical volume alone and 2.4% by maternal sensitivity. 
 
Maternal sensitivity did not moderate the association between subcortical volume at 4-6 
months and any other observed measure of infant behaviour at 36 months.  
 
4.4. Discussion 
In this longitudinal MRI study, brain volumes were compared between young infants with and 
without a familial risk of ASD. The study also examined whether any such differences were 
associated with subsequent ASD severity and/or clinical diagnostic status at 36 months. 
Whether early mother-infant interactions moderated the extent of differences in brain volume 
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and/or severity of ASD symptoms was also explored. There were no significant differences 
between high-risk and low-risk groups in either total brain tissue volume or head size (that is, 
intracranial volume). However, infants in the high-risk group had larger cerebellum and 
subcortical volumes at 4-6 months of age. These early differences in volume were also 
associated with the extent of autistic behaviours at 36 months. Moreover, preliminary 
evidence of a negative correlation between maternal sensitivity and subcortical volume within 
the high-risk group was identified, and the interaction between brain and parenting was 
predictive of ASD symptom severity at 36 months within the social domain. 
 
4.4.1. Cerebellum findings 
Cerebellar abnormalities are among the most consistently reported findings in ASD literature 
(for review see Becker and Stoodley, 2013; Fatemi et al., 2012; Rogers et al., 2013). Most 
prior investigations, however, were carried out in adolescents and adults with ASD, and 
mainly report hypoplasia rather than overgrowth (Courchesne et al., 1988; Levitt et al., 1999; 
McAlonan et al., 2002; Rojas et al., 2006). In contrast, studies of younger children have found 
enlargement of the cerebellum. For example, in studies of 2-5 year-olds, children with ASD 
were reported to have significantly larger total cerebellum (Sparks et al., 2002) and cerebellar 
white matter volume (Courchesne et al., 2001), as compared to typically developing controls. 
The results of this study extend these findings in children to younger ages, and indicate that a 
familial risk of ASD may alter cerebellar development by as early as 4-6 months of age. 
Although the underlying cause(s) of this early enlargement (and subsequent lower size) 
remain to be established, it most likely reflects an abnormal regulation of growth (Courchesne 
et al., 2001; Sparks et al., 2002). Some have suggested that this may involve an initial excess 
in synaptic proliferation, myelination, and neurogenesis, as well as enlarged glia, premature 
dendritic/axonal growth, and incomplete synaptic pruning (for review see Bauman and 
Kemper, 2005; Palmen et al., 2004), which is then followed by compensatory apoptotic and/or 
excitotoxic processes (Courchesne et al., 2001).  
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Unlike the subcortical region, enlargement of the cerebellum did not reach significance in the 
subgroup of infants who received an ASD diagnosis at 36 months. In contrast, across the 
entire high-risk group, there was a significant association between cerebellum volume and 
subsequent severity of repetitive behaviours. Moreover, when high-risk infants with ASD were 
excluded from the outcome correlation analyses, the associations between cerebellum 
volume, repetitive behaviours, and other autistic symptoms remained significant. Thus, the 
relationship between larger cerebellar volumes at 4-6 months and poorer behavioural 
outcomes at 36 months did not depend on those relatively few high-risk infants who received 
a diagnosis of ASD. However, since ASD diagnoses are more commonly made around 2-3 
years of age, 36 months is an early diagnosis. The possibility that other infants in this study 
will be diagnosed at an older age cannot therefore be excluded, and so, these infants will 
continue to be followed-up.  
 
A relationship between cerebellar volume and repetitive behaviours in ASD has been 
previously documented in older cohorts, with both smaller (D’Mello et al., 2015; Rojas et al., 
2015) and larger (D’Mello et al., 2015) volumes linked with repetitive and stereotyped 
behaviours. The measures of repetitive behaviours obtained in this study at 36 months may 
be particularly sensitive to motor stereotypies. Indeed, motor features appear to be one of the 
earliest infant manifestations of the disorder (Esposito et al., 2011; Focaroli et al., 2016; 
Zwaigenbaum et al., 2013), and findings from this study suggest that they could partly be 
explained by differences in the early development of the cerebellum. Similarly, a relationship 
between the cerebellum and social communication has been reported in ASD before. Studies 
of older individuals with ASD, however, found that smaller grey matter volumes of cerebellum 
lobules VIII were associated with more severe ratings on social communication scores 
(D’Mello et al., 2015; Rojas et al., 2006). In the present study, findings were in the opposite 
direction, but the entire cerebellum was measured. It is therefore not possible to say which 
sub-region(s) of the cerebellum might be driving the results. Further studies will be needed to 
map the trajectory of cerebellar development in infants at risk of ASD who go on to be 
diagnosed.  
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4.4.2. Subcortical findings 
In this study, the subcortical region was significantly larger in infants at risk of ASD compared 
to low-risk controls. Although high-risk infants who later received a diagnosis of ASD had the 
largest volumes, the size of the subcortical region at 4-6 months correlated with repetitive 
behaviours at 36 months, regardless of diagnostic classification. The caveat is that this study 
was not powered to identify diagnostic markers of ASD, as this would require a much larger 
sample size of high-risk infants. However, the observation that subcortical enlargement at 4-6 
months may be a feature of high-risk infants who receive a diagnosis, is worthy of follow-up.   
 
Although there are no published studies examining subcortical volume in infants at risk of 
ASD, there are many reports that older individuals diagnosed with ASD have significant 
differences in the anatomy of subcortical structures. For example, the caudate nucleus has 
been reported to be larger in children, adolescents, and adults (Estes et al., 2011; Haznedar 
et al., 2006; Herbert et al., 2003; Hollander et al., 2005; Langen et al., 2007; Rojas et al., 
2006; Sears et al., 1999). Caudate overgrowth has even been proposed as a core abnormality 
of ASD (Stanfield et al., 2008). Other regions such as the globus pallidus and putamen have 
also been reported to be enlarged in individuals with ASD (Estes et al., 2011; Herbert et al., 
2003; Hollander et al., 2005; Langen et al., 2007; Sato et al., 2014; Turner et al., 2016), 
although some of these findings may be confounded by differences in total brain volume 
(Estes et al., 2011; Herbert et al., 2003). Results from studies of the thalamus in ASD are less 
clear-cut, with reports of no difference (Haznedar et al., 2006), larger volumes (Herbert et al., 
2003), and smaller volumes (Hardan et al., 2006a; Tsatsanis et al., 2003).  
 
Subcortical volume differences have also been linked to ASD symptoms in older cohorts, 
although the direction of the relationship varies. For example, larger volume of the caudate in 
adolescents and adults with ASD has been reported to be both positively (Hollander et al., 
2005; Rojas et al., 2006) and negatively (Sears et al., 1999) correlated with severity of 
repetitive and stereotyped behaviours. Caudate volume in these individuals has also been 
positively correlated with social and communication scores (Rojas et al., 2006). In contrast, 
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studies of younger individuals (aged 3-4 years) found that more repetitive and stereotyped 
behaviours were linked to smaller volumes of several subcortical regions, including the left 
thalamus, right globus pallidus, putamen, and striatum (Estes et al., 2011). Therefore, 
regardless of the direction of the association, work to date clearly implicates abnormalities of 
the subcortical region with ASD symptoms, and especially repetitive behaviours.  
 
The findings of the present study extend current knowledge, and suggest that the subcortical 
region is already enlarged by 4-6 months of age in infants at high-risk of ASD who go on to 
develop a clinical diagnosis at 36 months. Results also suggests that, even when children who 
receive an ASD diagnosis are excluded from the analysis, larger subcortical volumes in early 
development are indicative of more repetitive behaviours at a later age.   
 
4.4.3. Non-significant CSF findings  
In contrast to what had been a priori predicted based on the findings documented in a recent 
study of infants at risk of ASD (Shen et al., 2013), this study did not identify any evidence of 
greater extracerebral CSF volume in the high-risk group. It also did not find differences in CSF 
proportions between groups. There are several reasons that could explain the divergent 
results in studies. First, this study focussed on infants aged 4-6 months, whereas the other 
examined infants aged 6-9 months, and it could be that enlarged extracerebral CSF volume is 
only present in individuals slightly older than 6 months. Second, the study by Shen et al., 
(2013) drew a horizontal slice through the anterior commissure in order to define a ventral 
boundary for the region of the extracerebral CSF. The present study did not, and therefore, 
this slight difference in the anatomical delineation of the region may have driven the non-
significant results. Finally, and although the study by Shen et al., (2013) had a similar sample 
size to that of the present study (high-risk: n = 33 vs. n = 24; low-risk: n = 22 vs. n = 26), the 





4.4.4. The impact of mother-infant interactions on early brain volume and severity of 
later autistic symptoms 
Finally, although this study reported that high-risk infants had larger subcortical volumes than 
low-risk controls, there was also preliminary evidence of a negative association between 
maternal sensitivity and subcortical volume within the high-risk group. That is, infants in the 
high-risk group exposed to more ‘sensitive’ mothers tended to have subcortical brain volumes 
more comparable to the low-risk (‘typical’) group. Maternal sensitivity also moderated the 
association between the volume of the subcortical region at 4-6 months and infant social 
affect at 36 months, suggesting that the interaction between brain and behaviour may be 
predictive of social difficulties at a later timepoint. Thus, not only do these results indicate that 
the subcortical region is altered in infants with a familial risk of ASD who go on to develop a 
clinical diagnosis, but also that this region may be responsive to the early parent-child 
environment.  
 
Others have shown that normative variations in early parenting may influence brain 
development. For example, higher levels of parental sensitivity have been associated with 
markers of more optimal brain development in 8 year-old children, including larger total brain 
and grey matter volumes, as well as more rapid cortical thinning (Kok et al., 2015). The 
findings of this study imply a similar protective effect of exposure to more ‘sensitive’ mothers. 
Sensitive parenting may reduce a child’s experience and perception of stress (Kertes et al., 
2009; Luijk et al., 2010), facilitating more appropriate brain and behavioural development. To 
be clear, however, the present study does not support the suggestion that differences in 
maternal behaviour cause their infant to develop ASD. Since infant and mother are closely 
genetically related, it is possible for instance that the associations observed in this study could 
be mediated through shared genetic variants, including an inherited brain volume and/or 
behavioural style (Klahr and Burt, 2014). Other factors, such as the infant’s behaviour, the 
presence of an older ASD sibling, and the parent’s own approach may also be playing a role 
here, influencing the mother-infant interaction. For example, mothers may unconsciously 
detect subtle behavioural differences in the social interactions of infants at risk of ASD, which 
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precede the onset of clinical symptoms (Jones et al., 2014), and are likely to cause the mother 
to adjust her behaviour in response to the infant’s affect and attention. Similarly, in families 
with an older sibling diagnosed with ASD, the strategies developed by parents to interact with 
the autistic child may be inadvertently transferred to the interaction with the later born infant. 
In line with this, high-risk infants may also pick-up on behaviours exhibited by the older sibling, 
and which to some extent, may mould the infant’s own behaviour. Finally, parents of high-risk 
infants may also demonstrate characteristics of the BAP themselves, and thus be less 
sensitive to their infant’s’ mental state (Bolton et al., 1998; Gerdts and Bernier, 2011), which 
may negatively impact upon the mother-infant interaction.  
 
4.4.5. Study limitations 
This study has several limitations. First, given the modest sample size and the need to 
understand the dimensional nature of ASD, this study focused on a comparison of high and 
low-risk infants at 4-6 months, rather than their behavioural outcomes. The comparison of 
high-risk infants with and without a diagnosis of ASD at 36 months should be considered 
exploratory only. Also given the small sample size and tentative nature of this study, no 
correction for multiple comparisons was conducted when examining mean volumetric 
differences between groups. The possibility of a false positive (type I) error cannot therefore 
be excluded. Second, outcome data was only collected for high-risk infants. If outcome 
measures for both risk groups had been obtained, this would have enabled a better 
classification of the cohort, and would have allowed for different questions to be asked. For 
example, how many low-risk infants developed ASD, and how did their regional brain volumes 
compare to that of high-risk infants who also received an ASD diagnosis? With this in mind, 
outcome measures for project 2 (conducted at 3T, and including both fetal and neonatal 
timepoints) are currently being collected for individuals enrolled in either risk group. Third, but 
in line with what has been reported by others (Hazlett et al., 2012), the differentiation of grey 
and white matter was not possible due to ongoing myelination at this age. Fourth, the images 
included in this study were acquired with a large slice gap of 2 mm, which may have affected 
the accuracy of the volumetric segmentation. Also owing to the low resolution of the images, 
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the cerebellum and the subcortical region could not be separated into their individual 
components. Specifically, the cerebellum was not partitioned into cerebellar hemispheres and 
vermis lobules, while the subcortical region was not subdivided into caudate nucleus, 
putamen, globus pallidus, thalamus, and internal capsule. Last, the parent-child interactions 
included in this study were limited to observations with only the mothers, and further research 
would benefit from the inclusion of paternal interactions.   
 
4.4.6. Conclusions 
To the best of my knowledge, this is the first MRI study to report that regional brain volume 
differences in infants at risk of ASD are present prior to 6 months of age, and correlate with 
subsequent ASD severity. Thus, this study adds to the existing evidence that a familial risk of 
ASD causes differences in brain structure which are associated with the subsequent 
development of autistic behaviours. Building on the findings from the prior study, which 
reported significant associations between maternal sensitivity and subcortical volume, this 
study extends this finding further by providing preliminary evidence of an association between 
maternal sensitivity and subcortical volume within the high-risk sample. This suggests that the 
subcortical region may be responsive to both genetic and environmental exposures from early 
on in infancy. Further investigation is warranted to establish the utility of the cerebellum and 
subcortical region as potential ‘risk’ markers. Finally, the possibility that the development of 
the subcortical region may be modifiable through parenting style should also be tested, with 
the ultimate goal of encouraging future parent-mediated intervention trials.  
 
To extend these results and given the evidence suggesting that ASD begins in prenatal life, 
the next step was to examine even earlier brain development, and to compare brain volumes 
between fetuses at high and low-risk of ASD. As such, the main aim was to investigate 




Chapter 5: Brain volumes in fetuses with and 
without a familial risk of ASD 
 
5.1. Introduction 
The previous experimental study made novel, albeit preliminary, contributions to our 
understanding of early brain development in infants genetically predisposed to ASD. As far as 
I am aware, it was the first MRI study to report that regional brain volume differences are 
present in high-risk infants prior to 6 months of age, and that brain volumes correlate with 
subsequent autistic behaviours. In order to explore whether a familial risk of ASD is also 
associated with differences in brain volume at an earlier time in development, the present 
study – aimed at investigating differences in fetal life – was carried out.  
 
The fetal period is a time of dynamic change during which the human brain undergoes 
extensive growth and development. Particularly important are the final weeks of gestation, as 
this is when a volumetric expansion of the brain is accompanied by folding of the cerebral 
cortex. This process of cortical development follows a co-ordinated sequence of steps, and is 
crucial for the establishment of appropriate connectivity across brain networks (Kostović and 
Jovanov-Milošević, 2006; Sur and Rubenstein, 2005). As described earlier in the introduction 
of this thesis, several cellular mechanisms underlie this important stage of development, 
including cell proliferation, differentiation, and migration. Errors in many of these processes 
have now been implicated in neurodevelopmental disorders like ASD. In addition, these errors 
are thought to result from multifactorial genetic and environmental risk factors, many of which 
manifest in the prenatal period. For example, some of the genes that regulate prenatal 
processes such as neurogenesis, cortical patterning, and neuronal differentiation, are 
reportedly deregulated in individuals with ASD (Chow et al., 2012; Pinto et al., 2010). 
Moreover, epidemiological evidence has associated ASD with environmental risk factors, such 
as high levels of maternal stress (Kinney et al., 2008; Rai et al., ,2013) and prenatal exposure 
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to anticonvulsants and/or antidepressants (Boukhris et al., 2015; Christensen et al., 2013; 
Croen et al., 2011; Williams et al., 2001).  
 
Considering these risk factors and the early postnatal brain differences observed in individuals 
exposed to a familial risk of ASD, previous attempts have been made to establish whether 
brain/head differences are already present amongst genetically predisposed individuals in 
utero. While retrospective studies using prenatal US found no significant difference in fetal 
head growth between individuals with and without ASD (Hobbs et al., 2007; Whitehouse et al., 
2011), other subtle differences have been identified. For example, there is evidence of 
enlarged fetal biparietal diameter relative to head circumference in individuals with ASD, as 
compared to controls (Hobbs et al., 2007). In addition, other retrospective evidence suggests 
that abnormalities in the development of the fetal ventricular system and cerebellum, both of 
which can be identified on US, may predate a later ASD diagnosis (for review see Gamliel et 
al., 2012).  
 
As such, prospective studies of fetuses with a familial risk of ASD have started to emerge. In 
the first published study of prenatal growth in siblings of individuals with and without ASD 
(Unwin et al., 2016), US scans were conducted at three separate timepoints in pregnancy. 
Fetal biometric measures, growth rates, and head-to-body ratios were compared between risk 
groups, but no significant differences were reported (Unwin et al., 2016). A serious limitation 
of this study was that measures of head circumference were used as a proxy measure of 
brain size. While the two are strongly correlated, especially at young ages (Bartholomeusz et 
al., 2002), this indirect approach limits the interpretation of results. Furthermore, although US 
is a reliable tool for measuring the macrostructure of the fetal brain, it does not allow for the 
analysis of specific sub-regions potentially implicated in ASD, such as the cerebellum. 
Instead, to explore subtle differences in brain regions between groups, fetal MRI may be a 
more suitable technique. 
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Thus, this study used fetal MRI to (i) first characterise the volumetric growth of brain regions 
between 28-38 gestational weeks, in a mixed sample of fetuses with and without a familial risk 
of ASD. Specifically, growth trajectories were constructed to qualitatively inspect whether 
there were any obvious outliers and/or deviations in brain growth between fetuses at high and 
low-risk of ASD. In addition, relative growth rates were calculated in order to compare with 
normative rates reported by others. Then, in order to formally assess volumetric differences 
between risk groups, the study (ii) compared total and regional brain volumes in fetuses with 
and without a familial risk of ASD. Based on the results of the previous infant study, 
subcortical and cerebellum volumes were a specific focus. Moreover, because the subcortex 
drives cortical development at this timepoint, (iii) the volumetric relationship between the 
cortex and subcortex was explored in each risk group separately. 
 
Owing to the limited information on prenatal brain development in fetuses at risk of ASD, no 
firm predictions were made regarding the direction of any differences observed.  
 
5.2. Materials and methods 
5.2.1. Participants 
This study included both high-risk and low-risk groups, with participants categorised based on 
the inclusion criteria previously described in the main methodology of this thesis (please see 
section 2.3.3 on page 108). Of the 89 participants enrolled in the study prenatally, 64 agreed 
to take part in the fetal MRI scan. The remaining 25 participants did not take part: 20 did not 
wish to participate at this time, and 5 could not be scanned (4 due to a high BMI, and 1 
because of a metallic implant). Of the 64 participants that did agree to take part, scanning was 
unsuccessful for 2 participants who began to experience anxiety once prepped in the 
scanning bed. Data was therefore successfully collected from a total of 62 participants. 
However, a further 9 participants were excluded from the main volumetric analysis due to poor 
image quality driven by fetal motion, which precluded an accurate fetal reconstruction. Hence, 
the final sample size consisted of 53 fetuses: 35 low-risk (n = 20 male; mean gestational age 
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at scan = 32.30 weeks, SD = 1.71) and 18 high-risk (n = 9 male; mean gestational age at scan 
= 32.33 weeks, SD = 2.03). 
 
5.2.2. Experimental procedures 
Participants taking part in the fetal timepoint were scanned between 28-38 gestational weeks.  
All experimental procedures were conducted as previously described in the methodology of 
this thesis (please see section 2.3.5.1 on page 111).  
 
5.2.3. Statistical analysis  
Normality of data distribution was assessed visually using box-plots, and statistically using the  
Shapiro-Wilk Test. Group differences in sample characteristics were tested using the 
Independent Samples t-test, the Mann-Whitney U-test, the Person’s Chi-Square test, or the 
Fisher’s exact test, as appropriate. Where regional brain volumes were not normally 
distributed, logarithmic transformations were performed. 
 
 Effects of gestational age on regional brain volumes 
The effects of gestational age on regional brain volumes were assessed for the whole sample 
(that is, for low-risk and high-risk groups combined). Depending on the data distribution, 
correlations between fetal gestational age and regional brain volumes were tested with either 
Pearson’s or Spearman’s rank correlation. Then, for each specific brain region, the curve of 
best fit was selected, and the mean volume of that region at 28, 33, and 38 gestational weeks 
was calculated. Growth trajectories for each brain region were plotted with the curve of best 
fit, and lines representing two standard deviations (±2SD) from the mean were included in 
these plots. Low-risk and high-risk fetuses were also labelled on these plots to allow visual 
inspection of any obvious outliers and/or deviations in growth between groups. To facilitate 
comparisons with other published studies, relative growth rates were calculated and 




 Group differences in regional brain volumes   
To test for any potential effect of risk group on regional brain volumes, an ANCOVA was run 
on the normally distributed data, with risk group (low-risk vs. high-risk) input as the fixed 
factor. The dependent variables of interest included: volume of supratentorial tissue, 
supratentorial white matter and subcortical grey matter tissue, cerebellum, pons, cortex, total 
brain tissue, lateral ventricles, third ventricle, fourth ventricle, extracerebral CSF, total CSF, 
and intracranium, as well as the proportion of extracerebral CSF to total CSF. Gestational age 
and intracranial volume were included as co-variates, whilst sex was included as a (between 
subjects) fixed factor. Although maternal and paternal education differed between risk groups 
(Table 5.1), a decision was made to only co-vary for biological factors rather than ‘over-
control’ for variables in this small sample.  
 
Finally, to examine the volumetric relationship between the cortex and the subcortex (using 
the volume of the supratentorial white matter and subcortical grey matter as an index for the 
subcortex), correlation analyses were run between these two measures in the high-risk and 
low-risk group separately.  
 
5.3. Results 
5.3.1. Sample characteristics 
The characteristics of the total sample, and split by risk group, are presented in Table 5.1. 
Fetuses (n = 53; 35 low-risk, 18 high-risk) were scanned at a mean gestational age of 32.31 
weeks (SD = 1.81, range = 28.29-38.29 weeks; Figure 5.1), and risk groups did not differ 
significantly in age or sex. In addition, risk groups did not differ significantly in most parental 
characteristics, including age at conception, ethnicity, marital status, or maternal smoking and 
alcohol consumption. However, both maternal and paternal education differed significantly 
between groups (p = 0.010 and p = 0.001, respectively), with high-risk parents being less well 
educated than those in the low-risk group. 
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The quality of some fetal reconstructions did not allow for cortical segmentation to be 
complete. Therefore, the volume of the cortex as well as the supratentorial white matter and 
subcortical grey matter tissue (which was calculated using the cortical volume) was available 
for only n = 41 fetuses, comprising 27 low-risk (n=18 male; mean gestational age at scan          
= 32.13 weeks, SD = 1.79) and 14 high-risk (n=8 male; mean gestational age at scan = 31.67 
weeks, SD = 1.39). As before, there were no group differences in age (p = 0.413) or sex           
(p = 0.548) in this sub-sample of fetuses. 
 
Figure 5.1: Distribution of the participants’ gestational age at the fetal timepoint.  
A histogram of fetal gestational age at the time of MRI acquisition is shown.  
































Table 5.1: Fetal and parental characteristics stratified by risk group 
Note: aPaternal age was only available for 50 participants (34 low-risk; 16 high-risk). The Fisher’s exact test does not have an associated statistic; thus, only        
p-values were reported. Significant results are in bold. Abbreviations: MRI = magnetic resonance imaging; Higher Education = undergraduate and/or 





(N = 53) 
 
Low-Risk Group 
(n = 35) 
 
High-Risk Group 













U = 293.00; p = 0.679 
Sex (male); n (%)  
Parental characteristics 
29 (54.71) 20 (57.14) 9 (50.00)   χ2 = 0.25; p = 0.621 
Maternal age at conception (years); mean (SD) 
Paternal age at conceptiona (years); mean (SD) 
Maternal alcohol intake during pregnancy; n (%) 
Never 
Weekly   
Monthly or less 
Not answered  
Maternal smoking during pregnancy; n (%) 
Yes  
No 
Not answered  
Marital status (married); n (%) 
Maternal ethnicity (white); n (%) 
Paternal ethnicity (white); n (%) 
Maternal education (higher education); n (%) 

















































t = 0.51, p = 0.614 
t = 0.77, p = 0.446 









p = 0.159 
p = 0.152 
p = 0.250 
p = 0.009 
p = 0.001 
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5.3.2. The effect of fetal gestational age: growth trajectories of regional brain volumes  
Correlations between fetal gestational age and regional brain volume are presented in Table 
5.2. This table also displays the mean volume (in cm3) of each region at 28, 33, and 38 
gestational weeks, as well as their relative growth rate (expressed as the % change in volume 
per week).  
 
Across risk groups, most brain regions showed evidence of a strong, positive, and statistically 
significant correlation between gestational age and brain volume (Table 5.2). However, for the 
lateral ventricles, extracerebral CSF, and total CSF, volumes appeared to remain relatively 
stable with advancing gestation [lateral ventricles: (r = 0.09, p = 0.501); extracerebral CSF:         
(r = -0.02, p = 0.911); total CSF: (r = 0.00, p = 0.978)]. The fastest growing region in this latter 
stage of gestation was the cortex, with a relative growth rate of 10.86% per week, from an 
average of 23.62 cm3 at 28 weeks gestation to 71.67 cm3 at 38 weeks. Not far behind was the 
cerebellum, increasing at a relative rate of 7.51%, followed by the supratentorial white matter 
and subcortical grey matter tissue, total brain tissue, supratentorial tissue, and pons – with 
growth rates ranging between 5.26% and 7.23%. The fourth ventricle was the fastest growing 
CSF-filled space, increasing at a relative rate of 5.60% per week, from an average of 0.04 cm3 
at 28 weeks to 0.12 cm3 at 38. In contrast, the slowest growing region was the third ventricle, 
with a growth rate of 2.74%. All other regions of the ventricular system decreased in volume 
from 28-38 gestational weeks, with values ranging between -4.72% and -5.62%.  
 
Linear and quadratic equations explained the growth trajectory of each region equally well, as 
shown in Figure 5.2 and 5.3. However, mean volumes were calculated based on quadratic 
equations, which best described the data according to the goodness-of-fit measure. An 
exception was the growth of the fourth ventricle, which followed an exponential trajectory 
(Figure 5.3C). Visual inspection of growth plots revealed little difference between groups, and 
no obvious outliers and/or deviations in growth within the high-risk group. High-risk fetuses 
mainly stayed within ±2SD of the mean, and in brain regions where outliers did exist, they 
were equally distributed between groups.    
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Table 5.2: Correlations between brain volumes and fetal gestational age, presented for the total sample (n=53)  
Note: The relative growth rate (% per week) represents the percent volume increase relative to the mean volume of the structure. aThese regional volumes were 
only available for 41 fetuses (27 low-risk; 14 high-risk). Significant results (p ≤ 0.05) are shown in bold. Abbreviations: CSF = cerebrospinal fluid; GW = 
gestational age in weeks; r = (Spearman’s rank or Pearson’s) correlation coefficient. 
 
Brain Region 
Correlation with Gestational Age Mean Volume (cm3) Relative Growth Rate  
r p-value 28 GW 33 GW 38 GW (% Per week) 
Supratentorial Tissue 0.83 <0.001 117.91 211.92 306.47 5.35 
Cerebellum 0.82 <0.001 4.86 11.42 17.28 7.51 
Pons 0.76 <0.001 1.19 1.96 2.67 5.26 
Cortexa 0.78 <0.001 23.62 43.07 71.67 10.86 
Supratentorial White Matter  & 
Subcortical Grey Matter Tissuea 
0.79 <0.001 118.19 164.96 300.45 7.23 
Total Brain Tissue 0.83 <0.001 124.08 225.46 326.64 5.45 
Lateral Ventricles 0.09 0.501 4.87 6.36 5.21 -5.62 
Third Ventricle 0.35 0.010 0.16 0.34 0.30 2.74 
Fourth Ventricle 0.54 <0.001 0.04 0.07 0.12 5.60 
Extracerebral CSF -0.02 0.911 66.06 85.93 59.09 -4.68 
Total CSF 0.00 0.978 71.04 92.63 64.62 -4.72 
Intracranium 0.75 <0.001 194.42 317.1 389.93 3.22 
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Figure 5.2: Growth trajectories of total and regional brain volumes acquired for the whole sample (low-risk and high-risk groups combined).  
(A) Supratentorial tissue, (B) cerebellum (C) pons, (D) supratentorial white matter and subcortical grey matter tissue, (E) cortex, and (F) total brain tissue.  
The trendlines (in black) indicate the correlation between gestational age and volume for the whole sample, and although a quadratic model provided the best fit, 
both linear (dashed line) and quadratic (solid line) curves are shown. The two horizontal red dotted lines represent ±2 SD from the mean.  








    (D)               (E)          (F) 
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Figure 5.3: Growth trajectories of the CSF spaces and intracranium, as acquired for the whole sample (low-risk and high-risk groups combined).                                 
(A) Lateral ventricles, (B) third ventricle, (C) fourth ventricle, (D) extracerebral CSF, (E) total CSF, and (F) intracranium. The trendlines (in black) indicate the 
correlation between gestational age and volume for the whole sample, and although a quadratic model provided the best fit, both linear (dashed line) and 
quadratic (solid line) curves are shown. The two horizontal red dotted lines represent ±2 SD from the mean. 







  (D)                (E)            (F) 
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5.3.3. Group differences in fetal brain volumes  
Significant group differences were identified for the cortex [F(1,35) = 5.21, p = 0.029], with 
high-risk fetuses having smaller cortical volumes than low-risk controls (Figure 5.4). No other 













Figure 5.4: Mean cortical volume in fetuses at low and high-risk of ASD. 
Fetuses in the high-risk group had a significantly smaller volume (cm3) of the cortex, when 




In both risk groups there was a strong positive correlation between the volume of the cortex 
and that of the supratentorial white matter and subcortical grey matter tissue, which was 
statistically significant [high-risk group: (r = 0.93, p < 0.001); low-risk group: (r = 0.87,                  
p < 0.001)]. There was no significant difference in correlation coefficients between groups 


























Table 5.3: Group differences in fetal brain volumes (cm3) and in proportions of volumes (au.) between low-risk and high-risk groups 
  Low-Risk Group (n = 35) High-Risk Group (n = 18) Group Difference 
  Mean SD Mean SD F p-value 
Brain Volumes (cm3) 
      
Supratentorial Tissue 201.37 38.57 193.38 46.17 0.10 0.749 
Cerebellum 10.58 2.58 10.39 3.17 1.14 0.292 
Pons 1.86 0.32 1.86 0.42 1.07 0.307 
Cortexa 40.68 9.45 35.23 8.70 5.21 0.029 
Supratentorial White Matter & 
Subcortical Grey Matter Tissuea 
157.35 30.60 144.29 30.70 0.38 0.543 
Total Brain Tissue 213.80 41.15 205.63 49.59 0.19 0.666 
Lateral Ventricles 6.41 1.47 5.63 2.90 2.42 0.126 
Third Ventricle 0.33 0.09 0.28 0.08 2.23 0.142 
Fourth Ventricle 0.07 0.03 0.07 0.03 0.40 0.532 
Extracerebral CSF 84.68 12.41 79.54 16.7 0.08 0.782 
Total CSF 91.49 12.79 85.52 17.07 0.19 0.666 
Intracraniumb 305.30 49.26 291.15 46.65 2.50 0.121 
       
Brain Proportions (au.) 
      
Extracerebral CSF/Total CSF 0.92 0.02 0.93 0.03 0.26 0.611 
Note: In this analysis of co-variance, gestational age and intracranial volume were included as co-variates, whilst sex was included as a fixed factor; hence, F = 
F(1, 47). aThese regional volumes were only available for 41 fetuses (27 low-risk; 14 high-risk), therefore F = F(1, 35). bIn this analysis, only gestational age and 
sex were corrected for; hence, F = F(1, 48). Significant results are in bold. Abbreviations: F = F-statistic; CSF = cerebrospinal fluid; SD=standard deviation.  
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5.4. Discussion  
To the best of my knowledge, this was the first MRI study to examine regional brain 
maturation in fetuses with and without a familial risk of ASD. Across both groups, the volume 
of all brain regions (with the exception of some CSF-filled spaces) increased significantly from 
28-38 gestational weeks. Visual inspection revealed little difference between groups, and no 
obvious outliers and/or deviations in growth within the high-risk group. Still, high-risk fetuses 
had significantly smaller cortical volumes than low-risk controls.  
 
5.4.1. Volumetric growth trajectories of fetal brain regions 
This study confirmed previous indications that a quadratic model best describes the fetal 
growth of most brain regions (Gholipour et al., 2011; Kyriakopoulou et al., 2014, 2016; 
Vatansever et al., 2013). When examining the full cohort, the cortex was the fastest growing 
region between 28 and 38 gestational weeks, with volumes increasing at a relative rate of 
10.86% per week. Only a small number of prior studies have measured cortical volumes using 
fetal MRI, but those that have report growth rates broadly in agreement with the present study 
[13.15% (Kyriakopoulou et al., 2014), 14.78% (Kyriakopoulou et al., 2016), and 18.00% (Scott 
et al., 2011)]. Within this timepoint, the second fastest growing region was the cerebellum, 
with a relative growth rate of 7.51%. Other studies using similar methodologies have observed 
slightly higher growth rates for this region, ranging between 12.87% and 17.31% (Clouchoux 
et al., 2012; Kyriakopoulou et al., 2016; Vatansever et al., 2013). However, these studies 
included fetuses of younger gestational ages than those included in the present study (< 28 
weeks), which could explain the difference in results.  
 
The rates of supratentorial and total brain tissue growth observed here (of 5.35% and 5.45% 
per week, respectively) were slower, compared to other studies reporting growth rates ranging 
between 10.22% and 17.00%; although again, these studies included measures from the 
second trimester (Clouchoux et al., 2012; Kyriakopoulou et al., 2014, 2016; Rajagopalan et 
al., 2011; Scott et al., 2011). However, since the mean volume of total brain tissue obtained in 
this study (225 cm3) was well within the range of that reported at equivalent ages by others 
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[for example, 200-250 cm3 at 32 weeks gestation (Clouchoux et al., 2012; Gholipour et al., 
2011)], it is likely that if the age-range of this study had been extended to second trimester 
fetuses, the growth rates observed here would be more closely aligned to those reported by 
others.  
 
All CSF-filled spaces, with the exception of the fourth ventricle, were only weakly correlated 
with gestational age. Moreover, upon visual inspection of the data (please refer back to Figure 
5.3 on page 190), the volumetric growth trajectories of these spaces appeared to follow more 
of an inverted U-shaped curve, as volumes decreased towards the end of gestation. In this 
study, lateral ventricular volumes decreased at a relative growth rate of -5.62% per week 
between 28-38 gestational weeks, in agreement with another study of a similar age-range, 
which reported a growth rate of -4.18% (Clouchoux et al., 2012). Others, however, have 
reported that the lateral ventricular volume both increases (Kyriakopoulou et al., 2014, 2016; 
Scott et al., 2011) or remains stable (Grossman et al., 2006) throughout gestation, and the 
inconsistency in results is likely due to the difference in ages examined. For example, post-
mortem studies have described a pattern whereby the volume of lateral ventricles gradually 
increases from 9-23 weeks, peaks at around 23-26 weeks, and decreases thereafter 
(Kinoshita et al., 2001; Lan et al., 2000). Hence, depending on what age-range is being 
examined, it is reasonable to expect different patterns of growth. Nonetheless, the decrease in 
lateral ventricular volume identified in studies examining the latter half of gestation, as was the 
case of the current study, is in agreement with post-mortem findings.  
 
In contrast, both the volume of the third and fourth ventricles increased with gestational age at 
corresponding growth rates of 2.74% and 5.60% per week. The only other study that has 
examined the third ventricle also observed a small increase in its volume, with a relative 
growth rate of 0.10% per week (Kyriakopoulou et al., 2014). In addition, volumetric studies 
examining the growth rate of the fourth ventricle have reported very distinct rates of 0.13% 
(Kyriakopoulou et al., 2014) and 12.00% (Vatansever et al., 2013), despite having assessed 
fetuses of the same gestational age-range. Thus, there appears to be considerable variability 
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in the growth rate of this region, most likely due to its small size and its reliance on the 
morphological changes of the surrounding tissue (Scott et al., 2012; Vatansever et al., 2013).  
 
To summarise, the fetal brain growth observed here was in line with what has been reported 
in the literature.  
 
5.4.2. Group differences in fetal brain volumes 
In the only other study of fetuses with and without a familial risk of ASD, US was used, and no 
group differences were identified on a range of biometric measurements, including 
occipitofrontal and biparietal distance (Unwin et al., 2016). Due to the limitations of US, this 
latter study was unable to directly examine brain volumes. Therefore, the use of MRI in the 
present study was a considerable advantage. Qualitatively, there were no obvious outliers 
and/or deviations in brain growth amongst fetuses with and without a familial risk of ASD. 
However this study revealed, albeit in a small cohort, that fetuses at risk of ASD have smaller 
cortical volumes than low-risk controls. This locus of potential pathology is in line with 
mounting evidence from older age groups implicating the cortex in the neuropathology of 
ASD. Nonetheless, variations in cortical volume may arise from alterations in cortical surface 
area, cortical thickness, or both, and my future analyses will examine these component 
indices.  
 
Some clues about the relative importance of different indices of cortical morphology in ASD 
come from studies of older cohorts. For example, individuals with ASD have been reported to 
have greater cortical thickness in some regions (Ecker et al., 2013b; Hardan et al., 2006b), but 
also cortical thinning (Hadjikhani et al., 2006; Wallace et al., 2010), enlarged surface areas 
(Hazlett et al., 2011; Ohta et al., 2016), and anomalies in cortical folding (Hardan et al., 2004; 
Jou et al., 2010; Nordahl et al., 2007; Wallace et al., 2013). Similarly, opposite abnormalities 
in cortical surface, such as polymicrogyria (multiple small gyri leading to excessive gyrification, 
thought to arise in prenatal life) and macrogyria (enlarged gyri) have been reported in 
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individuals with ASD, more often than in age-matched controls (Piven et al., 1990; Ritvo et al., 
1986; Schifter et al., 1994).  
 
Despite the complexity of cortical differences in ASD, there is consensus that cortical volume 
is greater in young children (aged 1-5 years) with ASD (Hazlett et al., 2011; Schumann et al., 
2010). However, here, in fetuses at risk of ASD, the cortex is smaller rather than larger. 
Therefore, it is critically important to note the key distinctions between this study and previous 
studies, specifically: (i) the timepoint of assessment and (ii) the sample population. For 
example, the current study did not measure brain volumes in young children with ASD; it 
measured brain volumes in fetuses at risk of ASD.  
 
Although not entirely comparable, several retrospective studies have shown that, at birth, 
individuals who later go on to develop ASD have head circumferences that are no different 
(Dawson et al., 2007; Hazlett et al., 2005; Surén et al., 2013), or smaller (Courchesne et al., 
2003; Mraz et al., 2007; Redcay and Courchesne, 2005), than those who do not receive a 
diagnosis. In contrast, at 6-14 months, head circumferences are significantly larger in 
individuals with ASD, relative to age-matched controls (Courchesne et al., 2003). Based on 
this evidence and on the findings of the present study, there appears to be an overshoot in 
head size during the early postnatal period, which is preceded by a prenatal period of delayed 
and/or abnormal maturation, especially of the cortex. 
 
The mechanisms underpinning these observations are not fully understood. Post-mortem 
studies have reported that individuals with ASD, compared to those unaffected, have more 
minicolumnar abnormalities (Buxhoeveden et al., 2006; Casanova et al., 2002, 2006; 
McKavanagh et al., 2015), focal patches of abnormal laminar cytoarchitecture (Stoner et al., 
2014), and irregularities in cell patterning at the cortical–white matter boundary (Avino and 
Hutsler, 2010). This evidence points towards a deregulation of cortical development in ASD, 
which could be explained by prenatal errors in neuron migration, layer-specific differentiation, 
and subplate dissolution (Avino and Hutsler, 2010; Stoner et al., 2014). In support of this, 
 197 
many of these processes have now been implicated in genetic studies of ASD (Chow et al., 
2012; Pinto et al., 2010).  
 
Another possible cause of the disruption in cortical development may be differences in 
prenatal hormones. For example, elevated levels of steroid hormones, such as testosterone, 
have been identified in the amniotic fluid of males who later received an ASD diagnosis 
(Baron-Cohen et al., 2015). Steroid hormones are essential for normal neurodevelopment. 
However, elevated levels of these hormones are thought to alter gene expression via 
epigenetic programming, which may modify neurodevelopmental processes. In addition, 
evidence suggests that high levels of testosterone can exert neuronal damage, both directly 
by the induction of the apoptotic cascade (Estrada et al., 2006), as well as indirectly via the 
exacerbation of glutamate neurotoxicity (Yang et al., 2002). However, steroid hormones were 
not measured in this study, and therefore this suggestion remains speculative.  
 
ASD risk did not measurably affect the volume of any other brain region examined in this 
study, including the cerebellum and subcortical region. However, as shown in Table 5.3, the 
mean volume of all brain regions was smaller in high-risk fetuses, relative to low-risk controls. 
There may be several reasons why no significant differences were identified in regions other 
than the cortex. For example, the analysis may have been underpowered to identify any 
differences that actually do exist (reflective of a false negative error), or there may actually be 
no differences in the volume of other brain regions at this time. Alternatively, the volume 
measures used may not have been sensitive enough to detect subtle differences. This may be 
especially true for the subcortical region, given that the specificity of the measurement was 
hugely limited by the fact that it also incorporated the volume of the supratentorial white 
matter. Thus, the possibility that subcortical differences were present, but undetected, cannot 
be ruled out.   
 
In fetal life there is also evidence that the subcortical region drives the development of cortex 
(Kostović and Jovanov-Milošević, 2006; Sur and Rubenstein, 2005), and therefore, it is 
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possible that the small cortical volumes identified in fetuses at risk of ASD are reflective of an 
underlying subcortical abnormality. That being said, the relationship between subcortical and 
cortical volumes was preserved in the high-risk group, and stronger, although not significantly 
different from low-risk controls (p = 0.189). In a recent study, individuals with ASD showed 
increased functional connectivity between subcortical and cortical brain regions, when 
compared to typically developing controls. This subcortico-cortical connectivity also decreased 
significantly with age amongst individuals in the ASD group (Cerliani et al., 2015). Future work 
should therefore focus on segmenting the fetal subcortical region in detail, to elucidate 
whether or not there is a disrupted relationship between cortical and subcortical regions, in 
individuals genetically predisposed to ASD at this time.  
 
5.4.3. Study limitations 
This study has a number of limitations. First, there was a small sample size in each risk group, 
which limited group comparisons in growth trajectories, and only allowed for comparisons in 
volumetric means. The small sample size also adds to the possibility of false negatives; 
hence, replications with larger samples will be necessary. In line with this, and partly due to 
the exploratory nature of this study, the statistical threshold was not corrected for the total 
number of comparisons, increasing the risk of false positives. Second, only biological co-
variates were used in the analysis, and factors such as socioeconomic status, likely to be 
important, were not controlled for. Third, cortical segmentations were only performed in a 
subset of the fetuses incorporated in this study. This was largely due to the poor image of 
some reconstructions, which limited the ability to obtain an accurate and detailed manual 
segmentation of this convoluted structure. In addition and as already mentioned, this study 
used a measure for the subcortex which included the supratentorial white matter, and hugely 
limited the specificity of the region under consideration. The team is currently working towards 
the development of an automated protocol for fetal brain segmentation (Wright et al., 2012), 
which will include a detailed parcellation of the subcortical region, and will facilitate and 
accelerate the quantification of fetal brain volume. Alongside this, a protocol for the 3D 
reconstruction of fetal cortical surfaces is also being developed (Wright et al., 2014, 2015). 
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Once fully validated, implementation of this protocol will allow for measures of cortical surface 
area, thickness, curvature, and gyrification to be obtained in a precise and reproducible 
manner. In future, characterisation and quantification of cortical surface development in 
fetuses at risk of ASD will be an important next step, as it may provide valuable insight into the 
cortical development of these fetuses, including subtle deviations from the norm that may help 
disentangle the findings of the present study.  
 
At the time of writing, the postnatal outcome data is not yet available; however, behavioural 
follow-up is currently underway. Hence, once the scanned fetuses reach a postnatal age at 
which autistic symptoms can be appraised, outcome data will help to elucidate on the clinical 
significance and specificity – if any – of these results.  
 
5.4.4. Conclusions 
In conclusion, this is the first study to provide preliminary evidence suggesting that brain 
differences (i.e. smaller cortical volumes) between individuals with and without a familial risk 
of ASD may already be evident in utero. If confirmed, these findings provide an important 
observation at a critical time in development, which may in future inform our understanding of 
the aetiological pathways to ASD.  
 
Based on these results, my next step was to compare total and regional brain volumes 
between neonates with and without a familial risk of ASD. The objective was to determine 
whether cortical abnormalities persist into neonatal life. In addition, I wished to determine 
whether any other brain regions linked to ASD in infancy and beyond, including the subcortical 
and cerebellar regions, are also affected in the neonate.  
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Chapter 6: Brain volumes in neonates with and 
without a familial risk of ASD  
 
6.1. Introduction 
In the previous experimental study, the first to directly compare total and regional brain 
volumes in fetuses with and without a familial risk of ASD, no significant group differences 
were identified in the subcortex or cerebellum (chapter 5) – regions with group differences in 
infants aged 4-6 months (chapter 4). However, fetuses at risk of ASD had smaller cortical 
volumes when compared to low-risk controls. Whether or not there are cortical volume 
differences between ASD risk groups at 4-6 months remains unknown, mainly because image 
quality did not allow for cortical segmentation. To establish the trajectory of brain maturation in 
individuals at low and high-risk of ASD, measurements between these two quite distinct 
developmental periods (i.e. between the fetal and infant period) are needed. The next step 
was therefore to investigate whether regional brain volume differences – especially in the 
cortex, subcortex, and/or cerebellum – are present in the neonatal period, shortly after birth.   
 
Birth is a critical time in development, as it is when the neonate first comes into contact with 
the environment outside the womb. As a result, there is an increasing interest in potential 
exposures and/or events occurring immediately prior to, during, and after birth, which could 
influence neurodevelopment. Thus far, factors such as a breech presentation, induced labour, 
premature birth, congenital malformation, and low Apgar score, have all been proposed to 
play a contributory role in the emergence of ASD (Gardener et al., 2011; Guinchat et al., 
2012). However, it is unlikely that any of these factors are specific to ASD, as some also seem 
to influence the risk of other neurodevelopmental disorders such as ADHD, intellectual 
disability, and epilepsy (Atladóttir et al., 2015). Moreover, there is currently insufficient 
evidence to implicate any one risk factor in a definite causal pathway to ASD. For example, 
being born with congenital malformations may not in itself cause ASD, but it may indicate that 
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fetal development has been abnormal and that the infant is on a trajectory towards atypical 
development (Bolton et al., 1997). Despite this, what is clear is that many of the risk factors 
associated with ASD, come into play at and around the time of birth. As such, birth has been 
suggested as a key stage in the divergence from typical neurodevelopment (Ben-Ari, 2015).  
 
This study therefore aimed to examine brain development in the critical period after birth. First, 
MRI was used to (i) characterise the growth of total and regional brain volumes within the first 
month of life, in a mixed sample of individuals with and without a familial risk of ASD. As 
before, growth trajectories allowed for a qualitative assessment of whether there were any 
obvious outliers and/or deviations in brain growth between individuals at high and low-risk of 
ASD. Relative growth rates were also calculated to extend information obtained from the fetal 
period, as well as to compare with other studies conducted at this age. Finally, this study also 
aimed to (ii) compare total and regional brain volumes in neonates with and without a familial 
risk of ASD. Specifically, it sought to determine whether cortical abnormalities, evident in 
utero, persisted in neonatal life. In addition, the study explored whether any other brain 
regions were affected at this time, particularly those commonly implicated in ASD, such as the 
cerebellum and subcortex.  
 
For this component of the thesis, it was possible to access more sophisticated neonatal MRI 
protocols, developed as part of the dHCP. This enabled a more detailed parcellation of 
subcortical (and other) structures, which was not possible at fetal and infant timepoints. Thus, 
this study also examined the caudate, subthalamic, and lentiform nucleus, as well as the 
thalamus, hippocampus, amygdala, and insula.  
 
In the present study, I tested the hypothesis that any differences in the neonatal brains of 
individuals with and without a familial risk of ASD would be localised to one or more of these 
subcortical structures and/or the cerebellum. Also, given findings from the fetal study and the 
emerging evidence implicating cortical abnormities in older cohorts with ASD, I also tested if 
there were differences in cortical volume at this age.  
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6.2. Materials and methods 
6.2.1. Participants 
As in prior experimental chapters, participants were assigned to either the high-risk or low-risk 
group, based on the criteria described in the methodology section of this thesis (please refer 
to section 2.3.3 on page 108). Of the 113 participants enrolled in the study postnatally, 71 
agreed to take part in assessment at the neonatal timepoint. The remaining 42 did not wish to 
participate at this time, either because it was too soon after the birth of the baby, or because 
the family was still recovering from minor complications associated with delivery. Of the 71 
participants that did agree to take part, scanning was unsuccessful for 10 of these: 8 did not 
settle to sleep, and 2 could not be scanned due to scheduling problems. Data was 
successfully collected from a total of 61 participants. However, a further 8 participants were 
excluded from the main volumetric analysis: 7 due to poor image quality driven by motion 
artefacts, and 1 due to an incidental neuroanatomical finding. Hence, the final sample size 
consisted of 53 neonates (22 of which were also scanned at the fetal timepoint), including 35 
low-risk (n = 18 male; mean corrected age at scan = 42.60 weeks, SD = 1.86) and 18 high-risk 
(n = 11 male; mean corrected age at scan = 42.16 weeks, SD = 2.57).  
 
6.2.2. Experimental procedures 
Participants taking part in the neonatal timepoint were scanned as soon as possible after birth, 
and at no more than one month of age. Some babies were born after 40 gestational weeks; 
therefore, even if scanned within the first month of postnatal life, their corrected age at scan 
would still be over 44 weeks. Thus, the ages included in this study ranged from 35-47 
corrected weeks. All experimental procedures were conducted as described earlier in the 
main methodology of this thesis (see section 2.3.5.2 on page 127).  
 
6.2.3. Statistical analysis  
Normality of data distribution was assessed as usual. Where regional brain volumes were not 
normally distributed, logarithmic transformations were performed. Group differences in sample 
characteristics were examined using the most appropriate test.  
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 Effects of age on regional brain volumes 
Contingent on the data distribution, correlations between neonatal age and regional brain 
volumes were assessed for the whole sample (that is, for low-risk and high-risk groups 
combined), using either Pearson’s or Spearman’s rank correlations. Then, for each specific 
brain region, the curve of best fit was selected, and the mean volume of that region at 38, 42, 
and 46 corrected weeks was calculated using the equation for the best-fit curve. Growth 
trajectories for each brain region were plotted with the curve of best fit, as well as with lines 
representing ±2 SD from the mean. In addition, low-risk and high-risk groups were labelled 
distinctly on these plots, to allow for visual inspection of any obvious outliers and/or deviations 
in growth between groups. Relative growth rates were also calculated in order to compare 
with growth rates reported at the fetal timepoint, as well as with normative rates reported in 
other neonatal studies.   
 
 Group differences in total and regional brain volumes   
In this analysis, the first priority was to determine whether total brain tissue and intracranial 
volume (i.e. brain and head size, respectively) varied significantly between groups. Therefore, 
an initial ANCOVA was run with risk group (low-risk vs. high-risk) as a fixed factor, and with 
total brain and intracranial volume as the dependent variables of interest. Since both age and 
sex are known to affect brain volume, and neonatal body weight was significantly different 
between groups (Table 6.1), these variables were all included as co-variates. Any significant 
findings were explored post-hoc, including any group difference in the relationship between 
intracranial volume and body weight. Although some socioeconomic factors were significantly 
different between groups (for example, maternal and paternal education), a decision was 
made to only co-vary for biological factors rather than ‘over-control’ for multiple variables.  
 
To assess group differences in regional brain volumes, an ANCOVA was run with risk group 
was entered as a fixed factor, and with sex, age, intracranial volume, and body weight input as 
co-variates. In addition, because prematurity is an independent risk factor for 
neurodevelopmental disorders like ASD (Goldin and Matson, 2016; Guy et al., 2015; Johnson 
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et al., 2010; Kuzniewicz et al., 2014), late-preterm neonates (born between 34-37 gestational 
weeks) were also included in this study. However, to determine if a late-preterm birth 
influenced the direction of findings, the analysis was repeated post-hoc after excluding these 
preterm neonates (n = 4 high-risk; no low-risk).   
 
 Supplementary work: exploratory longitudinal analysis 
An exploratory analysis of the available longitudinal data was conducted using a repeated 
measures mixed model analysis with unstructured co-variance matrices. This analytic 
approach was chosen as it allows for different patterns of missing data, and accommodates 
an unbalanced design. Timepoint (fetal vs. neonatal) and risk group (high-risk vs. low-risk) 
was input as a fixed factor, and the dependent variables of interest included all of the 
examined brain regions that were common to individuals scanned at both timepoints. Age and 
intracranial volume were included as co-variates, and sex as a (between subjects) fixed factor. 
  
6.3. Results 
6.3.1. Sample characteristics 
The characteristics of the total sample and of each risk group are presented in Table 6.1. 
Neonates (n = 53; 35 low-risk, 18 high-risk) were scanned at a mean corrected age of 42.45 
weeks (SD = 2.11, range = 35.14-46.57 corrected weeks; Figure 6.1), and risk groups did not 
differ significantly in age (at birth or at MRI). They also did not differ significantly in sex, head 
circumference (at birth and at MRI), ethnicity, mode of delivery, or Apgar scores (at 1 and 5 
minutes). Moreover, whilst body weight was not significantly different at birth, risk groups 
differed in body weight at MRI (p = 0.019), with the high-risk group weighing significantly more 
than the low-risk. Regarding parental characteristics, although marital status and parental age 
were not significantly different between groups, parental education was. Specifically, the 
parents of low-risk neonates were educated to a higher degree than those in the high-risk 














Figure 6.1: Distribution of the participants’ age at the neonatal timepoint.  
A histogram of the participants’ corrected age at the time of neonatal MRI is shown.  
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U = 257.50, p = 0.279  
Corrected age at MRI (weeks); mean (SD) 42.45 (2.11) 42.60 (1.86) 42.16 (2.57) t = 0.71, p = 0.480  
Sex (male); n (%) 
Ethnicity (white); n (%) 
Body weight at birth (kg); mean (SD) 
Body weight at MRI (kg); mean (SD) 
Head circumference at birtha (cm); mean (SD) 



















χ2 = 0.45, p = 0.502 
p = 0.163  
t = 0.30, p = 0.765 
t = -2.41, p = 0.019 
t = 0.62, p =0.536 
t = -0.08, p = 0.936 
Mode of delivery (caesarean section); n (%) 
Apgar score at 1 minuteb; mean (SD) 
Apgar score at 5 minuteb; mean (SD) 
Parental characteristics 
Maternal age at infant’s birth (years); mean (SD) 
Paternal age at infant’s birthc (years); mean (SD) 
Marital statusd (married); n (%) 
Maternal education (higher education); n (%) 




























p = 0.178  
U = 165.50, p = 0.901 
U = 166.50, p = 0.933 
 
t = 0.23, p = 0.819 
U = 242.00, p = 0.345 
p = 0.880  
p = 0.005  
p = 0.002  
Note: aThis measure was only available for 41 neonates (27 low-risk; 14 high-risk) and b39 neonates (26 low-risk; 13 high-risk). cThese measures were missing 
for 2 participants (1 low-risk and 1 high-risk), as was dthis measure (both low-risk). The Fisher’s exact test does not have an associated statistic; thus, only p-
values were reported. Significant results are shown in bold. Abbreviations: MRI = magnetic resonance imaging; Higher Education = undergraduate and/or 
postgraduate degree; SD = standard deviation; U = Mann-Whitney U-statistic; t = Independent samples t-statistic; X2 = Pearson’s Chi-Square.  
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6.3.2. The effect of neonatal age: growth trajectories of regional brain volumes  
Correlations between neonatal age and brain volumes are presented in Table 6.2. This table 
also displays the mean volume (in cm3) of each brain region at 38, 42, and 46 corrected 
weeks, as well as their relative growth rate (expressed as the % change in volume per week). 
Linear and quadratic equations explained the growth trajectory of each region equally well, as 
is shown in Figure 6.2 and 6.3. However, mean volumes were calculated based on quadratic 
equations, which best described the data according to the goodness-of-fit measures. Visual 
inspection of these plots also indicated that there was no obvious difference in growth 
between risk groups. The majority of neonates stayed within ±2 SD of the mean, and in brain 
regions where outliers did exist, they were equally distributed between groups.    
 
Across risk groups, all brain regions showed evidence of a strong, positive, and statistically 
significant correlation with age. The cerebellum and the cortex showed the strongest 
correlations [cerebellum: (r = 0. 85, p < 0.001); cortex: (r = 0.84, p < 0.001)], suggesting that 
these were amongst the fastest growing regions of all those examined. Specifically, the cortex 
increased at a relative growth rate of 51.54% per week, whilst the cerebellum increased at a 
rate of 63.63%, from a mean volume of 19.51 cm3 at 38 corrected weeks to 34.10 cm3 at 46. 
The corpus callosum also demonstrated a strong correlation with age (r = 0.68, p < 0.001), as 
well as a high growth rate of 53.54% – well above that of the total brain and intracranial 
volume (with relative rates of 34.21% and 34.57%, respectively). Most subcortical regions 
were strongly correlated with age, increasing in volume at relative growth rates ranging 
between 27.92% and 38.55%, with the latter representing the growth rate of the lentiform 
nucleus. In contrast, the volume of the lateral ventricles exhibited the weakest correlation of all 
(r = 0.32, p = 0.022). Its relative growth rate was the highest though, with a 68.86% increase 
per week, likely due to the large spread of the data – evident by comparing the mean volume 
of the lateral ventricles (5.71 cm3) with its standard deviation (2.54 cm3). The slowest growing 
region of all was the white matter, demonstrating both a weak correlation with age (r = 0.46,              
p = 0.001) and a relative growth rate of only 15.29% per week. Contrary to what was reported 
at the fetal period, there was no region with negative growth rates at this time (Table 6.2).  
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Table 6.2: Correlations between brain volume and neonatal age, presented for the total sample (n=53) 
  Correlation with Age Mean Volume (cm3) Relative Growth Rate 
 Brain Region r p-value 38 CW 42 CW 46 CW (% Per week) 
Cortex 0.84 0.001 119.63 161.16 205.91 51.54 
White Matter 0.46 0.001 145.00 158.99 173.84 15.29 
Subcortical Grey Matter 0.69 <0.001 23.62 28.87 32.95 29.71 
Thalamus 0.69 <0.001 7.93 9.60 11.14 31.18 
Caudate Nucleus 0.53 <0.001 3.26 4.00 4.25 27.92 
Subthalamic Nucleus 0.54 <0.001 0.42 0.50 0.65 37.28 
Lentiform Nucleus 0.78 <0.001 5.42 7.03 8.44 38.55 
Hippocampus 0.63 <0.001 1.33 1.54 1.89 29.20 
Amygdala 0.60 <0.001 0.86 1.07 1.19 28.85 
Insula 0.51 <0.001 7.81 9.10 10.78 31.83 
Corpus Callosum 0.68 <0.001 2.26 2.83 3.59 53.54 
Brainstem 0.68 <0.001 5.77 6.79 7.78 34.00 
Cerebellum 0.85 <0.001 19.51 27.49 34.10 63.63 
Total Brain Tissue 0.76 <0.001 315.72 385.90 457.66 34.21 
Lateral Ventricles 0.32 0.022 3.97 5.25 8.14 68.86 
Extracerebral CSF 0.51 <0.001 71.45 82.77 107.57 34.34 
Total CSF 0.53 <0.001 75.42 88.02 115.71 36.08 
Intracranium 0.75 <0.001 391.13 473.91 573.37 34.57 
Note: The relative growth rate (% per week) represents the percent volume increase relative to the mean volume of the structure. Significant results are shown in 
bold. Abbreviations: r = Correlation Coefficient (Pearson’s or Spearman’s rank), CW = Corrected age in weeks.  
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Figure 6.2: Growth trajectories of total and regional brain volumes acquired for the 
whole sample (low-risk and high-risk groups combined). 
(A) Cortex, (B) total brain tissue, (C) corpus callosum, (D) white matter, (E) lateral ventricles, 
(F) extracerebral CSF, (G) total CSF, and (H) intracranium. The trendlines (in black) indicate 
the correlation between volume and age for the whole sample, and although a quadratic 
model provided the best fit for the data, both linear (dashed line) and quadratic (solid line) 
curves are shown. The two horizontal red dotted lines represent ±2 SD from the mean. 




















(G)                    (H) 
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Figure 6.3: Growth trajectories of cortical and subcortical regions acquired for the 
whole sample (low-risk and high-risk groups combined). 
   






















     
(I)                (J) 
The trendlines (in black) indicate the correlation between volume and age for the 
whole sample, and although a quadratic model provided the best fit for the data, 
both linear (dashed line) and quadratic (solid line) curves are shown. The two 
horizontal red dotted lines represent ±2 SD from the mean. 
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6.3.3. Group differences  
 In total brain tissue and intracranial volume 
There were significant group differences in both brain and head size. High-risk neonates had 
a significantly smaller volume of the total brain tissue [F(1,47) = 4.76, p = 0.034] and 
intracranium [F(1,47) = 5.40, p = 0.024], when compared to low-risk controls (Table 6.3).  
 
 In head-to-body proportions 
At the neonatal timepoint, the high-risk group weighed considerably more than the low-risk 
(mean body weight: high-risk = 4.15 kg, low-risk = 3.73 kg; p = 0.019), but had significantly 
smaller intracranial volumes (mean intracranial volume: high-risk = 476.29 cm3, low-risk = 
491.76 cm3; p = 0.024). In addition, the head-to-body proportion (calculated as the intracranial 
volume over body weight) was significantly different between groups [F(1, 48) = 14.87,                 
p < 0.001]. Neonates in the high-risk group had significantly smaller head-to-body proportions, 
when compared to those in the low-risk group (Table 6.3, Figure 6.4), which suggests that 
high-risk neonates generally have smaller head sizes despite increased body weights.  
  









Figure 6.4: Mean head-to-body proportion in neonates at low and high-risk of ASD. 
Neonates in the high-risk group had a significantly smaller head-to-body proportion, when 
compared to low-risk controls. This suggests that high-risk neonates generally have smaller 
head sizes, despite increased body weights. Error bars represent one standard error of the 
mean, ***p≤0.001. 
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 In regional brain volumes  
There was a significant group difference in the volume of the lentiform nucleus [F(1, 46) = 
4.62, p = 0.037], with high-risk neonates having significantly smaller volumes than low-risk 
controls (Table 6.3, Figure 6.5). Results did not differ when the analysis was co-varied for total 
brain tissue, as opposed to intracranial volume. There were no other regional brain volumes or 














Figure 6.5: Mean lentiform volume in neonates at low and high-risk of ASD. 
Neonates in the high-risk group had a significantly smaller lentiform volume (cm3), when 





Supplementary analyses uncorrected for intracranial volume confirmed that group differences 
were mainly restricted to the cortical and subcortical regions. For example, the subcortical 
grey matter, subthalamic nucleus, lentiform nucleus, amygdala, and cortex were all 
significantly smaller in high-risk neonates, as compared to low-risk controls. The insula and 
caudate nucleus were also smaller in high-risk individuals, but these differences just failed to 



































 Post-hoc analysis: excluding late-preterm neonates 
When the analysis was re-run to exclude late-preterm neonates (n = 4, all high-risk; 3 male; 
mean corrected age at scan = 40.11 weeks, SD = 3.40), this did not alter the results. Group 
differences remained for the total brain tissue volume [F(1,43) = 7.32, p = 0.010], intracranial 
volume [F(1,43) = 8.75, p = 0.005], and head-to-body proportions [F(1,44) = 10.82, p = 0.002], 
with high-risk neonates consistently reporting smaller values than low-risk controls. In 
addition, the lentiform nucleus remained significantly smaller for the high-risk group, when 
compared to the low-risk [F(1,42) = 5.25, p = 0.027]. All other brain regions showed no 
significant differences, as before. 
 
 Supplementary results: exploratory longitudinal analysis  
Where volumetric data at both fetal and neonatal timepoints was available (n = 22; 14 low-risk, 
8 high-risk), an exploratory longitudinal analysis was run to test whether there was a 
significant main effect of timepoint (fetal vs. neonatal) and risk group (high-risk vs. low-risk) on 
total and regional brain volumes. Only brain regions that were common to both timepoints 
were assessed (i.e. lateral ventricles, extracerebral CSF, total CSF, supratentorial tissue, 
cerebellum, cortex, total brain tissue, and intracranium).  
 
Results showed a significant main effect of timepoint for all the brain regions examined, with 
larger volumes at the neonatal timepoint compared to the fetal. While there was no main effect 
of risk group for any of the brain regions examined, there was an indication of a possible 
interaction effect between timepoint and risk group (Timepoint x Risk Group), which was in 
line with results from the main cross-sectional analyses. For example, fetuses at high-risk of 
ASD had a smaller volume of the total brain tissue compared to those at low-risk; however, by 
the neonatal timepoint, the opposite was true (p = 0.074). To examine these questions more 
thoroughly in future, larger sample sizes will be necessary. 
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Table 6.3: Group differences in neonatal brain volumes and in brain and body proportions between low-risk and high-risk groups 
  
Risk Group Group Difference  
Low-Risk (n = 35) High-Risk (n = 18) aUnadjusted bAdjusted  
  Mean SD Mean SD F p-value F p-value 


















White Matter 161.98 14.95 158.29 19.51 3.04 0.088 0.16 0.691 
Subcortical Grey Matter 29.65 2.85 28.38 4.08 6.72 0.013 1.70 0.199 
Thalamus 9.86 0.97 9.56 1.41 2.57 0.116 0.10 0.759 
Caudate Nucleus 4.06 0.51 3.84 0.61 3.05 0.087 0.62 0.436 
Subthalamic Nucleus 0.54 0.11 0.49 0.09 4.91 0.032 1.63 0.209 
Lentiform Nucleus 7.35 0.91 6.84 1.19 10.11 0.003 4.62 0.037 
Hippocampus 1.61 0.21 1.56 0.26 2.56 0.117 0.16 0.692 
Amygdala 1.10 0.14 1.02 0.15 4.73 0.035 1.34 0.253 
Insula 9.63 1.39 8.74 2.33 3.33 0.074 0.93 0.339 
Corpus Callosum 2.96 0.48 2.87 0.57 0.91 0.345 0.31 0.581 
Brainstem 6.97 0.64 6.76 0.81 3.33 0.074 0.54 0.465 
Cerebellum 28.49 3.73 27.36 5.73 2.44 0.125 0.14 0.710 






































Intracranium/Body Weightc  

























Note: aIn this analysis, only age and body weight were included as co-variates, with sex as a fixed factor; hence, F = F(1,47). bHere, intracranial volume was 
added as a co-variate, and so F = F(1,46). cIn order to compare group differences in head-to-body proportions (units = cm3 kg-1), only age and sex were 
corrected for, and so F = F(1,48). Significant results are in bold. Abbreviations: CSF = cerebrospinal fluid; SD = standard deviation.  
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6.4. Discussion  
As far as I am aware, this was the first study to quantify brain volumes within the first month of 
postnatal life in individuals with and without a familial risk of ASD. Across risk groups, the 
volume of all brain regions increased significantly with age. High-risk neonates had 
significantly heavier body weights, but significantly smaller volumes of the intracranium, total 
brain tissue, and lentiform nucleus, when compared to low-risk controls. 
 
 
6.4.1. Volumetric growth trajectories of neonatal brain regions 
Compared to the fetal brain, much more is currently known about volumetric brain growth in 
the neonatal period. In agreement with other studies examining growth trajectories in the first 
few weeks after birth (Holland et al., 2014; Makropoulos et al., 2015), all of the brain volumes 
examined in this study were significantly and positively correlated with age. The relative 
growth rates reported here were considerably higher than those calculated at the fetal 
timepoint (chapter 5), and suggest that brain growth is more rapid in the first month of 
postnatal life, as compared to earlier during the third trimester of pregnancy. Nonetheless, 
both cerebellum and cortex were amongst the fastest growing regions in neonatal life, 
comparable to what was observed in the fetal period.  
 
Moreover, the regional growth rates observed here were in broad agreement with other 
studies carried out shortly after birth. For example, others have reported the cerebellum as the 
fastest growing region in the early postnatal period (Holland et al., 2014; Knickmeyer et al., 
2008), doubling in volume within the first three months of life (Holland et al., 2014). This is 
most probably due to the cerebellum’s role in early development, particularly regarding motor 
co-ordination and control – both of which are crucial outcomes of early brain maturation. Aside 
from its motor function the cerebellum has also been implicated in cognitive function 
(Schmahmann and Sherman, 1998), and the reciprocal connections that it shares with specific 
cortical regions via cortico-cerebellar circuits, are thought to mediate these ‘high-order’ skills 
(Makris et al., 2005; Schmahmann, 2001). It has even been suggested that the rapid growth of 
the cerebellum in the first months of life is a prerequisite for adequate cortical development 
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(Knickmeyer et al., 2008), and as evident in this study, the cortex also undergoes a steep 
growth trajectory in neonatal life.  
 
Relative to the cerebellum (increasing in volume at a rate of 63.63% per week), the 
hippocampus was amongst one of the slowest growing regions within the first postnatal month 
(increasing at a relative rate of 29.20%). This finding corroborates that of others, which have 
also reported a similarly low growth rate for the hippocampus (Holland et al., 2014). The 
disparity in regional growth rates observed in this and other studies may be due to the relative 
developmental importance of the abilities each region oversees. For example, spatial and 
episodic memory (skills largely overseen by the hippocampus) are potentially not as important 
in the first few months of life as motor skills (regulated by the cerebellum) are (Holland et al., 
2014; Knickmeyer et al., 2008).   
 
In other studies using MRI to examine brain development in the neonatal period and in the 
first 2 years after birth, brain maturation appears to be mainly driven by grey matter, as 
opposed to white matter growth (Gilmore et al., 2007; Knickmeyer et al., 2008). This too was 
evident in the present study, with white matter having the slowest growth rate of all (increasing 
in volume by 15.29% per week). Although it is poorly understood what the different 
developmental trajectories in grey and white matter tissue may signify, it could simply be that 
the slow growth rate of the white matter is a reflection of the protracted period of myelination, 
which persists well into postnatal life.  
 
In summary, this study identified volumetric growth trajectories in line with what is commonly 
reported in the neonatal literature. Visual inspection of growth plots also did not indicate any 
gross deviation from the established norm amongst individuals in the high-risk group. 





6.4.2. Group differences in neonatal head size and in total and regional brain volumes   
This study reported significant group differences in both brain and head size, with high-risk 
neonates having smaller total brain and intracranial volumes compared to low-risk controls. In 
addition, contrary to what is commonly reported in the literature (Gardener et al., 2011; 
Limperopoulos et al., 2008; Schieve et al., 2015), individuals in the high-risk group weighed 
significantly more than those considered to be at low-risk. Neonates at risk of ASD also had 
smaller head-to-body proportions, which implies a disproportionately smaller head size 
relative to body size, and suggests that the factors governing body and head growth are 
uncoupled in these high-risk individuals.    
 
To date, there have been no studies carried out in individuals genetically predisposed to ASD 
within the first month of postnatal life; therefore, direct comparisons with other studies are 
limited. However, as mentioned in the previous chapter, several retrospective studies have 
shown that at birth, individuals who later develop ASD, have head circumferences that are 
either smaller (Courchesne et al., 2003; Mraz et al., 2007; Redcay and Courchesne, 2005) or 
no different (Dawson et al., 2007; Hazlett et al., 2005; Surén et al., 2013) than typically 
developing controls. In some of these studies, individuals who later developed ASD also had a 
rapid increase in head circumference, when compared to controls. This started at 1-2 
postnatal months, and resulted in significant enlargements at 6, 10, and 14 months 
(Courchesne et al., 2003; Mraz et al., 2007). Smaller head circumferences at birth, and 
increased growth rates thereafter, were significantly associated with a greater number and 
greater severity of autistic symptoms (Courchesne et al., 2003). Hence, the initial trajectory of 
head (and perhaps brain) growth is abnormal in individuals with ASD. This early postnatal 
period of accelerated growth may reflect a protective and/or compensatory mechanism, in 
response to prior atypical neurodevelopmental processes (Courchesne et al., 2003; 
Dementieva et al., 2005; Mraz et al., 2007). Nonetheless, it is important to bear in mind that 
head circumference is not a direct measure of current brain size. In the present neonatal 
study, for example, although differences in intracranial and total brain volume were identified 
(and correspond to differences in head and brain size, respectively), there were no differences 
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in head circumference between risk groups at birth or in neonatal life. Recent reports have 
also suggested that many of the head circumference studies previously mentioned may have 
been influenced by biases in population norms (Raznahan et al., 2013), and so we cannot be 
entirely sure of the validity of their results.  
 
Studies like the present one that directly measure brain volume (as opposed to head size) and 
compare it with age-matched controls (as opposed to normative averages), avoid the risk of 
the biases associated with using historical population ‘norms’. They also provide stronger 
evidence for potential differences between groups, allowing for more reliable conclusions to 
be drawn. Thus far, however, there have been few studies reporting on neonatal brain 
volumes in individuals predisposed to ASD. The few studies that do exist have focussed on 
prematurity, rather than family history, as a risk factor for ASD (Padilla et al., 2015; Ure et al., 
2015). Still, the results of these studies are broadly in line with those of the current 
investigation. For example in one of these prior studies, poor brain growth was also identified; 
except that in this case it was observed at term-equivalent age in preterm neonates before the 
onset of ASD, and was localised to the temporal, occipital, insular, and limbic regions (Padilla 
et al., 2015). In another study, preterm infants who later developed ASD also had smaller 
brain volumes at term-equivalent age, compared to those who did not receive a diagnosis. 
This finding, however, was restricted to the cerebellum (Ure et al., 2015). Nonetheless, when 
placed together, these results suggest that preterm infants, who were subsequently diagnosed 
with ASD, had smaller regional brain volumes in neonatal life, when compared to preterm 
infants who did not go on to develop the disorder. Although outcome data is not yet available 
for the neonates included in the present study, a similar pattern of results was identified here, 
in neonates genetically predisposed to ASD. In conclusion, this suggests that small brain 
volumes around the time of birth may be associated with a later ASD diagnosis.  
 
Preterm born infants are at an increased risk of developing ASD (Johnson et al., 2010; 
Kuzniewicz et al., 2014; Pritchard et al., 2016); therefore, neonates born prematurely were 
also allowed in this study. However, compared to the studies previously described, which 
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focused on prematurity as a main risk factor for ASD and included infants born at < 30 
gestational weeks (Padilla et al., 2015; Ure et al., 2015), the present study only included late-
preterm neonates, born between 34-37 gestational weeks. In addition, preterm infants 
commonly show reduced brain volumes at term-equivalent age (Ball et al., 2012; Inder et al., 
2005; Peterson et al., 2003). Therefore, to assess the extent to which prematurity was a major 
contributing factor to the smaller brain volumes observed within the high-risk group of this 
study, the analysis was repeated after excluding these preterm infants. Findings remained 
unchanged suggesting that prematurity did not drive the results, and that neonates genetically 
predisposed to ASD have smaller brain volumes than low-risk controls.  
 
Besides the small volumes in intracranium and total brain tissue, individuals with a familial risk 
of ASD also had significantly smaller volumes of cortical and subcortical grey matter 
structures, when compared to age-matched controls. However, when this analysis was 
corrected for intracranial volume, the lentiform nucleus was the only region to remain 
significantly smaller in high-risk neonates. As a result, this finding cannot easily be explained 
by generalised influences acting on the whole brain.  
 
 
The lentiform nucleus encompasses the globus pallidus and putamen. Both these regions 
have been extensively implicated in ASD, and possibly also in 4-6 month-old infants at risk of 
the disorder (chapter 4). It is important to note, however, that according to the findings 
described in chapter 4, the entire subcortical region was affected in high-risk infants, with no 
way of determining what subcortical structure was driving the results. Nonetheless, the 
majority of studies published thus far have specifically identified enlarged lentiform nuclei in 
individuals with ASD. For example, in both children and adults with ASD, the globus pallidus 
and putamen are reportedly enlarged, compared to age-matched controls (Herbert et al., 
2003; Hollander et al., 2005; Langen et al., 2007; Sato et al., 2014; Turner et al., 2016). 
Similarly, greater lentiform volumes have been identified in children with ASD as young as 3-4 
years (Estes et al., 2011). In contrast, the results of the present study indicate that the 
lentiform nuclei is smaller in individuals at risk of ASD within the first month of postnatal life, 
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and that this region is more severely impacted than the whole brain. When taken in 
conjunction with the findings of older cohorts, it is therefore proposed that the lentiform 
nucleus may undergo an aberrant developmental trajectory in individuals with and at risk of 
ASD.  
 
Finally, this neonatal study did not identify any differences in cortical or cerebellar volumes 
between risk groups. Although cortical volumes were smaller in fetuses at risk of ASD, 
compared to low-risk controls (chapter 5), these differences were not present early in 
postnatal life. This suggests that they may have been temporarily resolved, or that only more 
subtle differences in cortical thickness, surface area, and/or curvature are identifiable at this 
time. Aside from the cortex, the cerebellum had also been a priori hypothesised to be altered 
in neonates at risk of ASD. The fact that no differences were found in neonatal life was 
therefore surprising, particularly given the evidence implicating the cerebellum at term-
equivalent age in preterm infants who later developed ASD (Limperopoulos, 2009; Ure et al., 
2015). Several reasons could explain why no differences were identified in the cerebellum at 
the neonatal timepoint. For example, although the cerebellum was enlarged in 4-6 month-old 
infants at risk of ASD (chapter 4), aside from no differences in neonatal life, there were also 
no observed differences at the fetal timepoint (chapter 5). Thus, it may be that alterations to 
the cerebellum are only present in infants genetically predisposed to ASD at and after 4-6 
months. Alternatively, since cerebellum enlargement correlated with ASD symptoms, but did 
not predict diagnostic outcome (chapter 4), its enlarged volume in infant life could be a 
consequence rather than a cause of atypical development. If true, this could also explain why 
no differences were observed in younger individuals at risk of ASD. Furthermore, as evident in 
this and other studies, the cerebellum is amongst one of the fastest growing regions in early 
prenatal and postnatal life. It may therefore be considerably more difficult to identify volumetric 
differences in this region using a cross-sectional design, and thus, my future work will address 




6.4.3. Study limitations 
This study has a number of limitations that need to be acknowledged. First, the sample size 
was small, which increases the risk of false negatives. In addition, since correction for multiple 
comparisons was not conducted, there is also increased risk of false positives. Second, 
socioeconomic status was not included as a co-variate because I did not want to ‘over-control’ 
for variables in this small sample-sized analysis. This may be viewed as problematic, given 
the significant difference in parental education between risk groups, and the growing body of 
evidence indicating the powerful effect of socioeconomic status on infant brain structure (Brito 
and Noble, 2014; Hackman and Farah, 2009; Noble et al., 2012, 2015). However, in an 
exploratory analysis including maternal education (an index of socioeconomic status) as an 
additional co-variate, results were not significantly different from those reported here. This is 
likely to be because infant weight, commonly associated with socioeconomic status (Gould 
and LeRoy, 1988; Parker et al., 1994; Wijlaars et al., 2011), was controlled for in this study.  
Third, and although there was a marked improvement in the quality of images acquired at this 
time (allowing for segmentation of brain regions not examined at the fetal and infant 
timepoints), the parcellation of the lentiform nucleus into its constituents (that is, the globus 
pallidus and putamen) was still not possible. With continued optimisation of measurement 
protocols, this situation may change in future. Last, while a supplementary exploratory 
analysis was conducted to assess the longitudinal trajectory of brain volume in individuals with 
and without a familial risk of ASD, the fact that only 8 high-risk participants were scanned at 
both fetal and neonatal timepoints, limited the analysis and interpretation of results. 
Nonetheless, there was some indication of a possible interaction effect between timepoint and 
risk group, which should encourage a formal longitudinal analysis to be conducted once more 
high-risk participants have been scanned.  
 
6.4.4. Conclusions 
In conclusion, the present study suggests that in the first few weeks after birth, individuals with 
a familial risk of ASD have altered brain growth, relative to those at low-risk. Specifically, high-
risk neonates had smaller intracranial and total brain volumes. They also had a reduced 
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volume of the lentiform nucleus, which could not be explained by the overall small brain and 
head sizes. Hence, the findings of this study indicate that an increased genetic risk of ASD is 
associated with an early alteration in brain growth. Further work will be needed to clarify if this 
atypical pattern of neurodevelopment predicts a later ASD diagnosis, and neonates included 
in this study are currently being followed-up to establish this.  
 
Considering the difference in lentiform volumes identified in this study, as well as the 
subcortical enlargement in 4-6 month-old infants at risk of ASD (chapter 4), it may be that the 
subcortical region is important in the underlying development of the disorder. The next step 
was therefore to explore this region in more detail, by examining whether there are subcortical 
neurochemical abnormalities in individuals genetically predisposed to ASD.   
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Chapter 7: Subcortical biochemistry from prenatal to 
early postnatal life, and metabolic 
differences in infants with and without a 
familial risk of ASD 
 
7.1. Introduction 
Thus far, I have presented evidence that the brain volume of individuals at risk of ASD differs 
from that of low-risk controls. During the fetal and neonatal timepoints, brain regions were 
smaller in high-risk individuals; the cortex was implicated in fetal life, while the intracranium, 
total brain tissue, and lentiform nucleus were affected in the first postnatal month (chapters 5 
and 6). In contrast, both the subcortical and cerebellar regions were enlarged in 4-6 month-old 
infants at risk of ASD (chapter 4). Therefore, although some brain regions were only altered at 
one timepoint, the subcortex (encompassing basal ganglia and thalami) was affected in both 
neonatal and infant timepoints, suggesting that it may be an important region in the early 
pathology of ASD. Brain metabolites, especially glutamate (but also GABA), are crucial to 
normal developmental processes (Coyle et al., 2002; Gallo and Ghiani, 2000; Yuan et al., 
1998). In addition, it is thought that differences in neurochemistry could predate, or even drive, 
subsequent structural alterations (Fayed et al., 2006). The deregulation of perinatal shifts in 
excitatory-to-inhibitory balance may also be a critical pathophysiological step in ASD (Tyzio et 
al., 2014). Yet, no one has compared subcortical glutamate levels in individuals with and 
without a familial risk of ASD.  
 
1HMRS is an invaluable tool for safely studying the typical and atypical metabolic development 
of the human brain in vivo. According to the current literature (discussed in section 1.2.7 on 
page 48), dynamic changes in brain metabolite concentrations are present in early life, but 
begin to stabilise by about three years of age. NAA, for example, is reported to increase with 
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postnatal age during these first few years of life, whilst the concentrations of both Ins and Cho 
are found to decrease (Blüml et al., 2013; Girard et al., 2006a, 2006b; Huppi et al., 1995; Kok 
et al., 2002; Kreis et al., 1993). In addition, there is evidence that Cr may increase during the 
first 2 years of postnatal life, rather than remain stable as previously thought (Blüml et al., 
2013; Degnan et al., 2014; Evangelou et al., 2016; Girard et al., 2006a; Huppi et al., 1995; 
Kreis et al., 1993, 2002). Glx has also been detected in the brain as early as 24 weeks 
gestation (Girard et al., 2006b), but there is limited information on its prenatal development. In 
contrast, there is preliminary evidence to suggest that Glx increases with postnatal age (Blüml 
et al., 2013; Degnan et al., 2014; Kornhuber et al., 1993; Kreis et al., 2002), but further 
research is required to confirm this. 
 
Aside from its application in studies of typical brain development, recent 1HMRS findings have 
begun to shed some light on the neurochemical differences potentially underpinning some of 
the developmental differences in ASD (for review see Baruth et al., 2013; Ford and Crewther, 
2016; Ipser et al., 2012). Despite discrepancies in the literature, spectroscopic studies mainly 
report that children with ASD have low levels of NAA, Cr, and Ins, when compared to age-
matched controls. The evidence from ASD studies assessing Cho and Glx is less clear. For 
example, children with ASD have reportedly exhibited lower (Corrigan et al., 2013; DeVito et 
al., 2007; Kubas et al., 2012), higher  (Bejjani et al., 2012; Doyle-Thomas et al., 2014), and no 
significant differences in Glx levels (Friedman et al., 2003, 2006), when compared to age-
matched controls. Studies assessing Cho in children with ASD are just as inconsistent (for 
review see Ford and Crewther, 2016). Moreover, although these studies have focused on 
paediatric populations, the neurochemistry of ASD has not been examined in individuals 
younger than 3-4 years. In addition, no studies have used 1HMRS to assess the 
neurometabolic properties of infants genetically predisposed to the disorder.  
 
Consequently, the main aims of this study were to: (i) characterise the subcortical levels of 
key metabolites across fetal, neonatal, and infant life, and (ii) investigate whether 4-6 month-
old infants at high familial risk of ASD have differences in the levels of subcortical metabolites, 
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when compared to low-risk controls. For (i), because the typical maturational profile of major 
metabolites (NAA, Cr, Cho, and Ins) has already been described in early life, this study first 
aimed to replicate previous findings (Blüml et al., 2013; Evangelou et al., 2016; Girard et al., 
2006a; Kreis et al., 2002). However, since the typical developmental trajectory of glutamate 
(or Glx) is still largely unknown, part of aim (i) was to extend understanding of its early 
maturational profile. For (ii), as this was the first study to compare brain metabolites in infants 
at low and high-risk of ASD, no definite a priori hypotheses were made regarding group 
differences. However, it was postulated that if any group differences did exist, an E/I 
imbalance in the ASD risk group would be reflected by differences in Glx (Nelson and Valakh, 
2015; Rubenstein and Merzenich, 2003).   
 
7.2. Materials and methods 
7.2.1. Participants 
High-risk and low-risk participants, scanned at least once in the fetal, neonatal, and/or infant 
timepoints, were included in this study. Participants were characterised by risk group based 
on the inclusion criteria previously described in the methodology of this thesis (please see 
section 2.3.3 on page 108).  
 
1HMRS data was acquired for as many participants as possible (fetal: n = 60, neonatal: n= 29, 
and infant: n = 33), but the data was not available for all of those scanned. This was because 
the spectroscopic sequence came at the end of the acquisition protocol, and there were times 
in which the scanning session had to be stopped before the spectroscopic sequence was 
even started. This was mainly due to fetal motion, or because the neonate/infant awoke and 
could no longer be settled. In addition, while the majority of neonatal and infant spectra were 
suitable for analysis (neonatal: n = 28, 99.55%; infant: n = 33, 100%), only n = 25 (41.67%) of 
the fetal spectra could be quantified, as the rest were disrupted by fetal motion. A low-risk 
neonatal participant was also excluded from the analysis due to an incidental neuroanatomical 
finding. Hence, a total of 25 fetal (5 high-risk, 20 low-risk), 27 neonatal (5 high-risk, 22 low-
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risk), and 33 infant (14 high-risk, 19 low-risk) 1HMRS datasets were included in this study, with 
some participants contributing to more than one timepoint. 
 
7.2.2. Experimental procedures 
1HMRS data was obtained using PRESS sequences sampled from the region of the left basal 
ganglia, and acquired at an echo time of 55 ms and 144 ms. All experimental procedures were 
conducted as described in the methodology section of this thesis, and spectroscopic analysis 
was performed using TARQUIN (as outlined in section 2.3.5.4 on page 142).  
 
In older age groups not assessed in this study, Cr is the most commonly used reference 
metabolite. However in the developing brain, Cr is not as stable as originally thought, having 
recently been reported to increase with age (Blüml et al., 2013; Degnan et al., 2014). 
According to the largest fetal 1HMRS study carried out to date, Cho appears more stable than 
Cr (Evangelou et al., 2016), suggesting that it may be a more appropriate metabolite to use as 
a reference at this age. Expressing the results relative to Cr may thus help to place them in 
the context of existing studies in older cohorts, whereas expressing them relative to Cho may 
provide a more accurate profile. Metabolites were therefore expressed in relation to both Cr 
and Cho, as follows: Cho/Cr, Ins/Cho, Ins/Cr, Glx/Cho, Glx/Cr, NAA/Cho, and NAA/Cr. 
 
7.2.3. Statistical analysis  
Normality of data distribution was verified as usual, using box-plots and the Shapiro-Wilk Test. 
 
7.2.3.1. The effect of timepoint on brain metabolite ratios 
Brain metabolite ratios were not normally distributed; hence, logarithmic transformations were 
performed. Then, using a repeated measures mixed model analysis, the longitudinal 
trajectories of these metabolite ratios were analysed across timepoints for the whole sample 
(that is, for low-risk and high-risk groups combined). As part of this analysis, an unstructured 
co-variance matrix was applied, given that it allows for different patterns of missing data and 
accommodates an unbalanced design. Timepoint (fetal vs. neonatal vs. infant) was input as a 
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fixed factor, and the dependent variables of interest included all of the examined metabolite 
ratios: Cho/Cr, Ins/Cho, Ins/Cr, Glx/Cho, Glx/Cr, NAA/Cho and NAA/Cr. Age was included as 
a co-variate, and sex as a (between subjects) fixed factor. Following significant results, 
Bonferroni corrected pairwise comparisons were performed.  
 
7.2.3.2. Group differences in brain metabolite ratios at 4-6 months of age  
The next question to examine was whether there was any effect of infant risk group on brain 
metabolite ratios at 4-6 months of age. Firstly, group differences in parental and infant 
demographic characteristics were assessed. Then, an ANCOVA was run on the normally 
distributed data, with infant risk group (low-risk vs. high-risk) input as a fixed factor. The 
dependent variables of interest included all of the measured metabolite ratios. Infant age was 
included as a co-variate, and sex as a (between subjects) fixed factor. Other control variables 
included any biological factors that were significantly different between groups, and which in 
this case included infant mode of delivery (Table 7.2). Although some socioeconomic factors 
were significantly different between groups (for example, marital status and parental 
education), as these were expected to influence biological factors, a decision was made to 
only co-vary for the biological factors rather than ‘over-control’ for variables. 
 
Group differences in brain metabolite ratios were not examined for the fetal or neonatal 
timepoints. This was due to the small number of high-risk participants (n = 5) at both these 
timepoints, which also precluded a longitudinal analysis from being conducted.   
 
7.3. Results 
7.3.1. The effect of timepoint on brain metabolite ratios 
There was a significant main effect of timepoint for all the metabolite ratios examined (Table 
7.1). Whilst Cho/Cr, Ins/Cho, and Ins/Cr all decreased significantly from the fetal to the infant 
timepoint, NAA/Cho and NAA/Cr increased across all three timepoints. In contrast, there was 
a significant decrease in the ratio of Glx/Cho and Glx/Cr from the fetal to the neonatal 
timepoint, followed by an increase from there up until early infancy (Figure 7.1).  
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Mean (SD) Brain Metabolite Ratio Main Effect of Timepoint 
Pairwise Comparisons 





















F > I***, N > I*** 
F > N***, F > I***, N > I*** 
Ins/Cr 1.42 (1.24) 0.48 (0.16) 0.24 (0.09) 1184.54 0.001 F > N***, F > I***, N > I*** 
Glx/Cho 4.49 (4.04) 1.89 (0.55) 3.16 (0.55) 218.87 <0.001 F > N***, F > I**, N < I*** 
Glx/Cr 1.53 (1.26) 0.62 (0.19) 0.93 (0.18) 36182.38 <0.001 F > N***, F > I***, N < I*** 
144 ms 
Cho/Cr 0.64 (0.19) 0.46 (0.13) 0.39 (0.03) 155.32 <0.001 F > N*, F > I***, N > I*** 
NAA/Cho 0.88 (0.38) 1.60 (0.47) 2.90 (0.33) 293.07 <0.001 F < N**, F < I***, N < I*** 
NAA/Cr 0.63 (0.29) 0.75 (0.27) 1.13 (0.11) 35.44 0.001 F < N*, N < I*** 
Note: Significant results are shown in bold or indicated by an asterisk (*), where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Abbreviations: F = Fetal, N = Neonatal, and 
I = Infant Timepoint; NAA = N-acetylaspartate and N-acetylaspartylglutamate; Cr = creatine and phosphocreatine; Cho = free choline, glycerophosphocholine, 
and phosphocholine; Ins = myo-inositol; Glx = glutamate and glutamine; SD = standard deviation.
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Figure 7.1: Longitudinal patterns of metabolic development from the fetal to the infant 
timepoint. These plots are representative of the whole sample (that is, low-risk and high-risk 
groups combined). (A-B) Cho/Cr, (C) Ins/Cho, (D) Ins/Cr, (E) Glx/Cho, (F) Glx/Cr, (G) 
NAA/Cho, and (H) NAA/Cr. Errors bars represent one standard error of the mean.  
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7.3.2. Group differences in brain metabolite ratios at 4-6 months of age 
7.3.2.1. Sample characteristics 
When stratified by risk group, infants did not differ significantly in age, sex, ethnicity, body 
weight (at birth and at MRI), head circumference (at birth and at MRI), or Apgar scores (at 1 
and 5 minutes) (Table 7.2). However, they did differ significantly in mode of delivery (p = 
0.024), with more low-risk infants being born via caesarean section. In addition, whilst 
maternal and paternal ages were not significantly different between groups, there were other 
parental characteristics that were. For instance, the parents of low-risk infants were educated 
to a higher level than those in the high-risk group (maternal education: p = 0.019; paternal 
education: p < 0.001). Also, there were slightly more parents in the low-risk group that were 
married, as compared to those in the high-risk group, although the difference was not entirely 
significant (p = 0.054).  
 
7.3.2.2. Group differences  
Infants in the high-risk group had significantly higher levels of Glx/Cho [F(1, 21) = 4.86, p = 
0.039] and Glx/Cr [F(1, 21) = 6.04, p = 0.023], when compared to those in the low-risk group 
(Figure 7.2). No other metabolite ratios showed significant group differences (Table 7.3). 
 
 
Figure 7.2: Mean differences in Glx ratios between infants at low-risk and high-risk of 
ASD. Infants at high-risk of ASD had elevated levels of (A) Glx/Cho and (B) Glx/Cr, when 
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(N = 33) 
 
Low-Risk Group 
(n = 19) 
 
High-Risk Group 
(n = 14) 
 
Group difference  
Statistic (p-value) 
Infant characteristics 








t = -0.27, p = 0.788 
Corrected age at MRI (weeks); mean (SD) 66.43 (1.51) 66.68 (1.42) 66.09 (1.63) t = 1.10, p = 0.280 
Sex (male); n (%) 







χ2 = 0.73, p = 0.393  
p = 0.134  
Body weight at birth (kg); mean (SD) 
Body weight at MRI (kg); mean (SD) 
Head circumference at birth (cm); mean (SD) 
Head circumference at MRI (cm); mean (SD) 
Mode of delivery (caesarean section); n (%) 
Apgar score at 1 minutea; mean (SD) 
Apgar score at 5 minutea; mean (SD) 
 
Parental characteristics  
Maternal age at infant’s birth (years); mean (SD) 
Paternal age at infant’s birth (years); mean (SD) 
Marital status (married); n (%) 
Maternal education (higher education); n (%) 











































t = 0.50, p = 0.622 
t = 1.43, p = 0.162 
t = 0.16, p = 0.875 
t = 0.80, p = 0.433 
p = 0.024  
U = 41.50, p = 0.384 
U = 47.50, p = 0.681 
 
 
t = 0.86, p = 0.397 
t = 0.37, p = 0.711 
p = 0.054 
p = 0.019 
p < 0.001 
Note: aApgar scores were only available for 21 infants (13 low-risk and 8 high-risk). The Fisher’s exact test does not have an associated statistic; thus, only p-
values were reported. Significant results are shown in bold. Abbreviations: MRI = magnetic resonance imaging; Higher Education = undergraduate and/or 
postgraduate degree; U = Mann-Whitney U-statistic; t = Independent samples t-statistic; X2 = Pearson’s Chi-Square; SD = standard deviation.  
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 Ins/Cho 18 0.73 (0.24) 11 0.95 (0.42) 0.48 0.871 
55 ms Ins/Cr 18 0.21 (0.06) 11 0.27 (0.12) 0.72 0.408 
 Glx/Cho 19 3.05 (0.62) 13 3.33 (0.40) 4.86 0.039 




























Note: In this analysis of co-variance, infant age at scan was included as a co-variate, whilst sex and mode of delivery were included as fixed factors. Significant 
results are shown in bold. Abbreviations: NAA = N-acetylaspartate and N-acetylaspartylglutamate; Cr = creatine and phosphocreatine; Cho = free choline, 





In this study, examining metabolic development from the fetal to the early postnatal period, 
Cho/Cr, Ins/Cho, and Ins/Cr all decreased with age, whilst NAA/Cho and NAA/Cr increased. In 
contrast, both Glx/Cho and Glx/Cr exhibited a more complex pattern of development; Glx 
ratios decreased from the fetal to the neonatal timepoint, but increased thereafter up until the 
period of early infancy. In addition, 4-6 month-old infants at high-risk of ASD had significantly 
higher levels of Glx when compared to low-risk controls.  
 
7.4.1. Typical metabolic development across the fetal, neonatal, and infant brain 
7.4.1.1. Cho 
Between fetal and infant timepoints, Cho/Cr decreased significantly with age. These results 
are in accordance with other studies, which report that Cho levels are highest around 22-28 
gestational weeks (Girard et al., 2006b), but rapidly decline from there up until 3-5 months of 
age, at which point they begin to plateau (Blüml et al., 2013; Kimura et al., 1995). Cho is 
considered as an essential component of cell membranes and is especially present in myelin. 
The overall decrease in Cho/Cr identified in both this and other studies, is therefore thought to 
correspond to the process of myelination, as well as the loss of immature myelin (Girard et al., 
2006b; Kok et al., 2002; Story et al., 2011).  
 
7.4.1.2. Cr 
Given that Cho/Cr decreases during early brain development, it can be assumed that Cr/Cho 
increases within this same time frame. Indeed, although originally considered as a stable 
metabolite, recent studies have reported that Cr levels increase from fetal to early postnatal 
life, only stabilising at around 2 years of age (Blüml et al., 2013; Degnan et al., 2014; 
Evangelou et al., 2016). High levels of Cr are required for energy production during 
myelination; this explains why the metabolite is found in such high concentrations in early life 





From the fetal to the infant period, both Ins/Cho and Ins/Cr ratios decreased significantly with 
age. More specifically and in agreement with the current literature (Blüml et al., 2013; Kok et 
al., 2001; Kreis et al., 1993), a dramatic drop in Ins ratios was evident between the fetal and 
neonatal period. This was followed by a less steep but still significant decrease between the 
first few months of postnatal life (for clarification, please see Figure 7.1C and D on page 229). 
Amongst its many roles, Ins is considered as an important glial marker (Brand et al., 1993; 
Kousi et al., 2013; Ross and Bluml, 2001). Thus, the high levels of Ins found between 22-28 
gestational weeks, may reflect the high density of glial cells present in the brain at this time 
(Fisher et al., 2002; Girard et al., 2006a). The observation that Ins levels decay across early 
development also suggests that the proliferation and/or growth of glial cells is decreasing, and 
that the metabolite is being ‘used up’ as white matter maturation progresses (Blüml et al., 
2013; Vigneron, 2006).  
 
7.4.1.4. NAA 
Perhaps the most consistent finding in the literature on typical metabolic development is that 
NAA increases with age (Degnan et al., 2014; Girard et al., 2006a, 2006b; Heerschap et al., 
2003; Huppi et al., 1995; Kimura et al., 1995; Kok et al., 2002; Ross and Bluml, 2001). This 
study corroborates these findings as both NAA/Cho and NAA/Cr increased significantly across 
timepoints, from fetal up until early infant life. In addition, this finding was more pronounced for 
NAA/Cho as compared to NAA/Cr, possibly because as discussed earlier, Cho may be more 
stable than Cr in early development (Evangelou et al., 2016). Furthermore, since NAA is an 
important marker of both neuronal and glial cells, the increase in NAA across development, 
evident in both this and other studies, is reflective of appropriate brain maturation (Bhakoo 
and Pearce, 2000).  
 
7.4.1.5. Glx 
Compared to other metabolites, Glx has not been as extensively studied and little is known 
about how it changes with age. Thus far, Glx has been visualised in utero as early as 24 
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weeks gestation (Girard et al., 2006a), but the current study extends this finding further to 
suggest that the Glx signal is already present at 22 weeks. Moreover, of the few studies that 
have examined Glx during the fetal period, none has identified significant variations with age 
(Girard et al., 2006a, 2006b). However, there have been studies examining Glx changes in 
early infancy, and aside from one study suggesting that Glx does not vary with increasing 
postnatal age (Kreis et al., 1993), all others have reported postnatal increases in Glx, which 
are reflective of appropriate brain maturation (Blüml et al., 2013; Degnan et al., 2014; Kreis et 
al., 2002). In the present study, Glx ratios increased from neonatal to infant life, and are 
therefore in agreement with these latter studies. However before this postnatal increase, both 
Glx/Cho and Glx/Cr decreased from the fetal to the neonatal period, illustrating a ‘dip’ in Glx 
around the time of birth (please refer back to Figure 7.1E and F on page 229).  
 
As the main excitatory neurotransmitter, glutamate (measured in this study as Glx) serves a 
multitude of functions in the developing human brain. One of its key functions is as the 
immediate precursor of GABA, which is largely involved in inhibitory neurotransmission. 
However, as described in the introduction of this thesis, early brain maturation is associated 
with a developmental switch in GABA, from excitatory to inhibitory (Ben-Ari, 2002). This is 
thought to occur during birth and implies that GABA exerts excitatory functions in early 
prenatal life. Overall, this switch is deemed crucial for normal brain development as it is partly 
responsible for the synchronisation of electrical activity, synaptic tuning, and neuronal wiring – 
all of which are necessary for appropriate neural connectivity and function (for review see 
Allene and Cossart, 2010; Khazipov and Luhmann, 2006).  
 
Considering that both glutamate and GABA are excitatory up until the time of birth may help to 
explain why, in this study, Glx is present in such low levels in neonatal life. Potentially, the 
decrease in Glx from the fetal to the neonatal timepoint counter-balances what is happening to 
GABA at this time. During fetal life when GABA is excitatory, for example, there is less of a 
need for glutamate to be present in high amounts. This is because the combined efforts of Glx 
and GABA provide enough excitatory activity to allow for normal neurodevelopmental 
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processes to occur, but not enough (due to decreasing Glx) to cause pathological 
hyperexcitability. After birth, once GABA has switched to its inhibitory mode of transmission, 
more glutamate is needed. Therefore, Glx levels increase (as evidenced in this study), to 
ensure that an adequate level of excitability is maintained for neurodevelopmental processes 
to continue as usual. This proposed hypothesis is partly corroborated by the findings of a 
recent post-mortem study, which reported that human GABAergic neurons increase in density 
from mid-gestation to term, peaking at term, and decreasing thereafter (Xu et al., 2011). 
Although GABAergic neurons cannot be directly compared to GABA levels, this finding is in 
juxtaposition to what was identified for Glx, and adds to the existing evidence. Thus it is 
possible that the findings of this study provide the first in vivo, albeit indirect proof, for a GABA 
excitatory-to-inhibitory switch in humans.  
 
In conclusion, the first aim of this study has been met; not only do these results replicate 
previous findings on the typical metabolic development of Cho, Cr, Ins, and NAA, they also 
extend our understanding of the maturational profile of glutamate (or Glx). Further work will be 
needed to replicate this finding, as well as to directly examine the human neurodevelopmental 
trajectory of GABA in vivo. 
 
7.4.2. Group differences in brain metabolite ratios at 4-6 months of age  
Infants at risk of ASD had significantly higher levels of Glx/Cho and Glx/Cr, when compared to 
low-risk controls. This suggests that absolute levels of Glx are elevated in these infants by 4-6 
months of age. In addition and as far as I am aware, this was the first 1HMRS study to 
examine the metabolic profile of infants genetically predisposed to ASD; therefore, direct 
comparisons with other studies were not possible. Moreover, the spectroscopic literature on 
young children and adolescents already diagnosed with ASD is inconsistent, with Glx levels 
reported to be higher (Bejjani et al., 2012; Doyle-Thomas et al., 2014), lower (Corrigan et al., 
2013; DeVito et al., 2007; Kubas et al., 2012), and similar (Friedman et al., 2003, 2006; 
Hardan et al., 2008) in individuals with ASD compared to typically-developing controls. The 
discrepancy in these findings can be partly explained by the different brain regions examined. 
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Indeed, when focussing only on studies that have sampled from the same region as this 
study, the story becomes a little clearer. To date, of the six studies investigating Glx in the 
basal ganglia of children and adolescents with ASD, the majority have reported no significant 
differences when compared to age-matched controls (Corrigan et al., 2013; Friedman et al., 
2003, 2006; Harada et al., 2011). However, studies reporting significant differences between 
groups have identified higher levels of putamen Glx/Cr (Doyle-Thomas et al., 2014), as well as 
blood and striatal glutamate (Hassan et al., 2013) in individuals with ASD. Thus, when placed 
together with the results of this study, it appears that an ASD risk status leads to elevated 
levels of subcortical Glx in infancy; levels which then either normalise or remain high in 
childhood.  
 
The methods adopted in the current study make it impossible to discern whether the elevated 
levels of Glx identified are due to glutamate, glutamine, or both. However, previous studies 
have cautiously attributed Glx differences to glutamate, given that it is the most abundant 
transmitter in the nervous system (DeVito et al., 2007; Hardan et al., 2008; Page et al., 2006). 
Furthermore, reports of increased glutamate (Zheng et al., 2016) and decreased glutamine 
(Shimmura et al., 2011) in the blood plasma of individuals with ASD, relative to controls, 
supports this notion. Aside from this, there is also clinical (Tuchman et al., 2010), post-mortem 
(Fatemi et al., 2002; Purcell et al., 2001), and genetic evidence (Brune et al., 2008; Jamain et 
al., 2002; Ramoz et al., 2004; Serajee et al., 2003) to suggest that glutamatergic dysfunction 
is present in ASD, and that it may be of aetiological relevance to the disorder. For instance, 
elevated levels of glutamatergic transporters and receptors have been identified in the post-
mortem brains of individuals with ASD (Purcell et al., 2001). Genetic studies have also 
reported associations between ASD and alleles encoding for genes involved in glutamatergic 
transmission (Jamain et al., 2002; Purcell et al., 2001; Serajee et al., 2003). Taken together, 
the findings of this and other studies support the hypothesis that the pathophysiology of ASD 
in early postnatal development may be characterised (at least partly) by an E/I imbalance, 
driven mainly by hyperglutamatergia (Fatemi, 2008; Polleux and Lauder, 2004; Rubenstein 
and Merzenich, 2003). 
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Glutamate is essential for several neurodevelopmental processes, including the proliferation 
and differentiation of oligodendrocytes, cell migration, plasticity, and synaptic pruning (Coyle 
et al., 2002; Gallo and Ghiani, 2000; Yuan et al., 1998). It is therefore not surprising that 
altered glutamatergic transmission, early in development, could result in neurodevelopmental 
abnormalities. In addition, since glutamate also facilitates neuronal synchronisation 
(Rodriguez et al., 2013), abnormalities of the glutamatergic system could impair typical brain 
function by impacting upon the formation of synapses and/or the functional connectivity of 
neural networks (Gatto and Broadie, 2010). Nonetheless, given the complementary action of 
glutamate and GABA, including the role they play in E/I balance, information about GABA in 
individuals with and at risk of ASD could augment our understanding of the underlying 
pathophysiology of the disorder.  
 
To examine GABA using 1HMRS is technically challenging, and therefore, only a few studies 
have been successful in quantifying this metabolite. Consequently, evidence for the 
involvement of GABA in ASD is still in its infancy. Thus far, the majority of studies have 
reported low levels of GABA in individuals with ASD, compared to controls (Cochran et al., 
2015; Gaetz et al., 2014; Harada et al., 2011; Kubas et al., 2012; Port et al., 2016; Puts et al., 
2016; Rojas et al., 2014). However, there have also been some studies reporting no 
significant differences in GABA levels between groups (Brix et al., 2015; Robertson et al., 
2015). Moreover, a recent study has observed both lower GABA and higher glutamate levels 
in high-functioning adolescents with ASD (Drenthen et al., 2016). This finding strengthens the 
hypothesis of an E/I imbalance in ASD, largely driven by high glutamate and low GABA levels. 
In addition, low levels of GABA have been identified in unaffected siblings of children with 
ASD; thus, E/I imbalance may be a feature of the BAP and potentially even act as a heritable 
biomarker and/or endophenotype of the disorder (Rojas et al., 2014).  
 
In summary, increased Glx ratios in 4-6 month-old infants at risk of ASD support the notion 
that an imbalance in E/I neurotransmission may partially underpin the pathophysiology of 
ASD. When the sample size permits, a key extension of the current study will be to examine 
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Glx differences in the fetal and neonatal period of individuals at high and low-risk of ASD. 
Future work will also seek to collect data on GABA simultaneously. This will allow for 
assessment of whether the GABA switch is disrupted in neurodevelopmental disorders like 
ASD, as recently proposed (Tyzio et al., 2014). Finally, proof that the glutamatergic pathway 
may be altered in individuals genetically predisposed to ASD, may incentivise the on-going 
search for pharmacological interventions targeting both glutamatergic and GABAergic 
systems (Chez et al., 2007; Erickson et al., 2014; Ghaleiha et al., 2013; Gürkan and 
Hagerman, 2012).   
 
Aside from elevated Glx levels, there were no other significant differences in metabolite ratios 
between infants at high and low-risk of ASD. The 1HMRS data acquired as part of this study 
was sampled solely from the region of the basal ganglia. Thus, it may be that other 
metabolites manifest differences in infants at risk of ASD only in other brain regions, such as 
the cerebellum, hippocampal-amygdala complex, and cortex (Chugani et al., 1999; DeVito et 
al., 2007; Fujii et al., 2010; Gabis et al., 2008; Otsuka et al., 1999; Vasconcelos et al., 2008). 
The present study may have also been underpowered due to its small sample size to detect 
subtle group differences in other metabolites. Also, the possibility of a false negative (type II) 
error cannot be excluded. This analysis will therefore be repeated once the sample size is 
larger. Future work will also extend this group comparison into younger populations, as we 
cannot rule out the possibility that other metabolites only show differences between risk 
groups at earlier (fetal and neonatal) timepoints.  
 
7.4.3. Study limitations 
The results of this study must be interpreted in the context of several limitations. First, the 
sample was of a modest size. This made it impossible to run risk group comparisons at fetal 
and neonatal timepoints; it also prohibited a longitudinal analysis, limiting our understanding of 
the trajectory and potential neurometabolic differences in individuals at risk of ASD younger 
than 4-6 months. Second, the presence of fetal motion meant that more than half (58.33%) of 
the acquired spectra could not be analysed, and so, the team is currently working to optimise 
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this. Third, the imaging protocol employed in this study did not allow for the resolution of Glx 
into its separate components (that is, glutamate and glutamine), nor did it allow for the 
quantification of GABA. Therefore, future studies employing optimised methods are needed to 
(i) confirm the results of this study, (ii) determine what specific metabolite is responsible for 
the changes in Glx, and (iii) examine any potential differences in GABA. Fourth, during 
1HMRS acquisition, a 20x20x20 mm voxel was placed in the region of the left basal ganglia, 
avoiding any CSF spaces, and ensuring adequate SNR. To maintain SNR, the same voxel 
size was used for all three timepoints, meaning that a relatively larger area of the fetal brain 
was sampled in comparison to that of the neonatal and infant brain. However, this limitation is 
unlikely to have affected results, as the longitudinal trajectory of Glx from the fetal to the infant 
timepoint was independent of the change in volume. Fifth, although essential to the successful 
completion of this study, a very low dose of chloral hydrate was used to encourage sleep 
during the scanning of infants aged 4-6 months, and represents a potential confounding 
factor. Other studies have also used this sedative (Kimura et al., 1995; Kreis et al., 1993) and 
their metabolite ratios, as well as those presented here, agree well with the values acquired 
without the use of sedation (Simões et al., 2015). In a recent fMRI study, the use of chloral 
hydrate also did not impact markedly upon functional activity within a number of neural 
networks (Doria et al., 2010). It is therefore unlikely that sedation affected the results, but 
caution in interpretation is advised. Sixth, this study reported relative ratios rather than 
absolute concentrations, which some argue is preferable especially in studies of development. 
However, metabolite ratios allow for comparison with other studies and therefore improve the 
interpretation of results. In future, unsuppressed water spectra will be acquired alongside the 
PRESS sequences used in this study, so that both absolute concentrations and relative ratios 
can be reported. Finally, this was a cross-sectional study that characterised infants in terms of 
high-risk and low-risk groups. Although not available at present, soon there will be data on the 
diagnostic outcomes of these infants, which will be useful to determine if the spectroscopic 
brain differences identified are linked with diagnostic outcome. Moreover, as undiagnosed 
siblings of children with ASD often develop the BAP, it would also be important to analyse this 
data in a dimensional manner.  
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7.4.4. Conclusions 
Despite these limitations, this study offered preliminary evidence on the metabolic 
development of both the typical and potentially atypical brain. Aside from strengthening 
existing knowledge on the early maturation of Cho, Cr, Ins, and NAA, by reporting on how Glx 
develops from fetal to infant life, the study also provided indirect proof for a GABA excitatory-
to-inhibitory switch in humans around the time of birth. In addition, this was the first study to 
report significant neurochemical differences in infants at risk of ASD, suggesting that 
increased levels of Glx may be an early biomarker and/or endophenotype of the disorder. 
Although in need of replication, these findings have implications for future pharmacological 
interventions, and for our understanding of the neural underpinnings of ASD. Finally, these 
preliminary results may incentivise longitudinal studies of infants at risk of ASD to incorporate 






Chapter 8: General Discussion 
 
8.1. Summary of rationale and findings 
With the advent of new imaging modalities, the past few years have hugely advanced our 
understanding of the human brain. Our knowledge of how the early prenatal and postnatal 
periods shape brain development, however, is limited. Furthermore, our understanding of how 
development may be disrupted in individuals predisposed to neurodevelopmental disorders is 
lacking. Hence, in an attempt to provide further insight into very early brain development, the 
studies included in this thesis examined the structure and chemistry of the fetal, neonatal, and 
infant human brain. By including individuals with a familial risk of ASD, the focus was also to 
investigate how genetic risk may disrupt typical neurodevelopment, and in so doing, 
compromise later behavioural outcomes pertaining to ASD and other related disorders.  
 
In the first experimental study of this thesis (chapter 3), normative variations in mother-infant 
interactions were found to be associated with differences in regional brain volumes. The next 
study, therefore, also incorporated measures of mother-infant interactions into a comparison 
of regional brain volumes in infants at low and high-risk of ASD. This second experiment 
(chapter 4) revealed that subcortical and cerebellar enlargements were present in infants at 
risk of ASD by 4-6 months of age, and that larger volumes were associated with more autistic 
symptoms at 36 months. In addition, this study provided preliminary evidence of a negative 
association between maternal sensitivity and subcortical volume within the high-risk group, 
meaning that high-risk infants exposed to more ‘sensitive’ mothers tended to have subcortical 
brain volumes more comparable to that of the low-risk group. Based on the results from these 
infant studies, the next step was to examine even younger individuals. The objective was to 
establish the trajectory of typical brain development, and to determine, when differences 
between infants at low and high-risk of ASD might first appear.  
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Consequently, the following two studies assessed total and regional brain volumes at fetal and 
neonatal timepoints in individuals with and without a familial risk of ASD. Across risk groups, 
the cerebellum and cortex were amongst the fastest growing regions. However, in contrast to 
the results at 4-6 months, the brains of fetuses and neonates genetically predisposed to ASD 
were smaller in volume than low-risk controls. In the fetal period (chapter 5), this finding was 
restricted to the cortex, but in the first month of postnatal life (chapter 6), there was a more 
generalised restriction in growth amongst neonates at risk of ASD. This included smaller 
intracranial and total brain volumes, as well as a smaller lentiform nucleus, which could not be 
explained solely by the smaller head size. Given that the lentiform nucleus constitutes a major 
part of the subcortical region, altered in high-risk infants at 4-6 months of age, a familial risk of 
ASD appears to be particularly disruptive to the development of this region. 
 
The subcortex was therefore selected as a region-of-interest in the final study (chapter 7), 
which examined metabolic maturation from the late prenatal to the early postnatal period. 
Across risk groups, Cho and Ins decreased significantly with age, whilst NAA and Cr 
increased. In contrast, glutamate (measured as Glx) decreased from fetal to neonatal life, with 
a marked ‘dip’ around the time of birth, before increasing in early infancy.  
 
This last study also allowed for an exploration of potential neurochemical differences in infants 
at low and high-risk of ASD. It provided the first evidence that high-risk infants have 
significantly elevated levels of subcortical Glx at 4-6 months, when compared to low-risk 
controls. An ASD risk status is thus associated with both neurochemical and neuroanatomical 
abnormalities of the subcortical region, evident before 6 months of age. 
 
Placed together, the results of the studies conducted here suggest that brain development in 
individuals genetically predisposed to ASD, begins to deviate from the typical 



















Figure 8.1: A graphical representation comparing brain development in individuals with 
and without a familial risk of ASD. Shortly prior to and after birth (during the fetal and 
neonatal periods, respectively), individuals at risk of ASD had smaller (A) total brain, (B) 
subcortical, and (C) cerebellar volumes, as well as lower (D) Glx/Cr ratios in fetal life, when 
compared to low-risk controls. In contrast, by 4-6 months of age, brain volumes were enlarged 
and Glx ratios elevated in high-risk individuals relative to controls. Although not all of these 
differences reached statistical significance, this graphical representation of the percentage 
difference of mean values between risk groups, attempts to demonstrate that individuals 
genetically predisposed to ASD show differences in typical brain development from the fetal 
period onwards. Abbreviations: Glx = glutamate/glutamine; Cr = creatine. 
 
 
8.2. Potential pathways leading to aberrant development in ASD 
Our understanding of brain development in ASD has improved significantly in recent years. 
However, since core symptoms of the disorder are usually already present in toddlers (aged 
2-4 years), it is difficult to determine whether the brain abnormalities observed in these 
    (A)                 (B) 
 
   (C)                (D) 
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individuals are a cause or consequence of the disorder. Studies of younger individuals prior to 
symptom manifestation are therefore needed to reveal causal pathways. Hence, by 
conducting early life studies of individuals genetically predisposed to ASD, the results of this 
thesis indicate that the genetic risk may be what constrains brain growth in the perinatal 
period, and what causes volumetric expansion of subcortical and cerebellar regions in early 
infancy. The alternative explanation is that a restriction of fetal and neonatal brain growth in 
individuals with a familial risk of ASD, triggers a compensatory overgrowth in brain volume 
that is measureable in infancy.  
 
8.2.1. Cellular mechanisms 
The perinatal period coincides with important neurodevelopmental processes, including neural 
proliferation, migration, and differentiation. One of the ways in which genetic pathways 
conferring risk for ASD might directly impact upon neurodevelopment, is by altering these 
processes. Evidence in support of this is now emerging (Casanova and Casanova, 2014; 
Chow et al., 2012; Voineagu et al., 2011). For example, in a study of individuals with and 
without ASD, an enrichment of CNVs disrupting gene-sets involved in cellular proliferation, 
projection, and motility, was identified in the ASD group (Pinto et al., 2010). Other biological 
processes, critical for development, such as chromatin remodelling, transcription, and splicing, 
also appear to be influenced by ASD genetic risk factors (Rubeis et al., 2014). In line with this, 
mutations in the ANKRD11 gene, encoding the Ankyrin repeat domain containing protein 11 
(Ankrd11), have recently been linked to ASD (Iossifov et al., 2014; Willemsen et al., 2010). 
Ankrd11 is an important chromatin regulator that controls histone acetylation and gene 
expression during neural development. Targeting this protein in rodent mice by in utero 
electroporation of small hairpin RNAs resulted in decreased proliferation, errors in neuronal 
positioning, and ASD-like behaviours (Gallagher et al., 2015). Thus, there is strong evidence 
for a link between genetic mutations associated with ASD, abnormally regulated perinatal 
processes, and an ASD behavioural phenotype.  
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Further evidence for a perinatal disruption of neurodevelopmental processes in ASD stems 
from post-mortem studies. For example, irregular cell patterning has been observed at the 
cortical grey and white matter boundary, suggesting that the brains of affected individuals may 
undergo migratory deficits, abnormalities in neurogenesis, and/or a failed apoptosis of the 
subplate (Avino and Hutsler, 2010). In another more recent post-mortem study, focal patches 
of abnormal laminar cytoarchitecture were identified in the majority (91%) of young ASD 
brains, as opposed to only a minority (9%) of age-matched controls (Stoner et al., 2014). 
Aside from supporting a possible deregulation in cortical layer formation, these findings are 
also consistent with prenatal errors in neurogenesis, neural migration, and neural 
differentiation. Prenatal disruption of neurogenesis and cellular proliferation may result in a 
fewer number of neurons, and hence, contribute to the smaller total and/or regional brain 
volumes observed here, in individuals at risk of ASD during fetal and neonatal timepoints.   
 
Finally, it is also possible that the large regional brain volumes observed in early infancy, are 
partly due to errors in proliferation. For example, recent work using induced pluripotent stem 
cells derived from a cohort of individuals with both ASD and brain overgrowth at 2-5 years of 
age, has shown that the neural stem cells of these individuals display abnormally rapid 
proliferation, when compared to the cells derived from unaffected controls (Marchetto et al., 
2016). Thus, although further work is needed to untangle the mechanisms underlying smaller 
brain volumes in perinatal life and enlarged volumes in early infancy amongst high-risk 
individuals, errors in proliferation are most likely of causal relevance. 
 
8.2.2. Biochemical mechanisms 
Neurochemical abnormalities in ASD may precede and/or accompany the errors in cellular 
mechanisms that alter important neurodevelopmental processes. Results from both preclinical 
and clinical work, for example, propose that an E/I imbalance may be especially relevant to 
ASD. Specifically, evidence stemming from genetic, animal, post-mortem, and neuroimaging 
work, suggests that the glutamatergic system is altered in ASD (for review see Nelson and 
Valakh, 2015; Rubenstein and Merzenich, 2003).  
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The results reported in this thesis extend these findings further to propose that glutamatergic 
abnormalities in ASD emerge in early life. Since glutamate is crucial for a variety of 
neurodevelopmental processes – including proliferation, migration, and differentiation, as well 
as synaptogenesis and neuroplasticity (Gallo and Ghiani, 2000; Huttenlocher et al., 1982; 
Yuan et al., 1998) – this could have important implications for brain maturation. Indeed, too 
much glutamate can be detrimental to the brain, resulting in excitotoxicity, oxidative stress, 
mitochondrial damage, and apoptosis (Debanne et al., 2003; James et al., 2004; Kern, 2003). 
Moreover, hyperglutamatergia in early life appears to have worse consequences than if it 
were to be present in adulthood (Rosenberg et al., 2003; Yoshioka et al., 1996). 
 
Hyperglutamatergia was clearly evident in the 4-6 month-old infants at risk of ASD studied 
here. In addition, although glutamate levels were not formally compared between fetuses and 
neonates at high and low-risk of ASD, there is a possibility that the glutamatergic system may 
already be aberrant in high-risk individuals during these earlier timepoints. As shown in Figure 
8.1, fetuses at risk of ASD tended to have less glutamate than those at low-risk. However, by 
the neonatal timepoint, glutamate levels were already elevated in the high-risk group, 
consistent with the findings in early infancy. These observations coincide with a recognised 
perinatal ‘shift’ in GABA function, from excitatory prenatally to inhibitory postnatally. A delay in 
this switch has recently been implicated in neurodevelopmental disorders, including ASD (He 
et al., 2014; Tyzio et al., 2014). Thus, aside from continuing to acquire spectroscopic 
glutamate measures from very young individuals with and without a familial risk of ASD, there 
is also a plan to start measuring GABA, by including a MEGA-PRESS sequence into the 
existing 1HMRS protocol (Mullins et al., 2014). 
 
Future work will also examine the relationship between glutamate measures and brain 
structure in individuals genetically predisposed to ASD. High levels of glutamate have been 
reported in association with glial activation (Laurence and Fatemi, 2005; Vargas et al., 2005), 
and when activated, microglia can become enlarged (Morgan et al., 2010) and contribute to 
pruning deficits (Paolicelli and Gross, 2011). Therefore, it is possible that hyperglutamatergia 
 248 
in the months after birth, as evident in high-risk individuals, could drive a compensatory 
increase in brain volume via glial activation. In support of this, human post-mortem studies 
have reported significantly increased activation of both astroglia and microglia in individuals 
with ASD, as compared to typically developing controls (Li et al., 2009; Morgan et al., 2010; 
Vargas et al., 2005).  
 
8.3. Is the subcortical region core to aberrant neurodevelopment 
in ASD? 
The subcortical region (encompassing basal ganglia and thalami) has been consistently 
implicated in the ASD literature (Calderoni et al., 2014; Estes et al., 2011; Hollander et al., 
2005; Qiu et al., 2010; Sears et al., 1999). Moreover, this brain region was reported as 
abnormal in the individuals genetically predisposed to ASD studied in this thesis. For example, 
both the volume and biochemistry of the subcortex were observed to be different in neonates 
and infants at risk of ASD, relative to age-matched controls. A significant association between 
the early caregiving environment and the infant’s subcortical volume was also present by 4-6 
months of age in both low-risk and high-risk samples. Thus, the subcortical region is sensitive 
to genetic risk factors, but also to environmental risk factors that can alter neurodevelopment. 
This is consistent with other evidence suggesting that the subcortical region may be 
particularly vulnerable to early environmental influences, although prior work has tended to 
focus on extreme exposures such as perinatal hypoxia (Okereafor et al., 2008; du Plessis and 
Volpe, 2002; Shalak and Perlman, 2004).  
 
Importantly, the subcortical region is thought to be crucial for normal brain development. For 
example, the subventricular zone within the subcortical region is a major locus for neuronal 
proliferation and migration. Aberrant development of this region may therefore be associated 
with some of the errors in prenatal processes frequently implicated in ASD. In addition, given 
that the subcortical region drives cortical development in fetal life (Kostović and Jovanov-
Milošević, 2006; Sur and Rubenstein, 2005), abnormal maturation of this region could also 
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result in some of the cortical irregularities identified in ASD (Ecker et al., 2013b; Hazlett et al., 
2011; Nordahl et al., 2007; Ohta et al., 2016; Wallace et al., 2013) and in fetuses at risk of 
ASD (chapter 5). It is possible, for instance, that the subcortical abnormalities reported in this 
thesis may contribute to the overall pattern of atypical neurodevelopment in ASD.  
 
Since the subcortical region also plays a crucial role in motor co-ordination and control, the 
early dysfunctional development of this region could lead to the repetitive (often motoric) 
behaviours commonly observed in ASD. For example, in individuals genetically predisposed 
to ASD, a larger subcortical volume at 4-6 months was significantly correlated with a greater 
number and severity of restricted and repetitive behaviours at 36 months (chapter 4). These 
symptoms have been suggested to be amongst some of the earliest to manifest in individuals 
with and at risk of ASD (Mooney et al., 2006). Therefore, it would make sense for the 
subcortical region of these individuals to be aberrant from an early age, and potentially play a 
significant role in the underlying development of the disorder.  
 
8.4. Implications for early therapeutic intervention 
8.4.1. Parent-mediated interventions 
According to the studies included in this thesis, by 6 months of age, individuals at risk of ASD 
have brain abnormalities that correlate with subsequent ASD-like symptoms. In addition, there 
is evidence indicating that the early caregiving environment is strongly associated with infant 
brain volume. With the caveat that the current work did not address therapeutic interventions, 
the results presented here suggest that parenting style is correlated with both infant brain and 
behaviour. Early parent-mediated interventions may therefore be beneficial for young infants 
with and at risk of ASD (for review see Oono et al., 2013). For example, in the first parent-
mediated intervention trial aimed at high-risk infants within the first year of life, significant 
reductions in ASD-like behaviours were observed (Green et al., 2015). Although promising, 
before any definite conclusions can be drawn, further research is needed to replicate these 
findings in larger samples of high-risk individuals.  
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Moreover, the large regional brain volumes identified in 4-6 month-old infants at risk of ASD 
were significantly associated with several autistic traits at 36 months, but especially with 
restricted and repetitive behaviours (chapter 4). Yet, an improvement in these behaviours is 
rarely included as an outcome measure within intervention trials for children with ASD. This is 
an important omission, as early interventions should be focused on reducing all core 
behaviours. In addition, aside from being one of the first symptoms to manifest in ASD 
(Mooney et al., 2006), restricted and repetitive behaviours can be stigmatising and detrimental 
to the infant’s consequent behavioural functioning by interfering with the acquisition of other 
skills (Gabriels et al., 2005; Lam et al., 2008; Loftin et al., 2008). As a result, recent work has 
focused on methods for reducing restricted and repetitive behaviours in infants with ASD; for 
instance, via environmental enrichment including exposure to multiple sensorimotor stimuli 
(Woo et al., 2015). Preliminary evidence suggests that these methods ameliorate restricted 
and repetitive symptoms in affected infants (Woo et al., 2015). Thus, this may be something 
worth including in future parent-mediated intervention trials, specifically those aimed at 
individuals with and at risk of ASD.  
 
8.4.2. Pharmacological treatment 
Although behavioural interventions should be viewed as the therapy of choice for young 
infants with and at risk of ASD, the possibility of early pharmacological interventions should 
not be excluded. However, since paediatric populations are rarely included in clinical trials, 
little is known about how infants and children respond to drugs (Bavdekar, 2013). When 
working towards the development of pharmacological agents with potential applicability to very 
young individuals, there is therefore a need (more so than usual) to conduct an appropriate 
risk-benefit assessment, and to carefully screen for any potential side effects.  
 
According to the final study of this thesis (chapter 7), hyperglutamatergia may be implicated in 
some aspects of early ASD pathophysiology, and thus, should encourage the ongoing search 
for pharmacological interventions targeting the E/I balance. For example, GABAA and GABAB 
receptor agonists reverse ASD-like features in a range of animal models (Han et al., 2012, 
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2014; Henderson et al., 2012; Heulens et al., 2012). In contrast, metabotropic glutamate 
receptor 5 antagonists rescue ASD-like behaviours in mouse models of ASD (Michalon et al., 
2014; Pop et al., 2013; Silverman et al., 2012). Translating these findings into the clinic, 
however, has been unsuccessful thus far (Berry-Kravis et al., 2009).  
 
E/I balance in early life can also be modulated indirectly using the diuretic bumetanide, a 
selective NKCC1 chloride-importer antagonist, which can restore the inhibitory action of GABA 
and prevent ASD-like behaviours in the offspring (Tyzio et al., 2014). In translation, a 3 month 
bumetanide treatment administered to children with ASD, significantly ameliorated symptom 
manifestation (Lemonnier and Ben-Ari, 2010; Lemonnier et al., 2012). Moreover, since there 
have been no serious side effects reported in association with bumetanide (Lemonnier et al., 
2012), this may be a promising new drug for ASD. Still, trials with larger sample sizes are 
necessary; for example, to determine whether there is an ASD subgroup population for whom 
this treatment would be most suitable.  
 
It has also recently been demonstrated that the combination of pharmacological and 
behavioural interventions is more effective in reducing behavioural difficulties in children with 
neurodevelopmental disorders, as compared to medication alone (Aman et al., 2009). 
Combining these two approaches and implementing them from early on may therefore be the 
best way forward to treating ASD. Early intervention, however, will only be possible once valid 
biomarkers have been developed, and so the search for these markers remains an important 
future direction.  
 
8.5. Limitations and considerations for future research  
Although the problems encountered within each study have been discussed in previous 
chapters, there are some limitations worthy of mentioning here. For example, we should be 
cautious not to over interpret findings due to the small sample size. Studies of larger sample 
sizes are therefore needed to replicate results, but also to enable an initial exploration of the 
underlying aetiological pathways leading to distinct ASD subtypes. 
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The lack of outcome data in some of the studies included here is yet another limitation, which 
restricts the interpretation of results. It was not within the scope of this thesis, for instance, to 
correlate the fetal, neonatal, and infant brain measures (collated as part of project 2) with later 
autistic and other related symptoms. However, as the infants begin to reach 36 months of age, 
outcome measures will soon become available. This will allow for the data to be analysed both 
in a categorical and dimensional manner, which will help to elucidate whether alterations in 
brain volume and chemistry during early prenatal and postnatal life, could be used as early 
predictors of risk and/or resilience for poor neurodevelopmental outcomes. It will be 
particularly interesting to examine whether these identified brain differences are specific to 
ASD, or whether they are present in individuals with associated co-morbidities, thus 
representing shared risk factors and elucidating on common pathways to clinically related 
difficulties. In addition, while the in utero diagnosis of ASD remains an ambitious goal that may 
never fully materialise, this thesis has shown that it is possible to study fetuses at risk of ASD 
and that this is an avenue worth pursuing. In future, once automated protocols for fetal 
segmentation are routinely implemented, fetal MRI may become an important research tool, 
which will hopefully encourage the development of early screening, and help to identify high-
risk infants most in need of early intervention. 
 
There are also specific limitations associated with studying infants at risk. Families of children 
with ASD may experience pressures beyond that of a typical family, which may lead to 
increased levels of stress and depression amongst parents (Baker et al., 2011; Ingersoll and 
Hambrick, 2011). Key features of stress such as social withdrawal, fatigue, and irritability may, 
in some cases, impact on early mother-infant interactions (Coyl et al., 2002; Murray et al., 
2010). Parents of high-risk infants may also demonstrate characteristics of the BAP and thus 
be less sensitive to their infant’s’ mental state (Bolton et al., 1998; Gerdts and Bernier, 2011). 
Altogether, this may negatively impact upon infant brain and behavioural outcomes. 
Consequently, future studies of infants at risk of ASD should aim to acquire comprehensive 
information on parental autistic traits and mood. 
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Another issue not yet addressed concerns the specificity of findings. For example, although 
the subcortical region was enlarged by 4-6 months in high-risk infants who received a clinical 
diagnosis of ASD, it is not possible to be sure that these results are ASD-specific. Anatomical 
abnormalities of the basal ganglia (of which the subcortical region is part of) have been 
reported in relation to other neurodevelopmental disorders, including ADHD (Seidman et al., 
2011). ADHD also shares genetic risk factors with ASD (Rommelse et al., 2010) and so, these 
shared factors could be what influence the (initial) abnormal development of the basal ganglia. 
Identifying which brain differences are related to subsequent behavioural difficulties may 
prove important in future, particularly when it comes to understanding the causal pathways to 
symptom development in a range of other related disorders. Future longitudinal research into 
high-risk infants would therefore benefit from the inclusion of a neurodevelopmental 
comparison group, to ascertain the specificity of findings. In line with this, an interesting 
question for future research is why – given the overlapping family histories and shared risk 
factors associated with a range of neurodevelopmental conditions (Consortium, 2013) – do 
some infants go on to be diagnosed with a disorder, whilst others born into the same family, 
do not? Also, what determines which infant will develop one disorder over another? And why 
is it that some individuals develop ASD, whilst others only show ASD-like traits, reminiscent of 
the BAP? Besides paving the way for more research, these questions should also prompt the 
search for protective, rather than just predictive, biomarkers. 
 
Finally, although an exploratory longitudinal analysis was conducted as part of this thesis, the 
fact that only 8 high-risk participants were scanned at both fetal and neonatal timepoints, 
limited the analysis and interpretation of results. Nonetheless, preliminary findings were 
suggestive of a possible interaction effect between timepoint and risk group, which was in line 
with results from the main cross-sectional analysis. By now, many more fetuses, neonates, 
and infants will have been scanned as part of project 2. The majority of participants will also 
have imaging data at more than one timepoint. Therefore, once the infant data has been 
segmented and analysed, the obvious next step will be to run a thorough longitudinal analysis. 
This will help to determine whether the individuals that have small total and regional brain 
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volumes in fetal and neonatal life, are the same ones that have enlarged volumes at 4-6 
months, and who then go on to develop ASD. In addition, this will allow for metabolic and 
volumetric trajectories to be compared between risk groups, rather than relying on 
comparisons of static measures alone. In a recent longitudinal study, the severity of repetitive 
behaviours in children with ASD was significantly correlated with an increased growth rate of 
the caudate, and not with caudate volume per se (Langen et al., 2014). As a result, it is likely 
that growth rates will allow for more subtle differences to be identified, and my future work with 
fetal, neonatal, and infant datasets will ensure that similar analyses be conducted.  
 
8.6. Conclusion 
The studies incorporated in this thesis have provided an important first step in identifying very 
early (fetal, neonatal, and infant) brain abnormalities that may underlie the emergence of ASD 
and other behavioural difficulties. Specifically, the neurodevelopmental trajectory of individuals 
genetically predisposed to ASD exhibits a deviation from the typical neurodevelopmental tract, 
evident from the fetal period onwards. This deviation occurs well before the onset of 
behavioural symptoms in ASD and therefore has important implications for the management 
of the disorder and its associated symptoms, particularly with regards to early identification 





Appendix 1: Post-hoc power calculations  
 
Study 2 – Chapter 4: Regional brain volumes and behavioural outcomes in infants with 
a familial risk of ASD 
This study reported that 4-6-month-old infants at risk of ASD had significantly larger 
cerebellum [F(1,44) = 6.92, p = 0.012] and subcortical volumes [F(1,44) = 4.64, p = 0.037] 
than age-matched low-risk controls. The results of the post-hoc calculations revealed an 
achieved power of 0.50 and 0.46 for the cerebellum and subcortical findings, respectively. The 
effect size for the cerebellum finding was larger than that for the subcortical, but both were 
considered to be of moderate size (cerebellum: p2 = 0.136; subcortical: p2 = 0.095). 
 
Study 3 – Chapter 5: Brain volumes in fetuses with and without a familial risk of ASD 
In the third study of this thesis, significant group differences were identified for the cortex 
[F(1,35) = 5.21, p = 0.029], with high-risk fetuses having smaller cortical volumes than low-risk 
controls. Post-hoc power calculations revealed an achieved power of 0.46, with moderate 
effect size (p2 = 0.130) reported for this finding. 
 
Study 4 – Chapter 6: Brain volumes in neonates with and without a familial risk of ASD 
In this experimental chapter, significant group differences were identified within the first month 
of postnatal life. Results revealed that high-risk neonates had a significantly smaller volume of 
the total brain tissue [F(1,47) = 4.76, p = 0.034] and intracranium [F(1,47) = 5.40, p = 0.024], 
when compared to low-risk controls. The results of the post-hoc calculations established an 
achieved power of a mere 0.13 and 0.11 for the total brain tissue and intracranium findings, 
respectively. Both these findings, however, revealed moderate effect sizes (total brain tissue: 
p2 = 0.092; intracranium: p2 = 0.103). In addition, this study identified significant differences 
in head-to-body proportions between groups [F(1,48) = 14.87, p < 0.001], with the high-risk 
group weighing considerably more than the low-risk, but having significantly smaller 
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intracranial volumes. The achieved power for this group difference was 0.99 and the effect 
size was large (p2 = 0.237).  
 
Finally, significant difference in the volume of the lentiform nucleus were also identified 
[F(1,46) = 4.62, p = 0.037], with high-risk neonates having significantly smaller volumes than 
low-risk controls. Post-hoc power calculations revealed an achieved power of 0.36 for this 
finding, with moderate effect size (p2 = 0.091).  
 
Study 5 – Chapter 7: Subcortical biochemistry from prenatal to early postnatal life, and 
metabolic differences in infants with and without a familial risk of ASD 
The final study provided evidence that 4-6-month-old infants at risk of ASD have significantly 
higher levels of Glx/Cho [F(1,21) = 4.86, p = 0.039] and Glx/Cr [F(1,21) = 6.04, p = 0.023], as 
compared to age-matched controls. The results of the post-hoc calculations revealed an 
achieved power of 0.34 and 0.28 for the Glx/Cho and Glx/Cr findings, respectively. Despite 
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